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                                                 Abstract 
 
Keywords: Hot melt extrusion, solid dispersion, crystallisation, Ibuprofen, 
Polyox, Soluplus®, AffinisolTMHPMC, controlled release. 
The feasibility of hot melt extrusion (HME) was explored for development of 
amorphous solid dispersion systems. Controlled release formulations were 
developed using a cellulose based derivative, AffinisolTMHPMC 100cP and 4M 
grades. BCS class II drugs ibuprofen and posaconazole were selected due to 
their difference in glass transition temperature and lipophilicity.     
This study focused on investigation of the impact the material attributes and 
process parameters on the critical quality attributes in preparation of 
amorphous solid dispersions using hot melt extrusion. The critical quality 
attributes were sub divided into three main attributes of material, process and 
product.  
Rheology of ibuprofen-Affinisol 100cP from melt phase to extrudate phase was 
tracked. A partial factorial design was carried out to investigate the critical 
parameters affecting HME. For optimisation of 40%IBU-Affinisol 100cP 
blends, a feed rate of 0.6kg/hr, screw speed of 500rpm and screw 
configuration with two mixing elements were found to be optimum for single 
phase extrudates. ATR-FTIR spectroscopy was found to be an indirect 
technique of choice in predicting the maximum ibuprofen drug load within 
extrudates. Prediction was based on the prepared extrudates without charging 
them to stability conditions.  
ii 
 
An alternative strategy of incorporation of di-carboxylic acids to increase the 
dissolution of posaconazole-Affinisol 4M blends was investigated. Succinic 
acid and L- malic acid incorporation was found to increase the dissolution of 
posaconazole. Although, the extrudates crystallised out quicker than the naïve 
posaconazole-Affinisol 4M, but free posaconazole formed eutectic and co-
crystal with succinic and L-malic acid within extrudates. This lead to an 
increase in dissolution of the extrudates compared to day 0.  
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Chapter 1: Introduction 
Hot melt extrusion (HME) has been applied in the pharmaceutical industry 
mainly to prepare solid dispersions for improving solubility of poorly water 
soluble drugs delivered using instantaneous release (IR) formulations. This is 
now becoming an established technology for compounds with low solubility in 
the pharmaceutical industry. HME offers advantages over traditional 
pharmaceutical operations such as solvent free and continuous processing, 
thus eliminating the drawbacks of batch processing (Shah et al. 2013). It is 
easily scalable and has the capability of producing sustained, targeted and 
modified release, providing better content uniformity over a wide range of 
dosages, applicability to a wide range of dosage forms, ability to maintain good 
product stability and formulating clinically advantageous dosage forms such 
as drug abuse and dose dumping deterrent products. The use of HME 
technology to achieve controlled release is starting to gain popularity. Its 
application should translate into a more robust controlled release formulation 
(e.g. reduced food effect liability) compared to conventional controlled release 
(CR) matrices. Another key component in preparation of amorphous solid 
dispersion using HME is the availability of approved suitable polymers. Lack 
of polymers has led to slow emergence of HME in pharmaceutical industry. 
The choice of polymer governs the drug release mechanism of solid 
dispersion, solid state miscibility and solubility with the active pharmaceutical 
ingredient and processing conditions. A detailed history of success stories of 
HME products marketed will be provided in chapter 2.   
Despite the potential for HME technology there are some important aspects 
which will affect critical quality attributes of any final drug product. Melt 
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attributes such as thermal properties and history of the polymer, melt rheology, 
drug miscibility and process parameters such as temperature, shear, feed rate, 
residence time, post extrusion processing conditions etc. are important 
variables (Crowley et al. 2007). These variables will affect critical quality 
attributes (CQA) such as level of dispersion, stability, mechanical properties, 
post extrusion processability, drug and polymer degradation and in vitro and 
in vivo performance. The large number of interdependent variables creates 
complexity in undertaking any study and its interpretation.  
1.1 Research objectives 
In order to study the interdependent variables of the application of HME, the 
focus of this work was on active pharmaceutical ingredients (APIs) known to 
be amorphous and were selected for formulation development using HME.  
 
Figure 1.1 Drug-Polymer combinations used for processing using HME 
Both APIs used during the study are categorised as poorly water-soluble drug 
according to BCS (Figure 1.1). Glass transition temperature and partition 
coefficient are one of the critical factors during formulation development of 
ASD. Taking them as reference factors, Ibuprofen and Posaconazole were 
selected. Ibuprofen has a low glass transition temperature and low partition 
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coefficient while Posaconazole has a high glass transition temperature and 
high partition coefficient. Additionally, Ibuprofen has a lower molecular weight 
compared to Posaconazole.  
One of the key drawbacks for suitability of HME in the Pharma industry has 
been the lack of FDA approved polymers. Conventionally used polymers in 
Pharma had major drawbacks of high Tg, high melt viscosity, and thermal 
degradation (Serajuddin 1999). To overcome this, various new polymers were 
introduced either by co-polymerisation or substitution/replacement within the 
monomers of the polymers (Gupta et al. 2016). This has led to the introduction 
of new polymers like Soluplus® (copolymer of PVC-PVA-PEG), HPMCAS, 
HPMCP, and AffinisolTMHPMC. AffinisolTMHPMC was recently launched as 
an improved HPMC especially for HME (Huang et al. 2016). Limited research 
data was available for the said polymer and hence was selected as a polymer 
of choice for the trials. Since the focus was on the sustained released 
formulation, higher molecular weight grades of 100cP and 4M were evaluated 
in the current studies.   
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Ibuprofen 
  
Figure 1.2 Chemical Structure of Ibuprofen 
Ibuprofen (IBU) or 2-(4-isobutylphenyl)propionic acid is a nonsteroidal anti-
inflammatory drug (NSAID) (Figure 1.2). It is used for reducing inflammation 
and pain in the body (Lerdkanchanaporn and Dollimore 1997). The intended 
use of Ibuprofen is to reduce fever and treat pain or inflammation caused by 
many conditions such as a headache, toothache, back pain, arthritis, 
menstrual cramps, or minor injury. 
 
 
 
 
 
 
 
CH3
CH3
OH
O
CH3
Molecular Formula:  C
13
H
18
O
2
Formula Weight:  206.28082
Composition:  C(75.69%) H(8.80%) O(15.51%)
Molar Refractivity:  60.77 ± 0.3 cm 3
Molar Volume:  200.3 ± 3.0 cm 3
Parachor:  497.6 ± 4.0 cm3
Index of Refraction:  1.518 ± 0.02
Surface Tension:  38.0 ± 3.0 dyne/cm
Density:  1.029 ± 0.06 g/cm3
Dielectric Constant:  Not available
Polarizability:  24.09 ± 0.5 10 -24cm3
RDBE:  5
Monoisotopic Mass:  206.13068 Da
Nominal Mass:  206 Da
Average Mass:  206.2808 Da
M+:  206.130131 Da
M-:  206.131228 Da
[M+H]+:  207.137956 Da
[M+H]-:  207.139053 Da
[M-H]+:  205.122306 Da
[M-H]-:  205.123403 Da
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Physical properties of Ibuprofen are summarised in table 1.1.  
Chemical Formula C13H18O2 
Appearance White solid powder 
Odour Characteristic odour 
Mol. Wt g/mol 206.29 
Solid State  Crystalline 
Melting Point °C 75 
Vapour Density  7.1 
Solubility Soluble in most of the organic 
solvents and water. Insoluble in 
cold water. 
Partition coefficient (Log P) 3.97 
pKa 4.91 
Glass transition temperature of the 
amorphous form (°C) 
-44.25 
Table 1.1 Typical properties of Ibuprofen 
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Posaconazole 
 
Figure 1.3 Chemical Structure of Posaconazole 
Posaconazole (POSA) or 4-[4-[4-[4-[[(3R,5R)-5-(2,4-difluorophenyl)-5-(1,2,4-
triazol-1-ylmethyl)oxolan-3-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-2-
[(2S,3S)-2-hydroxypentan-3-yl]-1,2,4-triazol-3-one is a broad spectrum, 
second generation, triazole compound with antifungal activity (Torres et al. 
2005) (Figure 1.3). It is an antifungal agent structurally related to itraconazole. 
It is a drug derived from itraconazole through the replacement of the chlorine 
substituents with fluorine in the phenyl ring, as well as hydroxylation of the 
triazolone side chain. These modifications enhance the potency and spectrum 
of activity of the drug. Posaconazole can be either fungicidal or fungistatic in 
action. 
It is a potent triazole antifungal agent used in the prevention of invasive fungal 
infections due to aspergillosis and candida in high-risk patients. Posaconazole 
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therapy is associated with transient, asymptomatic serum aminotransferase 
elevations and is a suspected but rare cause of clinically apparent acute drug-
induced liver injury (Dekkers et al. 2016). 
Physical properties of POSA are summarised in table 1.2. 
Chemical Formula C36H40F2N8O4 
Appearance White solid powder 
Odour Characteristic odour 
Mol. Wt g/mol 686.75 
Solid State  Crystalline  
Melting Point °C 170-172°C 
Density  1.38g/cm3 
Solubility Insoluble in water (0.027mg/L). 
Soluble in DMSO, DMF, Acetonitrile 
and Methanol. 
Partition coefficient (Log P) 5.5 
pKa 14.83 
Glass transition temperature of the 
amorphous form (°C) 
60.85°C 
Table 1.2 Physical properties of Posa 
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AffinisolTMHPMC 
Hypromellose (HPMC) is one of the polymers of choice when it comes to 
preparation of solid dispersions of pharmaceutical drugs (Figure 1.4). The key 
advantage it holds over the other polymers is it is a water-soluble polymer and 
helps to maintain stable solid dispersion and inhibit API crystallisation in the 
solution. It is widely reported for its use in immediate as well as modified 
release formulations. 
Although being amorphous in nature and water soluble, HPMC lacked certain 
aspects for being an ideal polymer of choice for HME. This was largely due to 
its high glass transition temperature (160-210°C), low decomposition 
temperatures (200-250°C) and high melt viscosity (Huang et al. 2016).  
To overcome the disadvantages of traditional HPMC grades available in the 
market, a new substituted version named AffinisolTMHPMC was marketed by 
DOW specifically for HME use. It is amorphous in nature and has a wide 
temperature window for melt processing. Three grades AffinisolTMHPMC 
15cP, 100cP and Affinisol 4M are commercially available grades of which only 
100cP and 4M grades were evaluated simultaneously for feasibility as the 
target release of the formulation in this study was controlled release. Physical 
properties of the Affinisol can be found in Table 1.3.  
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Figure 1.4 Chemical Structure of HPMC 
Appearance White free-flowing powder 
Bulk Density (g/cc) 0.42 
Tapped Density (g/cc) 0.55 
True Density (g/cc) 1.2 
Cloud Point (°C) 46 
Loss on Drying (%) 1-3 
The angle of Repose (°) 32 
CARR Index 16.2 
Table 1.3 Physical Properties of AffinisolTMHPMC 
Table 1.4 provides the difference between three grades of AffinisolTMHPMC. 
Properties AffinisolTMHP
MC 15cP 
AffinisolTMHPMC 
100cP 
AffinisolTMHPMC 
4M 
Mol wt (kDa) 83 179.3 552.8 
Particle Size (D90) 
(µm) 
207.068 208.87 237.12 
Hansen Solubility 
Parameter (Δδ) 
(J/cc)1/2 
18.0 17.9 17.8 
Glass transition 
temperature 
(reported) (°C) 
110-120°C 110-120°C 110-120°C 
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HME processing 
range 
135-190°C 145-195°C 155-200°C 
Decomposition 
temperature (°C) 
Above 250°C Above 250°C Above 250°C 
Table 1.4 Properties of different grades of AffinisolTMHPMC 
AffinisolTMHPMC is shown to be soluble in a variety of organic solvents 
extending its versatility in the aqueous free formulations. It is pure HPMC 
without any addition of plasticiser or additives. Thus, the toxicity data is similar 
to the HPMC and is considered to be low on toxicity with daily food intake level 
to be around 20g/person/day.  
Dicarboxylic acids as co-formers 
To overcome effect of food on the oral bioavailability of Posa, dicarboxylic 
acids were used as additives. Dicarboxylic acids were used as co-formers for 
the screening of Eutectics and co-crystals with Posaconazole (Table 1.5).  
Co-former 
name 
Source / Lot no Chemical structure 
Succinic Acid 
(SA) 
Sigma Aldrich, UK 
 
Chemical formula: C4H6O4 
Molecular weight:  118.09 g/mol 
Melting point: 185-190°C 
L-Malic Acid 
(MA) 
Sigma Aldrich, UK 
 
Chemical formula: C4H6O5 
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Molecular weight:134.087 
g/mol 
Melting point: 104-107°C 
Oxalic Acid 
(OA) 
Sigma Aldrich, UK 
 
Chemical formula: C2H2O4 
Molecular weight: 
90.1034g/mol 
Melting point: 188-189°C 
Maleic Acid 
(MeA) 
Sigma Aldrich, UK 
 
Chemical formula: C4H4O4 
Molecular weight:116.072 
g/mol 
Melting point: 130-131°C 
Ascorbic Acid 
(AA) 
Sigma Aldrich, UK 
 
Chemical formula: C6H8O6 
Molecular weight:176.124 
g/mol 
Melting point:  190-192°C 
Table 1.5 Dicarboxylic acids used as co-formers 
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The research will be divided in to three attributes which are material, process 
and product respectively (Figure 1.5). It is mainly focussed on indentifying, 
characterising and proposing solutions to overcome the challenges that arise 
in the material, process and product attributes during preparation of 
amorphous solid dispersion products using HME. 
Specific objectives of the study involve:  
1. To develop robust HME process for amorphous solid dispersion products 
using amorphous polymer and poorly soluble APIs.  
2. To identify and develop preformulatory methods to characterise the 
polymer and APIs.  
3. To investigate the effect of API concentration on the processing history and 
mechanical properties of extrudates.  
4. To study the effect of processing parameters on the performance of 
amorphous solid dispersion prepared using HME.  
5. To identify, confirm and present an indirect analytical method to predict the 
solid state stability of the extrudates prepared using HME.  
6. To understand effect of additives on the performance of amorphous solid 
dispersion products and suggest an alternative strategy to overcome the 
bioavailability issue due to effect of food.   
To achieve the objectives, the research revolved around three main aspects: 
1. Efficient experimental design of HME processing 
2. Characterisation using appropriate off-line and in-line tools for improved 
understanding during processing 
3. Product performance and characterisation.  
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Expected outcomes from the research:  
1. Knowledge about use of study designs (in-line tools) and data analysis for 
HME process for manufacturing of controlled release formulations 
2. In-dept understanding around characterisation (e.g. thermal, rheological, 
spectroscopic and chromatograpic analysis) of HME products.  
3. Understanding effect of process vairables on final product critical quality 
attributes.  
4. Use of additives as a strategy to tackle product perfomance affected due 
to presence of food for solid dispersion using HME. 
 
Figure 1.5 Research outline  
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1.2 Thesis outline 
The current report is divided into eight chapters. Chapter 2 provides a 
background and literature review which is divided into four sections. The first 
section provides information related to poorly soluble drugs, 
biopharmaceutical classification system and solubility enhancement 
techniques. The second section explains the solid state chemistry which is the 
basis for preparation of amorphous dispersions. The third section explains in 
brief about the solid dispersion and methods of preparation. The final section 
provides in-depth information about hot melt extrusion including its 
background, principle, characterisation tools and their applications in pharma 
industry. The report structure is provided in Figure 1.6.  
Chapter 3 gives detailed information about materials and methods. It provides 
the rationale for the selection of API and polymer and their advantages and 
disadvantages. It also describes the processing equipment used and provides 
rationale and parameters for the analytical instruments used.  
Chapter 4 provides a comprehensive study on the material attributes affecting 
formulation developments of amorphous solid dispersion. Physico-chemical 
properties of APIs and polymer were studied and analytical methods to 
characterise the same will be discussed. 
Chapter 5 investigates critical quality attributes affecting the formulation 
development of amorphous solid dispersions using ibuprofen and Affinisol 
100cP as API and polymer. Chapter 5 is further divided into three studies 
which will cover three CQAs of material, process and product attributes.  
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Chapter 6 focuses on formulation of amorphous solid dispersion using 
posaconazole and Affinisol 4M as API and polymer. The chapter is further 
divided into two parts of which 6.1 covers detailed study designs for 
preparation of amorphous solid dispersion using posaconazole. Chapter 6.2 
provides and alternative formulation strategy to overcome food effect on the 
oral bioavailability of posaconazole.  
Chapter 7 covers global conclusions of the studies carried out and provide 
suggestions for future work.  
Chapter 8 provides a list of references used for supporting the research carried 
out. 
 
Figure 1.6 Schematic representation of the research structure 
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Chapter 2: Literature review 
The current chapter will provide relevant background of the topic and the 
literature review on poorly soluble drugs, solid state chemistry, solid 
dispersions and hot melt extrusion (HME). The main aim of the chapter will be 
to provide a brief overview of the need of HME and its advances and 
capabilities. 
2.1 Introduction 
The poor solubility and bioavailability property of active pharmaceutical 
ingredients (API) is one of the prevalent challenges faced during the design 
and development of pharmaceutical dosage forms. Over past two decades, 
poor solubility has become major issue with the new chemical entities (NCEs) 
due to implementation of high throughput screening and combinatorial 
chemistry in the drug discovery process (Baird and Taylor 2012; Vo et al. 
2013). About 80% of the drugs are marketed in the form of oral solids (tablets) 
and around 30-40% of the drugs under development stage have poor 
solubility. The oral route of administration  for drugs is the most commonly 
used due to its high patient compliance, low sterility constraints, flexibility in 
the design of dosage forms and low cost (Baghel et al. 2016). Upon 
administration of the dosage form, drug molecule need to cross barriers like 
dissolution into gastrointestinal fluids (GIT), passing through gut membranes 
and first-pass metabolism in order to reach to the site of action through 
systemic circulation. To categorise the drug moieties based on the solubility 
and permeability parameters, Biopharmaceutics classification system (BCS) 
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was generated. According to the BCS classification system, drug moieties are 
classified into four categories (Figure 2.1). BCS is an indicator of the  solubility 
and permeability of API solely as an aid for post-approval changes based on 
in-vitro data wherever applicable and also during development phase 
(CDER/FDA 2015). 
 
Figure 2.1 Biopharmaceutical classification system 
Based on the seminal work, Amidon postulated that the drug absorbtion in the 
GI tract is controlled by membrane permeability and solubility/dissolution rate. 
The membrane permeability of a particular drug component is calculated 
based on the partition coefficient of the uncharged or neutral state of drug 
molecule between n-octanol and water, which is represented as log P and C 
log P parameters (Dahan et al. 2009). The reference standard for addressing 
high permeability or low permeability boundaries in the n-octanol/water 
partition coefficient for metoprolol (log P 1.72). The drug components having 
log P value greater than 1.72 are categorised as high-permeability 
components because it has been reported that metoprolol undergoes 95% 
absorbtion in the GI tract. To date only 29 reference drugs have been screened 
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for human jejunal membrane permeability and all the experimental and 
calculated values are in good agreement. The permeability of the drug 
component was determined based on the caculated value of log P or C log P 
value of drug component. The solubility parameter of the drug component is 
calculated based on the Dose number (Do), which is the ratio of the highest 
strength of the drug dose in the administered volume (taken as 250 mL= a 
glass of water) to the saturation solubility of the drug in water (mg/L). Drug 
components with Do value <1 are considered as highly soluble drugs where 
as Do value > 1 are considered as poorly soluble drug components. Based on 
the Do value the drug components are classified as low, moderate and highly 
soluble components. 
Recently, it is estimated that 80-90% of the drug components in the R&D 
pipeline may face failure due to low solubility issues (Babu and Nangia 
2011).The drugs with low solubility in the aqueous media over pH range  (~pH 
<7.5) at 37°C ( however high permeability)come under class II BSC 
classification system (Babu and Nangia 2011; Dengale et al. 2016). These 
drugs despite having high permeability  display low oral bioavailability due to 
the slow and delayed release  into intestinal fluids (Vasconcelos et al. 2007). 
A well-known example is Danazol which shows low aqueous solubility 
(approximately 1µg/mL) and needs to be administered with a daily dose of 
600mg/d. Hence to completely dissolve this dose into GI fluids would require 
approximately 200L of aqueous media (physiological pH) which is practically 
not possible considering in vivo conditions. Hence these  poorly soluble APIs 
may exhibit limited absorption as they pass through their absorption site 
(Baghel et al. 2016). As a consquence, formulation scientists focusing on the 
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development of novel, reliable and cost-efficient strategies to enhance the 
apparent solubility/dissolution rate of poorly soluble drugs. For this purpose, 
various approaches have been investigated in the drug development process. 
Most popularly used approaches are  salt formation (Baghel et al. 2016), 
particle size reductions (Rabinow 2004), prodrug approach (Rautio et al. 2008) 
, complex formation (Loftsson and Duchêne 2007) , micelles (Lavasanifar et 
al. 2002), micro and nano-emulsions (Mueller et al. 1994; Fatouros et al. 
2007), solid-lipid nanoparticles (Potta et al.), co-crystallisation (Babu and 
Nangia 2011) and solid dispersion. In particular, solid dispersion is gaining 
significant popularity in the pharmaceutical industry  to enhance the solubility 
and dissolution profile of poorly soluble drugs (Vasconcelos et al. 2007). The 
choice of preferred strategy depends on the physicochemical properties of the 
API and its intended application. 
2.1.1 Solid State chemistry 
Solids are forms of matter which have rigid defined molecular arrangement 
due to their deifinte shape and volume. Strong interactions are observed in 
their intermolecular forces and only vibrate upon application of external force 
and stress. Thus solids are tend to form rigid defined structures called as 
crystals. A crystal structure is a highly ordered and repeating arrangement of 
molecules or atoms held together with non-covalent forces. This property of 
the molecule influences its physicochemical properties. 
2.1.2 Classification of Solid forms  
Two main classifications of solids are amorphous and crystalline solid forms 
(Sekhon 2009). Figure 2.2 illustrates the classification of different solid forms 
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of API into its substituent’s based on its chemical structure, composition and 
molecular arrangements. A solid can exist in two forms either amorphous or 
crystalline. In crystalline form a solid can exist as polymorph, hydrate, solvate, 
or co-crystal. 
Polymorphs arise when molecules of a compound attain different 
conformations with differing energies of stabilisation. Although their chemical 
properties may be the same, they differ in structural orientation. Generally a 
less stable polymorph converts into its stable polymorph. However, the 
conversion may take years or just a few seconds to occur as it depends on the 
activation energy supplied to the polymorph and free energy of that solid. The 
lowest energy form is more stable. Irreversible transition of one form to another 
below the melting point are monotorpic while reversible transitions are seen 
for enantiotropic polymorphs. When the crystal’s repeating arrangement unit 
has a molecule of solvent attached to it then it is called a solvate. When the 
solvate molecule is replaced by water molecule then it is called a hydrate. A 
co-crystal is a distinct solid-state material with unique, unpredictable structure 
and physical property profile.  
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Figure 2.2 Classification of Solid forms based on structure and composition. 
2.2 Cocrystals  
Intermolecular interaction between multi components due to hydrogen 
bonding leads to formation of co-crystals. A prominent rise in the 
commercialisation using co-crystals as a strategy for API stabilisation has 
gained importance in the pharmaceutical sector. This is due to the ability of 
co-crystals to improve physicochemical properties such as solubility, chemical 
and physical stability, dissolution rate and bioavailability without affecting the 
pharmacological activity of the API. FDA guidelines of 2003 define co-crystals 
as a molecular association of two or more ingredients in the same chemical 
crystal lattice (Trask et al. 2006).  
From a pharmaceutical perspective, the multicomponent system will consist of 
an active (API) and excipient (co-former). The co-former is selected on the 
basis of its ability to form weak non-covalent interactions with an API (Jones 
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et al. 2011). Selection of co-former depends on various factors like individual 
component solubility, lattice-free energy, pKa values etc. Several reports are 
published where different approaches like liquid assisted grinding (Trask et al. 
2006), solution crystallisation, spray drying (Mehta 2013), hot melt extrusion 
(Kelly et al. 2012), ultrasound crystallisation (Aher et al. 2010) and supercritical 
fluid (Subramaniam et al. 1997) are used as processing techniques to prepare 
co-crystals.  
Cocrystallisation occurs due to competition of molecular association between 
similar (homomers) or different (heteromers) of functional group of API and co-
former. Co-former selection is guided by its chemical nature. It should posses 
functional moities which can posses the ability to form non-covalent 
intermolecular interactions such as hydrogen bonds, Van-der-waals forces 
and π-π interactions (Jampílek 2012). One approach of selection is by the 
supramolecular synthon approach (Desiraju 1995). Synthon approach is to 
focus on the functional group present on the API and co-former to form a 
supramolecular synthon. Carboxylic acid-acid synthon, amide-amide synthon, 
the acid-pyridine heterosynthon and acid-amide synthon are some of the 
typical supramolecular synthons (Thakuria et al. 2013) (Figure 2.3). 
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Figure 2.3 Types of hydrogen bonding between two synthons (a) acid-acid, (b) 
acid-amine, (c) acid-amide, (d) acid-imide, (e) amide-amide and (f) alcohol-
ether (Thakuria et al. 2013) 
The synthon approach limits itself to only functional group interaction and lacks 
in consideration of factors such as steric hindrance and density, and molecular 
arrangement. To overcome this, other approaches such as use of polar density 
and crystal shape and computational prediction possibilities based on unit cell 
measurements were also used (Thakuria et al. 2013). Currently FDA proposes 
to still consider the selection process on the basis of difference in the pKa 
values which should be less than 3.  
Selection of co-former was the first step in prediction of formation of co-
crystals. These lead researchers to study the mechanisms of co-
crystallisation. Of which, solution state crystallisation, thermal fusion method, 
eutectic and vapour phase, and deliquescence methods were proposed as the 
mechanisms for co-crystallisation (Figure 2.4).   
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Figure 2.4 Proposed mechanisms of co-crystallisation  
Solution state crystallisation is the traditional approach which involves 
solubilising solute within a solvent. Co-crystallisation is achieved on the 
principle of supersaturation where molecule will get just about enough energy 
for molecular rearrangement. This by far is still the preferred choice for scale-
up (Nehm et al. 2006).  
The heat fusion method involves fusion of API and co-former by application of 
thermal energy which works on the principle of mixing within thermal 
depression zone created due to concomitant melting of API and co-former 
(Berry et al. 2008).  
Eutectic or vapour phase mechanism involves generation of co-crystals using 
mechanical grinding. To assist the eutectic mixing, solvent may be added in 
small quantities. In such trials co-crystallisation process occurs during vapour 
evaporation of solvent (Chadwick et al. 2007).  
The deliquescence method involves use of hygroscopicity as a mode for 
achieving co-crystals. Phase transformations between API and co-former are 
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achieved by exposure to humid conditions and co-crystals are formed due to 
molecular rearrangement (Jayasankar et al. 2007).  
To summarise, co-crystals are one of the emerging strategies used for crystal 
engineering. Attempts and guidelines are available for co-former selection. 
Mechanisms are proposed to understand in depth the factors promoting co-
crystallisation. Applications of co-crystals range from enhancement of physical 
as well as chemical properties of drugs (Figure 2.5).  
 
Figure 2.5 Applications of co-crystals 
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2.3 Amorphous systems 
Amorphous means lack of form, and has no long range order of molecular 
packing or conformations (Yu 2001). An amorphous system thus, is actually 
fluid but appears to be a solid in the given time scale observation. Amorphous 
materials play a significant role in different industries ranging from polymers, 
ceramics, food and pharmaceuticals. Amorphous forms are very common for 
certain polymers, proteins, peptides and certain sugars, and they can be 
generated by using certain standard pharmaceutical processes. The 
amorphous phase in the solid state is referred as the high energy solid state 
due to increase in the specific volume and intermolecular energy which 
enhances solubility/dissolution rate. 
Amorphous forms can be generated by using four major ways while 
processing the Pharmaceutical compounds (Figure 2.6) (Hancock and Zografi 
1997). 
 
Figure 2.6 Schematic representations of four common pathways to obtain 
amorphous compounds 
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Pharmaceutical amorphous dosage forms are multicomponent systems 
containing drug substances as the active component and polymeric material 
as an excipient. Figure 2.7 represents the correlation between the enthalpy 
(ΔH) and specific volume (V) of a material as a function of temperature. In 
crystalline materials, we may see at very low temperatures a small increase in 
enthalpy and specific volume with respect to the temperature indicative of a 
certain heat capacity (Cp) and thermal expansion coefficient (α). When a 
crystalline material reaches its melting temperature (Tm) discontinuity in both 
ΔH and ΔV represent a first-order transition to liquid state. Upon rapid cooling 
beyond its melting temperature values of ΔH and ΔV may follow equilibrium or 
first order in “super cooled region”. On further cooling, a change in slope is 
seen at a characteristic temperature called the “glass transition temperature” 
(Tg) (Figure 2.7).Tg is a significant property for the characterisation of 
pharmaceutical solids. At Tg, the properties of the glassy material deviate from 
those of the equilibrium super-cooled liquid to give a non-equilibrium state 
having even higher H and V than the super-cooled liquid (Kumar and Singh 
2013). Tg is a thermodynamic requirement otherwise the system would 
collapse as it will possess the lower enthalpy than its crystalline phase. The 
temperature at which it collapses is called the Kauzmann Temperature (Tk). 
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Figure 2.7 Schematic depiction of the variation of enthalpy (or volume) with 
temperature (Hancock and Zografi 1997) 
The high internal energy and specific volume of an amorphous state can lead 
to an increased dissolution rate and enhanced bioavailability (Randall et al. 
1995; Serajuddin 1999). Amorphous forms on the other hand although 
improve apparent dissolution rate of the poorly soluble drugs but are likely to 
be unstable and there are more chances of them re-crystallising into the stable 
crystalline form depending upon various factors like temperature, humidity, 
pressure and time (Yoshioka et al. 1994). To overcome this drawback, the 
solid dispersion (SD) approach has gained importance and received wide 
acceptance in the pharmaceutical industry. 
2.3.1 Limitations of amorphous form 
Glass transition temperature plays a pivotal role in understanding the stability 
of the amorphous system. By definition glass transition temperature is the 
temperature below which the solid form acts like glass, this term was 
extrapolated from polymer chemistry. Stability issues associated with 
amorphous systems arise due to the relaxation of the glass transition 
temperature, this happens due to a decrease in molecular mobility of the 
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molecules. The amorphous state is not generally preferred by the molecules 
and will tend to crystallise out the moment they receive the necessary energy 
to form bonds. Pharmaceutical stability is limited if the glass transition 
temperature of the API reaches below the environmental conditions due to 
various extraneous parameters such as temperature, pressure, hygroscopicity 
etc.  This acts as a precursor for the molecules to form bonds and get 
converted into thermodynamically stable crystalline phase by releasing 
energy. Thus, the phase conversion remains a limiting factor during the 
formulation of pure amorphous systems; as there is always risk of conversion 
of amorphous form to crystalline form over the period of time. 
2.3.2 Stabilisation of amorphous form 
The dissolution rate of the amorphous form of an API is significantly higher 
than its crystalline counterpart, and thereby shows increased bioavailability. 
The amorphous material is easy to formulate into different dosage forms like 
tablets, capsules, freeze dried powders and gels than the crystalline material 
due to its high internal energy, increased mobility and compressibility. But the 
amorphous state is unstable and hence the molecules try to release the energy 
and recrystallize to a more stable crystalline form. Little change in temperature 
or humidity may largely affect the stability of the dosage form. Various 
pharmaceutical processes affect the final form of the drug.  
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2.4 Solid dispersion 
To overcome the limitation of the amorphous state, an alternative strategy of 
solid dispersions (SD) is generally used. The strategy is to have molecular 
dispersion of the drug and the polymer (Figure 2.8) (Huang and Dai 2014). 
Solid dispersions can also be described as products formed by converting a 
fluid drug-carrier combination to solid state (Craig 2002). One of the key 
shortcomings of the amorphous forms is the low glass transition temperature. 
Solid dispersion overcomes this problem by incorporating the drug within an 
inert carrier with high glass transition temperature. This will in turn increase 
the glass transition temperature of the binary system and makes the final 
system more stable. Solid dispersions therefore provide an alternative 
approach to increase the dissolution rate of the drug in a system stable.  
 
 
Figure 2.8 Overview of solid dispersion process (Kumar and Gupta 2013) 
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Figure 2.9 Types of solid dispersion (Craig 2002) 
Another important aspect related to solid dispersions is the type of system that 
is formed. There are still some uncertainties regarding mechanism of formation 
of different types of solid dispersion. Currently, solid dispersions can be 
divided in to four types  which vary in terms of its final product (Figure 2.9) 
(Craig 2002). 
 Solid solutions are the type of solid dispersions where the drug is present 
as a molecular dispersion with the carrier. This type of solid dispersion is 
difficult to detect as most of the solid dispersions are molecularly mixed at 
lower concentrations. Since the drug is molecularly mixed within the 
polymer the stability of the solid dispersion is highest compared to other 
types of solid dispersion. 
 Eutectic system is the type of solid dispersion in which the drug and carrier 
are uniformly mixed only at a particular concentration to form a solid 
dispersion. In this type of the system the melting point of the eutectic is 
below the melting point of both the drug and carrier alone (Nidhi et al. 
2011). 
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 Glassy matrix systems are those where the drug is in dispersion within the 
carrier. These types of systems are commonly found in the semi-crystalline 
or amorphous polymers. It becomes difficult to predict the dispersion of 
drug whether it is in the crystalline or the amorphous domain of the 
polymer. 
 Monotectic systems are basically those systems where the eutectic point 
and meting depression point of the solid dispersion is overlapping. In this 
type of systems the melting point of the carrier is unchanged in presence 
of the drug moiety   
2.4.1 Factors affecting solubility of solid dispersions 
Another interesting aspect regarding solid dispersions is the type of drug 
release through the drug-polymer matrix. Before moving onto the mechanism 
of drug release it is important to understand the factors affecting the apparent 
solubility of the drug in the particular form of solid dispersion.  Several aspects 
are responsible for the increase in the apparent solubility of the drug.  
1) Particle Size reduction: One of the reason for the increase in the dissolution 
rate of the API molecule in amorphous or solid dispersion form compared to 
the crystalline phase is reduction in particle size due to which the surface 
energy properties are enhanced. Particle size reduction will have a direct 
impact on the specific surface area exposed during dissolution which will in 
turn increase the drug release. Additionally, polymers used as carriers act as 
wetting agents and hence promote dissolution.  
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2) Increased apparent solubility or dissolution rate: Apparent solubility or 
dissolution rate increase depends on various reasons. It could be due to the 
increased solubility of the API solid dispersion because of complex formation 
as seen in the cyclodextrins type of complexes. Another reason could be the 
decrease in the degree of crystallinity having direct impact on the dissolution 
rate of the drug component. 
Understanding the drug release mechanism is important while formulating 
solid dispersions. In binary systems such as solid dispersion, two types of 
release mechanism are possible namely carrier controlled dissolution and 
drug-controlled diffusion (Figure 2.10).  
 
Figure 2.10 Drug release mechanisms during the dissolution process, carrier-
controlled dissolution (left) and drug-controlled dissolution (right) (Craig 2002) 
In carrier-controlled dissolution, the drug molecules dissolve in the diffusion 
layer dominated by polymer; and it will be slowly released either through 
erosion or swelling of the polymer. This type of phenomenon is generally seen 
in the solid dispersion with low drug loadings as they are molecularly mixed at 
low concentrations within the polymer. 
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In drug controlled dissolution, the polymer diffusion layer will be thin and the 
drug will be released as solid particles. Thus, the rate of the dissolution will be 
dependent on the physicochemical properties of the drug and not the polymer 
(Craig et al. 2001). Amorphous solid dispersions are normally considered as 
thermodynamically unstable but can be formulated and processed to adjust 
kinetic stability for the desired shelf life of 24-36 months. Ideally, a solid 
solution type is preferred as there is an absence of any entrapped free 
crystalline drug which can act as nuclei if the system receives some energy. 
There are several processes by which solid dispersions can be prepared (as 
shown in Figure 2.11).  
 
Figure 2.11 Routes of producing solid dispersions  
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2.4.2 Limitations of solid dispersions  
Although Solid dispersions provide an attractive alternative to enhance the 
solubility/dissolution rate of poorly soluble APIs, however it has few limitations 
(Vasconcelos et al. 2007):  
 Processes development and optimisation: The process to prepare solid 
dispersion requires stringent controls of temperature; solubility, miscibility 
etc. hence are not easy to develop and optimise.  
 Repeatability and reproducibility: It is possible that products obtained can 
vary in surface properties and hence it is difficult to obtain a product in a 
reproducible manner.  
 Solid and solution state stability: In the solid dispersion system there is 
always some change of the drug crystallisation. As drug is entrapped in 
the amorphous state (high energy state) and as soon as it receives 
sufficient energy from extraneous factors it crystallises out. However, this 
process also depends on the kinetics and use of suitable 
polymers/stabilisers can suppress this process.  
 Selectivity: Not all drugs are suitable for solid dispersion technique due to 
several constraints. Thermo-labile drugs cannot be formulated using hot 
melt extrusion, and drugs with poor solubility in organic solvents can be 
processed using solvent evaporation technique. 
2.5 Screening techniques for amorphisation 
The methods used to convert crystalline forms of drugs into amorphous forms 
are categorised into two types 
In the first type, the stable crystalline API or material is converted into an 
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unstable noncrystalline material form by quench cooling, melt amorphisation 
or through the rapid precipitation using spray drying. In the second type, 
transformation of crystalline material into amorphous form is mechanically 
performed through molecular disruption such as milling.  
In the first type of mechanism, using the solubilisation or melting of API the 
crystalline properties are completely lost in the intermediate phase (which is a 
solution or melt phase); while in the second case the crystalline property is not 
lost completely due to incomplete loss of molecular arrangement. It should 
also be noted that amorphous material or solid dispersions prepared using 
different techniques may exhibit different physicochemical properties 
(Hancock and Zografi 1997). One of the example is of Simvastatin (BCS class 
II). When this API was cryo-milled it exhibited lower recrystallisation rate and 
low solubility compared to quench cooled samples (Yu 2001). Karmwar et al., 
reported that cryo-milled indomethacin exhibited low stability compared to the 
quench cooled amorphous form (Angell 1995; Saleki‐Gerhardt et al. 1995; 
Dahan et al. 2009). The properties of amorphous material prepared using 
different techniques can be measured on a molecular level using solid-state 
NMR (ss-NMR) or tetrahertz spectroscopic tools (Karmwar et al. 2011; Otsuka 
et al. 2012). 
Based on the annealing time and the route used to produce amorphous 
materials a term called “polyamorphism” has been derived.  Polyamorphism is 
also described as the presence of different amorphous phases which are 
separated by first-order phase transition, and further investigation is needed 
to understand the complexity associated with this terminology (Angell 1988; 
Patterson et al. 2005). Besides, the possibility of the presence of different 
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phases of amorphous materials (polyamorphs), a new concept of Rigid 
Amorphous Fraction (RAF) has been derived based on the intermediate phase 
between crystalline and amorphous stage. The RAF phase in  amorphous 
material is very closely associated with the crystalline phase thus the striking 
difference between the RAF  and pure amorphous material is that, an 
amorphous material consisting of  RAF phase will exhibit a very narrow change 
in the heat capacity (ΔCp) and glass transition temperature  Tg as compared 
to the same amorphous material without RAF (Craig et al. 2001).  
2.5.1 Amorphisation- solution based techniques 
2.5.1.1 Melting and quench cooling 
This is a relatively simple and conventionally used technique to prepare 
amorphous material. In this technique the molten API is suddenly frozen below 
the freezing point of the materials using liquid nitrogen in a Dewar flask. DSC 
coupled with a chiller unit is also used to generate amorphous materials using 
the same principle.  
The stability and purity of the amorphous material is based on the time needed 
to lower the temperature below the freezing point of the material. Sudden 
decrease in temperature results in the hindering of the molecular motion or 
rearrangement of the molecules, and hence upon cooling a significantly 
disordered state is obtained as the process of crystallisation is hindered. 
Slower rate of cooling provides longer time to the molecules for the 
configurational changes at a given temperature and hence enthalpy value of 
the end product varies from the starting material. Hence the rate of cooling 
should be optimised as material may crystallize out during this cooling step. 
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Thermal degradation of API and excipients is a major drawback using this 
approach (Angell 1988). The PXRD pattern of crystalline and amorphous 
Itraconazole (ITZ) is shown in Figure 2.12 and it highlights the difference in 
crystalline and amorphous phases of the drug. The crystalline ITZ is 
represented by characteristic PXRD peaks while the amorphous material 
domed shaped pattern is observed.  Quench cooling or cryo-grinding for 30 
min results in the loss of crystalline phase and disruption of the crystal lattice. 
The loss of peaks in the PXRD confirms the formation of amorphous phase 
(Engers et al. 2010). This approach has been successfully used to prepare 
amorphous forms of APIs and excipients (Liu et al. 2002).  
  
Figure 2.12 Overlay of PXRD pattern (top to bottom) of melt-quenched cooled 
Itraconazole (ITZ), cryo-ground ITZ and crystalline ITZ (Engers et al. 2010) 
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2.5.1.2 Spray drying 
In this solution based approach, an amorphous material is prepared by 
solubilisation of an API into a suitable solvent followed by solvent evaporation. 
Amorphous material is produced either alone or in combination with excipients 
such as polymers. The important parameters to be considered to obtain stable 
amorphous material using this approach are feed rate, inlet/outlet 
temperature, concentration of solution, droplet size (atomiser rate) and drying 
temperature. Figure 2.13 schematically represents the spray drying setup and 
lists critical instrumental and process parameters to produce a desired end 
product (Chiou et al. 2008). 
 
Figure 2.13 Schematic representation of spray drying setup and list of different 
parameters  
In this technology,  saturated solution, suspension or emulsion of API alone in 
combination of polymer/API solution is pumped to the atomiser device which 
leads to the formation of droplets. The chamber is heated using a hot air 
stream which leads to evaporation of the solvent when droplets come in 
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contact with the hot air stream. This results in the formation of dry mass which 
is suspended in the hot air stream. The crystallisation of the solid dispersion 
material within the spray dryer may occur in the liquid phase when the droplet 
is dried leading to an increase in the concentration of solute above its solubility 
limit, or in a solid amorphous state. The rate of solid-state crystallisation is 
based on the difference between the particle temperature and its Tg. The rate 
of solvent evaporation is an important factor which controls the extent of 
nucleation; higher solvent evaporation implies enhanced transfer of thermal 
energy per unit time to the solute molecule present in the droplet. Thus at 
higher solvent evaporation the solute component undergoes turbulent 
molecular motion and faster diffusion within the particle droplet which can 
prevent the formation of three-dimensional crystalline phase. Not all spray 
dried materials display the similar trend, an increase in the inlet air temperature 
to 134-210°C resulted in a higher degree of crystallinity for spray dried lactose 
(Chiou et al. 2008). This process could be challenging for drugs with relatively 
low Tg to obtain a stable amorphous material; as external temperature could 
be higher than the Tg and in such cases final product obtained may be a partly 
amorphous, super cooled rubbery mass as  this type of rubbery material may 
be sticky in nature which ultimately affects the product recovery and thereby 
results in the poor process yield (Takeuchi et al. 1987; Broadhead et al. 1992; 
Takeuchi et al. 2004; Haque and Roos 2005). Spray drying is widely used in 
the pharmaceutical industry to produce amorphous materials.  
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2.5.1.3 Freeze drying 
This technique is a sublimation process also called lyophilisation. It is a widely 
used  technique  in the pharmaceutical industries for the development of 
parenteral products where drying at low temperature is preferred (Liu 2006). 
In this approach, formation of water crystals (ice) occurs at low temperature 
and it is followed by sublimation of water vapour from the solid state at reduced 
pressure.  Conversion of crystalline to amorphous state involves preparation 
of concentrated solution which is dried at low temperature and high pressure 
conditions.  Based on the cooling rate, solutes from certain solutions may 
crystallise out during the freezing step. The solutes which do not crystallise get 
converted in to the amorphous phase due to a decrease in temperature below 
the individual transition temperature of maximally concentrated solute 
(Bhardwaj and Suryanarayanan 2012). At the end of the freeze-drying process 
the solvent is completely removed through sublimation, amorphous or partially 
amorphous material is formed. The transition temperature of the end product 
is determined based on the composition of the formulation and residual water 
content, which acts like a plasticiser lowering the Tg (O'Donnell and Woodward 
2015).  
2.5.1.4 Flash evaporation /Rotary evaporation  
Solvent evaporation is the key limiting step which governs the stability of 
products such as solid dispersions. Heating of solvent mixtures may have an 
impact on the phase separation due to increased molecular mobility. Thus, 
vacuum dryer and rotary evaporators are preferred for solvent evaporation. 
These processes are carried out at moderate temperatures to restrict the 
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thermal degradation of the solid dispersions. A major  disadvantage of these 
processes is that they are time-consuming and can act as precursor to phase 
separation of solid dispersion and the process is also not scalable (Bennett et 
al. 2015). 
2.5.1.5 Supercritical fluid processing  
In this process, supercritical carbon dioxide is used as a solvent system to 
solubilise the drug/mixture of drugs and excipients. The mixture is sprayed 
through a nozzle into an expansion vessel where low pressure conditions are 
maintained. The only difference between supercritical fluid processing and 
spray drying is the use of supercritical carbon dioxide to replace organic 
solvents. The rapid expansion and drying of materials leads to formation of 
amorphous materials or solid dispersions with different particle size 
distribution (Moneghini et al. 2001). The major drawback of this process is the 
difficulty in optimization of process parameters and selectivity of the solvent 
and drug component. 
2.5.2 Amorphisation- Solid-state techniques 
2.5.2.1 Dehydration of crystalline hydrates 
This approach is reported as a simple and feasible route to obtain an 
amorphous phase of organic molecules (Saleki‐Gerhardt et al. 1995). Hang et 
al.,  reported the formation of the amorphous raffinose by heating raffinose 
pentahydrate at 60°C under vacuum conditions., The product obtained by this 
approach was similar to lyophilised raffinose (Li et al. 2000) They 
demonstrated the formation of amorphous carbamazepine by heating 
crystalline carbamazepine dihydrate at 45°C under a nitrogen environment. 
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The resultant amorphous state of carbamazepine undergoes glass transition 
at 56°C, which is higher than the drying temperature (45°C). Upon further 
heating at 86°C, the crystalline phase is crystallized out. Recently Hang Li et 
al., has investigated the formation of the amorphous phase of crystalline 
polymorph of trehalose dihydrate upon dehydration (Li et al. 2000). Thus, 
dehydration of crystalline hydrates can be used as a potential route to 
amorphisation. Drying of crystalline hydrates of organic materials may impact 
the physical and chemical stability due to the loss of crystallinity 
2.5.2.2 Milling 
Milling is a widely used process for particle size reduction in the 
pharmaceutical industry (G.Cole; Parikh 2005). This process is also named 
grinding or comminution in the processing industries. Particle size reduction 
leads to an increase in the surface area of poorly soluble drugs and hence an 
increase in dissolution rate and bioavailability can be achieved (R.Liu 2008).  
Milling instruments used in pharmaceutical processes can be divided into three 
categories based on the mechanism of energy transfer between the materials 
as follows: ball milling, shock action milling, and shear action milling. During 
the milling process, the materials undergo different deformations due to shear 
and stress conditions.  Initially materials undergo elastic deformation followed 
by plastic and shear deformation and finally partially or completely amorphous 
materials can be obtained. Figure 2.14 below represents the milling process.  
In the ball milling process, the energy transfer to the material subjected to 
micronization occurs through balls (milling bodies or impellers) where the 
materials are exposed to normal shear and stress conditions. In shear action 
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milling the material is ground by directly crushing with mechanical crushing 
elements. On the other hand, in case of shock action milling the energy is 
directly transferred to the materials; this occurs through collision of materials 
which leads to generation of heat and stress energy between the particles and 
enables them to undergo structural and configurational deformation. 
  
Figure 2.14 Schematic presentation of (a)milling process, (b)effect of milling 
on spherical particles (Jung et al. 2013) 
Although the milling process is a widely used approach to reduce particle size, 
it is also accompanied by certain drawbacks. Milling results in unintended 
changes in morphology or crystal habit and crystallinity of materials (R.Liu 
2008; Jung et al. 2013). It can also impact polymorphism and glass transition 
temperature as well as chemical stability of the milled material. Researchers 
have investigated the effect of temperature on milling, especially the 
relationship between the temperature of milling and Tg of the corresponding 
materials. It is postulated that, when cryo-milling is performed below the Tg of 
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the materials that the amorphous form is generated while operation at 
temperatures above the Tg  results in polymorphic transformation (Willart et al. 
2004; Willart et al. 2006; Descamps et al. 2007).    
Co-milling:- In order to accelerate amorphization and solid state stability, drug 
and excipients are employed together in the co-milling process. Stable solid 
dispersions of indomethacin were produced by this process using 
polyvinylpyrrolidone or silica as an excipient (Dong et al. 2010).   
2.5.2.3 Vacuum compression moulding   
Film casting is one of the easiest methods used to prepare amorphous 
materials/solid dispersions. Film casting involves melting of the API-polymer 
mixtures above their eutectic point to form a solid dispersion upon cooling. 
API-polymer mixtures are fused together to form a miscible hot liquid, which is 
cooled down or solidified using different techniques.  
This method benefits from being solvent free and is a quick way of preparing 
amorphous materials. A hot-press coupled with a vacuum chamber is used for 
this approach; amorphous materials are produced by varying temperature and 
pressure conditions as required. Samples are placed between a separating 
foil (PTFE coated glass fibre foil) and further subjected to temperature and 
pressure cycles where the sample material is melted and compressed to form 
an amorphous material. This technique is often implemented in the 
pharmaceutical industry to control the rheological properties of the amorphous 
material. 
MeltPrep is an advanced version of the film casting process, where vacuum 
compression moulding (VCM) is used to prepare amorphous thermoplastic 
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specimens. This technique minimises heat pressure and mechanical stress to 
the solid materials and chances of degradation are lower. Figure 2.15 
describes different settings and assembly of MeltPrep process (Treffer et al. 
2015). Film casting is a method of choice for the feasibility studies; however it 
has some limitations as it could adversely affect the stability of the material. 
The major limitation of the technique is its suitability only for the drug-polymer 
combinations with acceptable solid state miscibility and solubility. It is not 
suitable for polymers with high melting point and molecular weight. 
Furthermore, solid state mixing of the blends is not easy and can result in 
phase separation. 
 
    
Figure 2.15 Description of different components of vacuum compression 
moulding VCM, b: Setup design of vacuum  compression moulding -MeltPrep 
(Treffer et al. 2015) 
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2.6 Hot melt extrusion (HME) 
Hot-melt extrusion (HME) is another widely used process for the 
amorphisation of the APIs. This technique is extensively used in plastics 
industry and gaining importance in the pharmaceutical industry to obtain 
different solid phases of drugs such as cocrystals, polymorphs, and 
amorphous solid dispersions. The hot melt extrusion  process involves feeding 
the material (API or API/excipient) into the feeder using a rotating screw at 
high temperature to force the material through a die to form amorphous 
product (Qi et al. 2008). This process offers many advantages over other 
technologies, as it is a continuous, solvent free and scalable. In this process, 
drug moiety alone or in combination with excipients (especially polymer matrix) 
can be used to generate amorphous materials. In the HME process, the 
polymer acts as a solid solvent for the drug molecules to become miscible in 
the polymer matrix and generate amorphous solid dispersions. During the 
extrusion process, the molten polymer acts as a drug-depot or thermal binder 
to lower the transition temperature so that the process takes place at lower 
temperature and shear conditions (Crowley et al. 2007). Solid state mixing of 
the two or more ingredients may impact the success of the process 
significantly. In an ideal case, the drug should be molecularly dissolved within 
the polymer matrix to produce a solid solution. Often plasticisers are added to 
aid in the mixing process and to lower the Tg of the drug-polymer blend; this 
can also result in raising the softening temperature of the drug-polymer blend. 
Two types of the extruders are used in the HME process ram extruders and 
screw extruders. In case of screw extrusion, rotating screws (single and twin 
screw) are placed inside a heated barrel; while in case of the latter extruder a 
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positive displacement capable of generating high pressure to push the 
material through the die is used. Figure 2.16 shows the schematic 
representation of twin screw extrusion process.  
 
Figure 2.16 Schematic presentation of extrusion process in rotating screw 
extruder  
2.6.1 Background and need in pharma 
There is a long history of extrusion in the food and plastics industries. The first 
ram extruder was developed in 1845 in England by Henry Brewley and Richar 
Brooman for wire coating. Ram extruders are batch extruders and with growing 
demand for continuous processing, the single screw extruder was first 
patented by Mathew Grey in 1879 (Crowley et al. 2007). This lead to increase 
in the use of single screw extruders and by 1881 multiple extruders appeared 
in the market. The first counter rotating twin screw extruder appeared in 1916 
(Herrmann 1972).  
While using the ram extruder, material is placed in a heated cylinder; and once 
the material softens a ram (piston) pressurises the soft material through a die 
to produce materials with a desired shape (Perdikoulias and Dobbie 2003).  
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Major drawbacks of ram extrusion are lack of material homogeneity and poor 
temperature uniformity due to the limited melting capacity of the instrument.  
Twin screw extrusion is most widely used design in pharmaceutical 
processing; it has several advantages over single screw extrusion such as 
easy material feeding, high kneading and dispersing capacities.  
The extrusion process however was first applied in 1969 in pharmaceuticals 
by Rippie and Johnson (Rippie and Johnson 1969) where drug release was 
studied with respect to the effect of pellet geometry. Since then, there have 
been numerous studies reporting the use of HME in pharmaceutical 
formulations (Forster et al. 2001; Patterson et al. 2005; Dong et al. 2008; 
Maniruzzaman et al. 2012).  
Many conventional pharmaceutical processing techniques had major 
drawback of increased solvent use. Solvents are prone to be harmful for the 
human consumption hence most of the regulatory bodies have set limits for 
commonly used solvents. Especially for amorphous formulations, solvent 
entrapped during processing can act as a precursor for recrystallisation of the 
API. Hot melt extrusion provides an attractive alternative single-step green 
technology for pharmaceutical development.  The versatility of HME is 
explained in Figure 2.17. Solubility enhancement is achieved by using HME 
for preparation of solid dispersion.  
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Figure 2.17 Applications for HME in pharma industry 
Although first use of HME in pharma was reported in 1969, it took many years 
to consider HME as a viable process for product development. This can be 
correlated with the slow emergence of solid dispersion as strategy and linked 
to the lack of approved polymers suitable for HME. This is highlighted by the 
relative lack of approved products in the market prepared by HME. A few 
commercially marketed products can be seen in Table 2.1 (Shah et al. 2013; 
Patil et al. 2016).  
Product name Treatment HME purpose Company 
Lacrisert® (Opthalmic 
Insert) 
Dry eye 
syndrome 
Shaped 
system 
Merck 
Resulin® Hyperglycemia Oral IR tablet Parke-
Davis 
Zoladex™ (Goserelin 
Acetate Injectable Implant) 
Prostate 
cancer 
Shaped 
system 
AstraZene
ca 
Implanon® (Etonogestrel 
Implant) 
Contraceptive Shaped 
system 
Organon 
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Gris-PEG (Griseofulvin) Anti-fungal Crystalline 
dispersion 
Pedinol 
Pharmacal 
Inc. 
NuvaRing® (Etonogestrel, 
Ethinyl Estradiol depot 
system) 
Contraceptive Shaped 
system 
Merck 
Norvir® (Ritonavir) Anti-viral (HIV) Amorphous 
dispersion 
Abbott 
Laboratori
es 
Kaletra® (Ritonavir/Lopina
vir) 
Anti-viral (HIV) Amorphous 
dispersion 
Abbott 
Laboratori
es 
Eucreas® (Vildagliptin/Metf
ormin HCl) 
Diabetes Melt 
granulation 
Novartis 
Zithromax® (Azythromycin 
enteric-coated 
multiparticulates) 
Anti-biotic Melt congeal Pfizer 
Orzurdex® (Dexamethason
e Implantable Device) 
Macular 
edema 
Shaped 
system 
Allergan 
Fenoglide™ (Fenofibrate) Dyslipidemia MeltDose® (sol
id dispersion) 
Life Cycle 
Pharma 
Anacetrapib 
(Discontinued) 
Atherosclerosi
s 
Amorphous 
dispersion 
Merck 
Posaconazole  Antifungal Amorphous 
dispersion 
Merck 
Table 2.1 Marketed products of HME 
Lacrisert® was one of the first marketed ophthalmic insert prepared using 
HME. It was prepared and manufactured by Merck in 1981 using hydrophilic 
polymer hydroxypropyl cellulose (HPC). Although, the first insert was 
approved in 1981, it took pharmaceutical industry sixteen years to come up 
with conventional solid tablet using HME. In 1997, Parke-Davis prepared and 
manufactured Resulin®. It is an oral immediate release tablet where 
troglitazone API used to lower insulin level was used along povidone as 
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polymer of choice. Since then, a lot of pharmaceutical companies started 
evaluating HME as an alternate process for preparation of solid dispersions. 
A contraceptive vaginal ring was with ethinyl estradiol and etonorgestrel was 
prepared and manufactured by Merck. Coaxial fibres were prepared using hot 
melt extrusion using ethylene vinylacetate as polymer. Abbott laboratories 
came up with first drug combination tablets prepared using HME. Kaletra® 
which contained lopinavir and ritonavir as APIs was prepared and 
manufactured using copovidone as polymer to make an immediate release 
oral tablet. Pfizer came up with targeted enteric coated multi particulates 
Zithromax®. Azythromycin was the API used as an antibiotic was extruded 
using hydrophilic polymer HPMC. In 2013, Merck prepared and manufactured 
Noxafil. Noxafil® contains posaconazole and uses hypromellose acetate 
succinate (HPMCAS) to form amorphous solid dispersion using HME. The 
extrudates formed are further milled and other excipients were added to form 
oral tablets which were enteric coated for immediate drug release in small 
intestine. Detailed history about Noxafil® will be discussed in chapter 6.  
Although, with shrinkage of NCE market and growing generic competition 
pharmaceutical companies have finally started acknowledging HME as an 
alternate choice. More drug candidates in pipeline are checked for its feasibility 
with HME. Additionally, polymer companies are conducting extensive research 
with already pharmaceutical approved polymers and preparing similar 
monomer analogues which would be suitable for HME processing.  
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2.6.2 Mechanism of Hot Melt Extrusion 
In HME, the drug/API is homogenously mixed with the polymer and melted in 
eutectic proportions to form a uniform dissolved state or softened phase which 
is then passed through a die to form extrudes (Qi et al. 2008). 
 
Figure 2.18 Typical Hot Melt Extrusion Process (Michael M. Crowley 2007).  
Solid state mixing is pre-requisite for a robust HME process. In HME, polymer 
acts as a solid solvent for the drug molecules. In an ideal case, the drug should 
be molecularly dissolved within the polymer matrix to give rise to solid 
dispersion solution. Sometimes to aid this mixing, plasticisers are used. 
Alternatively, plasticisers are used to lower the glass transition temperature of 
the drug-polymer blend and/or raise the softening temperature of the drug-
polymer blend. The crystal lattice energy of the crystalline material must be 
exceeded to form a stable amorphous material. Furthermore, the drug and 
excipients (polymer component) must be blended and co-dispersed 
subsequently. This step is performed in the extrusion process by applying 
shear stress to both the components. The crystal lattice energy is exceeded 
because of the temperature and energy generated due to the friction through 
78 
 
shear stress ; it further leads to softening of the polymer matrices.  Rotating 
screws and various kneading elements lead to the desired amorphisation; and 
precise selection of process parameters as well as drug-excipient combination 
leads to formation of the stable amorphous solid dispersion (K.Kolter 2012). 
A typical extruder can either have a single screw or twin screw conveyor 
(Figure 2.18 and 2.19). Twin-screw extruder have several advantages like 
easier material feeding, high kneading, dispersing capacities, less tendency to 
over-heat and decrease in residence time over single screw extruder. 
Depending on the orientation of the screws, shear and mixing can be varied. 
The screws are the main components of HME and along with temperature are 
responsible for formulation of solid dispersion in a single continuous process. 
Generally, dimensions of screws are given by L/D ratio i.e. length of the screw 
divided by the diameter. Typically, the screw configuration ranges from 20 to 
40:1 in L/D ratio (Michael M. Crowley 2007). Screw configuration is assembled 
using various elements of the screw which are responsible for feeding, mixing, 
compression and metering. The screws are thus further classified into two 
types of elements; conveying and kneading elements (Figure 2.20) (Dhumal 
et al. 2010). Typically, kneading elements are responsible for adding more 
shears to the process and are further classified as 30°, 60° and 90°. Conveying 
elements are responsible for pushing the mixture ahead towards the 
discharge. Orientation of the kneading elements governs the shear rate and 
uniform mixing of the melt (Dhumal et al. 2010). Table 2.2 outlines the 
application of the screw elements. A combination of the conveying and 
kneading elements is one of the critical parameters for HME. Each screw 
element has certain advantages either in conveying or mixing. A certain 
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combination of these can help serve the purpose of shear and mixing 
depending on the need for the drug-polymer blend mixing for the HME. 
 
Figure 2.19 Schematic Diagram of twin screw extruder 
 
Figure 2.20 Configuration of Twin screws (Top left), screw elements (Right), 
and mixing zones (Bottom left) (Dhumal et al. 2010) 
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Table 2.2 Application of screw elements (Daurio et al. 2014) 
The hot melt extruder can be divided into four zones viz. (Daurio et al. 2014)  
1. Feed: Input materials are placed in the feed either as a physical mixture of 
the drug and polymer or are placed separately in the feed.  
2. Melting zone: Predominately, this screw orientation in the zone is made up 
of only conveying elements. Temperature for this zone should be kept 
according to the melt of the physical mixture of the drug and polymer.  
3. Mixing Zone: This is the most important zone. The type of solid dispersion 
formed is dependent on the uniform mixing of the melt. Screw configuration of 
this zone consists of only kneading element (Figure 2.20). Orientation of the 
kneading elements governs the type and texture of the solid dispersion 
product.  
4. Homogeneous Discharge: If a uniform solid dispersion melt mix or eutectic 
mix is formed in the mixing zone then discharge zone is responsible for 
conveying of the melt. The screw configuration of this zone consists of only 
metering elements. Additionally, this zone is responsible for uniformly passing 
the mix through die to produce the extrudates. 
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2.6.3 Selection of drug candidate  
Despite the various advantages offered by HME, it still remains a niche 
technique for certain type of drugs. There are certain aspects related to the 
drug properties which need to be taken in to consideration before proceeding 
with the HME formulation strategy. Figure 2.21 outlines the typical properties 
which the drug candidate must have to be considered for HME. 
 
Figure 2.21 Selection of drug candidate for HME (Michael M. Crowley 2007) 
Hence, HME can be selected as a formulation strategy provided the drug 
candidate does not melt with degradation, have suitable glass transition 
temperature, is not a pseudo-polymorph and is lipophilic in nature.  
2.6.4 Polymer selection for HME  
One of the main reasons for the slow uptake of HME in the pharmaceutical 
industry is the selection of polymer. Not many polymers typically used in the 
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Pharma industry were specifically developed for HME. Most them were 
prepared for the conventional process like granulation, roller compaction etc. 
The role of polymer as excipients can be outlined as follows:  
1. Polymer needs to act as a solvent or co-solvent.  
2. They should have a solubilising or wetting effect.  
3. Should exhibit thermoplastic behaviour.  
4. Should have weak to strong interactions with the API.  
5. Should offer wide range of glass transition temperatures.  
6. Offer a broad range of dissolution behaviours.  
Thermoplastic properties for the polymer are summarised in table 2.3 
 
Table 2.3 Selection of Polymer for HME 
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2.6.5 Pre-formulation and characterisation  
Due to its selectivity, there is a need for deeper understanding of drug and 
polymer of choice. Thus this makes pre-formulation studies for HME important. 
There are two main challenges for extrusion chemical stability of the drug 
substance and physical stability of the drug substance.  
1. Chemical stability of drug substance: 
Stability of the drug in consideration should be closely monitored during HME 
as it is typically carried out at elevated temperatures. Degradation of the drug 
thus poses a serious threat in consideration of HME as a formulation strategy. 
Degradation can occur by three mechanism hydrolysis, solvolysis and 
oxidation (Michael M. Crowley 2007). For hydrolysis and solvolysis to take 
place, the presence of water or solvent is needed. Since HME is a solvent free 
technology, hydrolysis and solvolysis generally are not the most likely 
mechanisms for degradation. On the other hand, oxidation which is a free-
radical chain reaction is reported to cause significant degradation during HME. 
Formation of peroxides of the drug and polymer during extrusion can have a 
direct effect on the chemical stability of the product and thus decrease its 
potency. Addition of antioxidants have been shown to significantly decrease 
the oxidation phenomenon but that means inclusion of an excipient in the 
binary solid system to make it ternary which can affect the miscibility and 
solubility of the product.  
2. Physical stability of drug substance 
In HME the drug and polymer are subjected to elevated temperatures, which 
increase solubility between the drug and polymer. The drug either melts and 
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mixes with the polymer or solubilises within the polymer matrix to for solid 
dispersion. Re-crystallisation of the drug can occur upon cooling of the 
extrudate. Thus, studying solid state solubility and miscibility becomes 
important for prediction of the stability of the solid dispersion. DSC and DMA 
are the techniques of choice which are proven to detect glass transition 
temperature of the solid dispersion and help in determination and confirmation 
of the miscibility of the drug within the polymer. Confirmation of the 
concentration of the drug within the solid dispersion can be carried out by 
chromatographic techniques. Table 2.4 provides an overview of the pre-
formulation studies along with characterisation techniques needed for HME 
(Sarode et al. 2013; Tian et al. 2013):  
Parameters Characterisation 
technique 
Potential Outcome 
Glass Transition DSC, DMA Miscibility determination and 
type of solid dispersion 
prediction 
Solubility Parameter  Van Krevelen and 
Hoftyzer’s solubility 
parameters 
Solubility predictions for 
eutectic mixture. 
Fragility index DSC Understanding the type of 
glass formed by the drug 
Solid State 
Characterisation 
DSC,TGA, XRD, Raman, 
FTIR, Viscometers, SEM 
and Solid State NMR 
Form confirmation, Raw 
materials characterisations 
and solid dispersion 
confirmations 
Miscibility Predictions Fox Equation or Gordon-
Taylor Equation 
Miscibility prediction of the 
solid dispersion 
Related substance  HPLC, UPLC and TGA Determination of Impurity 
levels  
In-vitro Dissolution Dissolution Apparatus Dissolution profiling 
Table 2.4 Pre-formulation studies along with characterisation techniques 
needed for HME 
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2.6.7 Process analytical technology (PAT)  
According to the revised FDA’s process analytical technology (PAT) guidance, 
ICH Q8, Q8 (R2), Q9 and Q10 guidelines, it is mandatory to provide the 
robustness of the process by providing a design space according to the Quality 
by Design (QbD) concept (Wu et al. 2011). In QbD concept, the impact of the 
raw materials and processing parameters on the critical quality attributes 
(CQA) of the products needs to be studied and demonstrated (Wu et al. 2011). 
Pharmaceutical processes are generally not univariate in nature and hence 
have a lot of critical factors/variables for consideration (Wu et al. 2011). For 
formation of a robust design space, understanding the impact of all the critical 
factors affecting the critical quality attributes (CQA) is of utmost importance. 
Following Fig 2.22 lists down the typical variables in HME process which have 
a significant impact on the critical quality attributes (CQA) of the HME 
products.  
  
Figure 2.22 Typical process variables of HME affecting Critical Quality 
Attributes (Vigh et al. 2014) 
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Independent variables are those which have a direct impact on the critical 
quality attributes of the product. Dependent variables are those which can be 
considered as responses to the independent variables (Montgomery 2000). 
For understanding the effect of critical process parameters on the critical 
quality attributes, design of experiments or multivariate analysis is carried out. 
Depending on the criticality, level of the factorial design is fixed (Montgomery 
2000). A full factorial design provides insight on effect of single parameter as 
well as interaction between parameters. 
 Process analytical technology (PAT) is defined by US FDA as mechanism to 
design, analyse, and control pharmaceutical manufacturing processes via 
measurement of critical process parameters that affect critical quality 
attributes (Patil et al. 2016). Ultimate goal of PAT is to select and develop 
methods which will help in complete understanding of the HME process and 
provide data to track consistent quality of the product. For determination of the 
design space, on-line, in-line and at-line monitoring of the process using non-
destructive tools like spectroscopic probes are used which helps in 
understanding the uniformity of the process by providing data for statistical 
evaluation (Wu et al. 2011). This helps in understanding the critical process 
parameters (CPP) and forming of a robust design space. At-line 
measurements are the ones where sample is removed from the process and 
analysed. On-line measurements are those where sample is removed for 
analysis and re-circulated back in the manufacturing process after analysis. 
In-line measurements provide near-real time data and sample is analysed by 
invasive or non-invasive techniques within the process.  
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Due to recent advances and stringent regulations PAT has gained much 
attention and application in pharmaceutical industry (Wahl et al. 2013; Hitzer 
et al. 2017; Repka et al. 2018). Kelly et al. studied real time measurement of 
melt rheology to track the API within polymer matrix during HME (Kelly et al. 
2018). Critical process parameters of HME were investigated using in-line 
responses of torque, shear and extensional rheometry (Kelly 1997; Köster and 
Thommes 2010; Aho et al. 2015; Aho et al. 2016). However, these PAT tools 
are important when there is solid state insolubility between drug and polymer.  
Drug degradation and solid state purity are two main critical quality attributes 
during HME which can have a direct impact on the product performance. 
Hence, tracking of these attributes through non-invasive spectroscopic tools is 
on the rise (Troup and Georgakis 2013; Wahl et al. 2013). Several studies 
have been reported about use of NIR and Raman spectroscopy as PAT tools 
of choice for HME (Tumuluri et al. 2008; De Beer et al. 2011). Non-invasive 
spectroscopic studies were also used for investigation of drug-polymer 
interactions and quantifications (Saerens et al. 2011; Saerens et al. 2012; 
Martínez et al. 2013). API quantification, solid state tracking and purity were 
also monitored using NIR and Raman spectroscopy (Saerens et al. 2014; Vigh 
et al. 2014; Netchacovitch et al. 2015; Netchacovitch et al. 2017; Park et al. 
2017). Apart from the conventional uses, non-invasive spectroscopic 
techniques were also used for confirmation of co-crystals and solid-state 
transformation (Kelly et al. 2012; Islam et al. 2015; Van Renterghem et al. 
2017a). Another important process variable is mean residence time (MRT) 
which will be discussed in chapter 5.2.     
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2.6.7 Advantages of HME  
HME provides an attractive alternative green technology process for 
formulation of poorly soluble drugs. Advantages include:  
1. Improved solubility of many drug substances (BCS class II and IV). 
2. Drug release retardation possible. 
3. Uniform mixing. 
4. Fewer processing steps. 
5. Continuous processing/ High throughput.  
6. No solvents required-no drying step required. 
7. Short residence time. 
2.6.8 Challenges and Shortcomings  
Although there are a lot of positives for formulating poorly soluble drugs using 
HME, there are some shortcomings as well (Shah et al. 2013):  
1. Not viable for thermolabile materials (drug/polymer). 
2.  Limited number of polymers available.  
3.  Typically limited to drug loading NMT 40 %. 
4.  Thermodynamically unstable.  
5. Potential for polymorphic transition (conversion of forms of drug). 
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2.6.9 Summary  
Hot Melt Extrusion (HME) provides an attractive alternative single-step green 
technology for pharmaceutical development. However, the process is 
selective in nature and requires a lot of process optimisation. To overcome 
this, there is a great need for profound understanding of the drug and polymer 
of interest. Recent advances in its suitability have led a lot of major 
pharmaceutical drug makers to invest heavily in its research and development 
with currently more than 10 pharmaceutical products in the market. This 
process also benefits from being PAT enabled with use of invasive and non-
invasive analytical tools and products can be manufactured with QbD 
approach. However, HME has its fair share of shortcomings of elevated 
processing temperatures, drug loading, degradation, thermolabile drugs and 
availability of limited number of suitable approved polymers. Products 
obtained by HME are generally intermediate products and requires 
downstream processing to form into final product. Additionally, processing 
parameters will have a direct effect on the properties of the finished products. 
Therefore, HME was selected to study the impact of the material and process 
attributes on critical quality attributes of amorphous solid dispersion products 
obtained using hot melt extrusion.    
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Chapter 3: Materials and Methods 
A detailed explanation of materials and methods is provided in this chapter. 
The rationale for selection of the materials is explained. Methods will be further 
classified according to pre-formulation, processing, and characterisation 
techniques. The section also includes brief details about the principles and 
software of the different characterisation instruments used. 
3.1 Materials 
Ibuprofen was procured from Medex UK. AffinisolTMHPMC 100cP and 4M 
were provided as gift samples by DOW chemicals. Posaconazole was 
supplied by the funding partner Merck & Co., Inc. as a gift sample.  
3.2 Methods 
3.2.1 Preformulation and characterisation of polymer, API and co-former 
properties 
This section briefly describes the applicative principles of the analytical 
instruments used in Preformulation. Preformulation studies provide a deep 
understanding of the physicochemical properties of materials used during 
formulation and try to provide an overview of the challenges arising during the 
actual formulation process. 
3.2.1.1 Thermo-analytical instruments 
3.2.1.1.1 Differential Scanning Calorimetry (DSC) 
Thermal analysis is one of the prominent approaches to characterise 
pharmaceutical solids, semisolids, amorphous material, crystalline solids etc. 
DSC is one of the thermal tools which is used to investigate phase behaviour 
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of pharmaceutical solids including the quantification of amorphous solid 
materials (Newman et al. 2008).  Based on the design of the instrument, 
experimental conditions and measuring parameters, varied range of 
methodologies can be implemented to analyse the sample. Among them are 
DSC, modulated temperature DSC (MTDSC) and high-speed DSC (HSDSC) 
(Nollenberger et al. 2009). Conventional DSC works on the principle of linear 
temperature heating rate. In MTDSC apart from the temperature heating rate, 
a small temperature modulation is done to enhance the sensitivity of detecting 
a small amorphous fraction of crystalline materials. In newly developed, hyper 
or high-speed DSC the temperature modulation can be controlled by fast 
heating and cooling rates of 50-500° min-1. Hyper-DSC due to increasing the 
heating scan rate leads to higher heat flux which makes easy to analyse most 
of the amorphous materials by displaying glass transition temperature with 
increased sensitivity and less time. This property is lacking in conventional 
DSC instrument. 
DSC runs were performed using TA Q.2000 and TA discovery DSC. Standard 
aluminum pans were used. Around 2-5mg of the sample was weighed in the 
standard aluminum pans and was crimped with a pinhole aluminum lid. 
Samples were run at the heating rate of 10°C/min up to just before the reported 
degradation of the samples. Additionally, samples were run from -60°C up to 
melting for detection of glass transition events. Modulated DSC was run to 
confirm the events observed and to affirm the same. For fragility studies, 
samples were run with varying heating rate in a Heat-Cool-Heat cycle. Melting 
point depression studies were carried out at a heating rate of 2°C/min. 
Thermograms generated was analysed using TA universal software. Both TA 
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Q.2000 and TA discovery DSC are typical Heat flux DSC (Figure 3.1). These 
consist of a sample and a reference disc respectively. Standard aluminum 
pans crimped with aluminum lids containing the sample are placed on the 
sample disc whilst an empty pan is placed on the reference disc. Both the 
discs are connected to the thermocouples which are connected to a power 
unit. Any deflection observed due to solid state changes in the sample pan 
provides a change in the baseline which is recorded as a function of 
temperature.  
 
Figure 3.1 Typical Heat Flux DSC (left) and TA Q2000 DSC (right) 
One of the key parameters in DSC is the heating rate. A slow heating rate is 
advised for increasing the resolution while faster heating rates can aid in 
separation of events or can help to skim any re-crystallisation events. In this 
study, a heating rate of 10°C/min was used as melting of the compound was 
of interest and that would not vary with respect to heating rate.  
Typically, events observed in DSC are either exothermic or endothermic in 
nature. For this study, the interest will be for the glass transition temperature 
and melting temperature events.  
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3.2.1.1.2 Thermo Gravimetric Analyser (TGA) 
TGA runs were carried out using TA Q.5000 TGA and Discovery TGA (Figure 
3.2). Samples were placed in platinum pans which were previously tared in 
TGA. Samples were run up to 500°C with a heating rate of 10°C/min. TGA 
runs were analysed using TA universal analysis software. TGA works on the 
principle of recording change in mass as a function of temperature. The 
reference and sample platinum pans are connected to a microbalance which 
records changes in the sample. Mass loss occurs either due to water/solvent 
loss and/or degradation. These two events are typically seen in 
pharmaceutical powders. The focus for this study was to find out the 
degradation temperature of polymers used so as to fine-tune them for hot melt 
extrusion.  
 
Figure 3.2 TA Q.5000 TGA 
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3.2.1.2 Vibrational Spectroscopy 
Unlike crystalline materials, amorphous solids do not exhibit orientation and 
positional long-range crystal order in all three-dimensional space. However, 
molecular association characterised by the short-range order can occur in 
amorphous materials. Vibrational spectroscopy techniques like Raman 
spectroscopy, near-infrared (NIR), mid-Infra-red (IR) and recently Terahertz 
pulsed spectroscopy (TPS) have exhibited promising results in characterising 
pharmaceutical amorphous materials in pharmaceutical settings. These 
techniques have gained importance as they can investigate molecular 
assemblies of amorphous solids; it is non-destructive, fast and require little 
sample preparation. 
3.2.1.2.1 Mid-infrared spectroscopy 
Based on the type of pharmaceutical solids analysed, MID-IR spectroscopy 
can show significant spectral variation between crystalline and amorphous 
phases of the sample, thus this technique is also used for quantification of 
crystalline content, as the intensity of the vibrational bands correlates directly 
with the presence of the concentration of concerned phase. The amorphous 
phase of pharmaceutical solids exhibit different IR spectra in comparison with 
the crystalline phase of the similar sample. The difference in the IR spectra 
can be attributed to the presence of a wider range of conformations typically 
in amorphous solids, which normally leads to the presence of different 
intermolecular interactions and broader peaks compared to crystalline solid. 
When performing quantification studies, firstly identification of characteristic 
crystalline peaks which is independent of crystal state of the sample needs to 
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be identifed and then based on the intensity compared with the reference 
peak, degree of crystallinity can be determined.  
Fourier transform infrared (FTIR) spectra of the samples were acquired using 
a Thermo-Scientific Nicolet iS50 FTIR spectrophotometer equipped with a 
single reflection diamond attenuated total reflection (ATR) module. Around 2-
5mg of the sample was placed on the ATR and clamped to avoid spaces 
between holder and sample. Spectra were recorded in absorbance mode from 
4000 cm–1 to 400 cm–1 at 4 cm–1 resolution, and averaged over 64 scans. Total 
scan time was 1 min 35 secs. 
3.2.1.2.2 Raman spectroscopy 
The process of inelastic light scattering is referred as Raman radiations and 
was first reported by Raman and Krishnan in 1928. When samples are 
irradiated with a beam of monochromatic light, most of the scattered energy 
consists of energy derived from the incident frequency (Rayleigh scattering). 
In addition, minor amount of photons accompanied with shift is observed. The 
fraction of photon energy scattered from the center of the sample which 
consists of less energy before interaction is called Stokes scattering. Both IR 
and Raman spectroscopy works on the principle of measurement of molecular 
rotational and vibrational energy. However, in case of Raman, the requirement 
of vibrational energy is not related to change in the dipole moment (in case of 
IR) but it is associated with the change in polarisation of molecules 
(Vankeirsbilck et al. 2002). It probes the molecular property, and changes in 
the solid phase of the material are inferred by a change in the molecular 
environment and molecular conformation. The difference in the solid-state 
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properties can be seen by the subtle changes in the spectral position and 
intensity. 
Two types of Raman spectrometers were primarily used namely Dispersive 
Raman & Raman Mapping.  
 
Figure 3.3 DXR Dispersive Raman (left) and DXRi Raman Microscope (right) 
In Dispersive Raman, DXR Dispersive Raman of Thermo Scientific was used 
(Figure 3.3). The laser of 780nm wavelength and 50mW power was used. 
Aperture was 50µm slit to get the estimated area spot size of 3.1µm. Samples 
were either placed in glass vials (for powder samples) or were placed as it is 
(for extrudates) on the sampling plate. Samples were exposed for 30 sec to 
the laser and 64 scans were collected within the spectral range of 50-3360 cm-
1. Total time of collection was 33 mins. 
For Raman Mapping, DXRi Raman Microscope of Thermo Scientific was used 
(Figure 3.3). The laser of 780nm wavelength and 24mW power was used. 
Aperture was 50µm slit to get the estimated image pixel size of 70µm using 
10X objective lens. Fine flat sections of samples were placed on aluminum 
slide. Samples were exposed for 3 sec to the laser and 5 scans were collected 
within the spectral range of 50-3360 cm-1. Total time of collection varied from 
16mins to 1 hr 7mins.  
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Spectra and images were analysed for both Dispersive Raman and Raman 
Mapping using TQ Analyst and OMNICXi software respectively. 
To confirm the spectral regions for amorphous ibuprofen and posaconazole, 
DSC coupled with Raman probe was used (Figure 3.4). A Renishaw Raman 
probe of the laser of 780nm wavelength and 17.8mW power was used. 
Aperture was 25µm slit to get the estimated image pixel size of 70µm using 
10X objective lens. Samples were exposed for 2 sec to the laser and 3 scans 
were collected within the spectral range of 100-2000 cm-1.  
 
Figure 3.4 DSC-coupled with Raman probe 
3.2.1.3 Hygroscopicity Studies 
DVS experiments were carried out using DVS intrinsic from SMS (Figure 3.5). 
Samples were weighed in the previously tared aluminum pan and were 
enclosed in the DVS chamber within the instrument. A humidity cycle from 
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0%RH to 90%RH with a step change of 10% was set. Desorption cycle from 
with similar parameters was carried out. Step change to next humidity 
condition happens when the difference between ratios of change in mass with 
time was less than 0.002%.   
 
Figure 3.5 DVS intrinsic 
DVS works on a similar principle as TGA but the main difference is that the 
change in mass is recorded as a function of humidity. The experiment is run 
at isothermal temperatures typically 25°C. For humidity generation a mixture 
of water vapour and nitrogen gas is used. DVS was used to provide an 
overview of the water uptake capability of the polymers, API and the 
extrudates prepared.  
3.2.1.4 X-Ray Diffraction 
X-ray powder diffraction is a powerful non-destructive technique for analysis 
of the crystalline structure and atomic spacing of different materials. In 1912, 
Max Von Laue and Co. proposed that a crystalline substance is made up of a 
three-dimensional structure which is diffracted by the X-ray wavelength 
according to the arrangement of the crystal planes or crystal lattice (Bunaciu 
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et al. 2015). In this XRD technique, a cathode source is used to generate 
monochromatic radiations, scattered to concentrate and focus towards the 
particular sample material. These X-ray diffractions are generated by the 
constructive interference of monochromatic X-rays and crystalline samples. 
The X-ray radiations are directed towards the sample region the interactions 
of the incident rays with the sample materials generate interference when 
Bragg’s Law is satisfied. Below figure 3.6 represents a schematic 
representation of Bragg’s Law reflection (Bunaciu et al. 2015). 
 
Figure 3.6 Bragg’s Law: X-ray diffraction path exhibit an interference when the 
distance between path ABC and A’B’C’ differs by an integer wavelength 
number (Eby 2004). 
X-ray diffractometer consists of three basic components, X-ray cathode tube, 
sample holder, and detector. To understand the working of XRD, consider the 
crystal lattice planar distance of a crystal sample is d, where the difference 
between the path length between the path ABC and A’B’C’ is an integer 
multiple of wavelength (λ). When X-ray is incident on the crystalline sample 
then each planar phase of the sample will undergo individual refraction with a 
unique angle (θ), constructive interference takes place in a combination of 
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particular wavelength, lattice spacing (d) and angle of incidence (θ) (Eby 
2004). The general relationship between wavelength of X-rays, planar 
distance and angle of incidence is known as Bragg’s Law, expressed as : 
(𝑛𝜆 = 2𝑑𝑠𝑖𝑛𝜃), where n is an integer, λ- wavelength of X-rays, d- is the 
interplanar spacing produced due to diffraction and θ is the interplanar 
diffraction angle. By analysing the sample through a particular angle 2θ, the 
sample will undergo diffraction in all possible directions based on the planar 
phase arrangement of solid material and conversion of these diffracted peaks 
to d-spacing allows us to investigate the crystalline properties of the unknown 
sample.  Basically more finely ground samples will display all the possible 
orientations when analysed as most of the planes come in contact with the 
rays. According to Smith, the powder X-ray diffraction experiments can be 
conducted in two different ways: automated X-ray diffraction analysis yielding 
digital computer output and Debye-Sherer diffractometer providing analogue 
film output. Both these instruments provide the diffraction intensities beam as 
a function of angle of diffraction. The collected theta degree is processed using 
the Rietveld method to minimise the bad signals or function by using non-linear 
algorithms. 
X-ray scattering of the samples was acquired using a SAXSspace from Anton 
Paar Austria. The samples were placed on the stainless steel sample holder 
and sealed with transparent film. The distance between sample and detector 
was 112mm and the intensity I (q) was monitored at a wavelength of 
0.15418nm. An XYZ stage was used for auto-recognition of the sample stages. 
A fast read-out detector (Pilatus 100K-S) was used with the total acquisition of 
20 frames with an exposure time of 60 secs and data was analyzed using 
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SAXSdrive™ software. The scattering vector q range was used to calculate 
2Ө values (q = 4π/λ sin θ, where λ = 0.15418nm) (Pauw 2014; Kimanius et al. 
2015; Li et al. 2016a).     
3.2.1.5 Theoretical considerations 
3.2.1.5.1 Solubility Parameters  
The term solubility corresponds to the dissolution of one component into 
another to form a single phase. The term solubility, when extended to solid 
state solubility of a compound within a polymer purely, depends on the 
chemical structures of both compounds and their cohesive properties. Thus 
solid state solubility of these materials can be predicted based on their 
similarity of the solubility parameters (Tian et al. 2013) (P. Sakellariou 1986).  
The concept of solubility parameter basically works on two principle properties 
cohesive energy density and molar volume. Cohesive energy density is the 
energy required for any molecule to free it up from its neighbouring molecule 
(Cowie 1968). Molar volume refers to the volume occupied by the fragments 
of the compound in contention.  
Hildebrand and Hansen were considered pioneers in this area. Hildebrand’s 
method focused on the dispersion forces between two solutions while 
Hansen’s method along with the dispersion forces took into considerations the 
interactions between polar groups and hydrogen bond capacity (Hansen 
1999). 
Thus, solubility parameter (δ) is the first initial step of theoretically predicting 
the miscibility between drug and the polymer based on the measurement of 
the cohesive energy density (David J. Greenhalgh 1999) (Verhoeven et al. 
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2008). Cohesive energy density comprises of all the inter-intra-atomic and 
molecular interactions and types of bonds with the molecules. The method 
chosen was the Van Krevelen and Hoftyzer’s group contribution method (δ 
MPa1/2) (Adamska and Voelkel 2005).  
δ2 = (δ d) 2 + (δ p) 2 + (δ h) 2                                                               Equation 3.1 
Where  
δ d = ΣFdi/V   δ p = (√ΣF2pi)/V    δ h = √(ΣEdi/V)                                  Equation 3.2 
δ is the total solubility parameter, δd is the contribution from dispersion forces, 
δp is the contribution from polar forces, δh is the contribution from hydrogen 
bonding, Fdi is the molar attraction constant due to the dispersion component, 
Fpi is the molar attraction constant due to the polar component, Ehi is the 
hydrogen bonding energy, and V is the molar volume (Van Krevelen 1990). 
The solubility parameter is measured in MPa1/2. When the difference between 
the total solubility of drug and polymer i.e. Δδ is less than 7 MPa1/2 then they 
are considered to be miscible whereas above 10 MPa1/2 predicts immiscibility 
(Forster et al. 2001) (David J. Greenhalgh 1999); (Garekani et al. 2001). 
Solubility parameters were calculated using Van Krevelen and Hoftzyer's 
group contribution method. Molecular weight and density of the API and 
polymers were calculated using ACD Chemsketch software. Since the Affinisol 
monomer structure was unavailable, HPMC structure was used. 
3.2.1.5.2 Fragility Index 
One of the critical parameters from the viewpoint of stabilisation of the 
amorphous form is the glass transition temperature (𝑇𝑔). 𝑇𝑔 is considered as 
the most important factor in prediction of the stability of the ASDs and provides 
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an indication of its molecular mobility. Below 𝑇𝑔 the molecule behaves like a 
glass which in turn suggests a decrease in its molecular mobility and thus 
protects molecular conformation from collapsing.  
Thus glasses can be explained as a combination of mechanistic strength of 
crystals and spatial uniformity of liquids in amorphous materials. These are 
formed by cooling of liquids and considered as non-equilibrium solids (Angell 
1988; Angell 1991). Glasses of small molecules typically used in 
pharmaceutical industries as APIs are brittle in nature and easily fractured. 
This can lead to free surfaces which promote crystallisation. From HME point 
of view, identification of glass transition temperature (𝑇𝑔) is one of the critical 
parameters for consideration for the selection of the drug/polymer candidates. 
𝑇𝑔 plays a significant role in the stability of the products of solid dispersions. 
Hence, it is important to understand the ability and type of glass formed by the 
drug/polymers of interest. This will in turn help in understanding the molecular 
mobility offered by the drugs/polymer of choice in its amorphous state.  
The glass is obtained due to the structural relaxation within the molecule of an 
amorphous or a crystalline material. This structural relaxation is a direct 
function of its cooling rates and kinetics (Baird and Taylor 2012). The ability of 
the compound to form a glass is determined by a factor called as the fragility 
parameter which is calculated by determining the glass transition temperature 
(𝑇𝑔) as a function of cooling rate. This concept of fragility parameter and 
categorising them into different types of glasses was first conceived by Angell 
in 1991. The classification of types of glasses was further divided into fragile 
or strong glasses (Angell 1991). It is proven to an extent that the fragility 
parameter can be co-related to its molecular mobility. 
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The fragility of a compound is considered to be the energy during the structural 
relaxation of the material when cooled under its glass transition temperature. 
For a generation of glass transition of Ibuprofen with varying cooling rates, 
DSC was used. The activation energy (ΔH) of the materials can be correlated 
with the glass transition temperature obtained by varying the cooling rates. 
The activation energy (ΔH) for the material in consideration is the one near or 
at its Tg value (Borde et al.). For the current study, the following equations were 
used for calculation of the fragility parameter 
𝑚= ΔH / (2.303∗𝑅∗𝑇𝑔)                      Equation 3.3 
𝑑ln (𝑄) / 𝑑 (1/𝑇𝑔) = ΔH / 𝑅                      Equation 3.4 
Where R is the ideal gas constant, and Q is the cooling rate from DSC. 
The fragility parameters for IBU and POSA was quantified using DSC at 
cooling rates of 1, 2, 5, 10, 12 16, 18 and 20 °C/min respectively. Equation 2 
was utilised and a plot of ln (Q) against 1/Tg was produced – the slope of the 
line being utilised to calculate ΔH/ R for the crystalline components. ΔH/ R 
value obtained was replaced by the equation 3.3 to calculate the fragility 
parameter (m). If the fragility parameter values of m is < 70 and m is> 100 
indicates formation of strong and fragile glass respectively (Borde et al.). 
3.2.1.5.2 Theoretical Binary Phase Diagram  
 Melting point depression approach  
Flory-Huggins polymer solution theory proposes the drug-polymer 
temperature-composition phase diagram by understanding the interaction 
parameter 𝜒 between the drug-polymer and its change with temperature (Tian 
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et al. 2015). This can be achieved by using melting point depression data to 
predict 𝜒 by using Equation 3.5: (Lin and Huang 2010; Huang et al. 2016) 
1
𝑇𝑚
−  
1
𝑇𝑚𝑜
= −
𝑅
𝛥𝐻
[𝑙𝑜𝑔 𝜙𝑑𝑟𝑢𝑔 + 𝜙𝑝𝑜𝑙𝑦 (1 −
1
𝑚
) +  𝜒ϕ 𝑝𝑜𝑙𝑦
2 ]                Equation 3.5 
Where 𝑚 = [(Mol wt_poly/Density_poly )/(Mol wt_drug/Density_drug )] 
Tm and Tmo are the melting points of the drug-polymer blend and pure drug 
respectively, 𝜙 is the volume fraction of the components. ΔH and R denote 
enthalpy of fusion and the gas constant respectively.  
𝜒 is a function of temperature which can be empirically described by Equation 
3.6: 
𝜒 = 𝐴 + 𝐵/𝑇                                                                                            Equation 3.6 
Where A is the entropic contribution and B is enthalpy contribution of the 
system.(Lin and Huang 2010; Huang et al. 2016) 
Prediction of spinodal curve 
According to the Flory–Huggins theory, the free energy of mixing for a drug-
polymer solid dispersion can be described by Equation 3.7: 
𝛥𝐺𝑚𝑖𝑥 = 𝑅𝑇[ϕdrug log 𝜙𝑑𝑟𝑢𝑔 +
ϕpoly
m
 log 𝜙𝑝𝑜𝑙𝑦 + 𝜒 ϕdrugϕpoly]         Equation 3.7 
The second derivative of 𝛥𝐺𝑚𝑖𝑥 for at different temperature will give the 
spinodal curve.  
Theoretical glass transition temperature calculation by Fox equation 
Researchers often co-relate the extent of plasticisation based on 𝑇𝑔 values of 
polymeric blends. Generally, values of 𝑇𝑔 reduce with increase in plasticiser 
concentration and a plot of 𝑇𝑔 of polymeric blend against concentration of 
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plasticiser yields a relationship which determines the plasticisation efficiency. 
Such a relationship can also be obtained theoretically by use of the Fox 
equation.(Lin and Huang 2010)  
1
𝑇𝑔𝑚𝑖𝑥𝑡𝑢𝑟𝑒⁄
= (
𝑤1
𝑇𝑔1 ⁄
) + (
𝑤2
𝑇𝑔2 ⁄
)                                                 Equation 3.8 
where 𝑤1 & 𝑤2 are weight fractions while 𝑇𝑔1 & 𝑇𝑔2 are the glass transition 
temperatures of drug and polymer respectively.  
3.2.1.6 Melt Rheology  
3.2.1.6.1 Rotational rheometer 
All rotational rheological testing was carried out using a Physica MCR 501 
rheometer (Anton Paar, Austria) with parallel plate geometry (diameter 25mm) 
and gap size of 1mm. For each test, polymeric sample films were used. Three 
sets of oscillatory tests: a strain amplitude test, frequency sweep test, and time 
sweep tests were carried out. 
• Amplitude Sweep (AS) 
For the identification of Linear Visco-elastic region (LVR) amplitude sweep was 
carried out at a constant angular frequency of 10 rad/sec. The prepared films 
were subjected to the extrusion temperature used to generate the extrudates 
for determination of LVR. The samples were subjected to % strains from 
0.01%-100%. The linear viscoelastic regions (LVER) was calculated from the 
straight line of G' and G'' until it deviates and taken into consideration for 
frequency sweep tests.  
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• Frequency sweep (FS) 
Frequency sweep (FS) was carried out at constant %strain of 0.1% for all the 
samples. To check the G' & G'' over a range of frequency at a constant 
temperature, the samples were subjected to angular frequency ranges of 100 
rad/sec to 0.1 rad/sec respectively. All the %IBU-AffinisolTMHPMC 100cP films 
were carried out at the temperature at which these blends were extruded and 
two temperatures below. The aim was to have common temperatures between 
the varying samples of %IBU-AffinisolTMHPMC 100cP for comparison.  
• Time sweep (TS) 
The degradation of samples as a function of time was measured using time 
sweep tests at low shear rates. This test was performed to study the viscosity 
of polymers over 30mins at a specific temperature, at fixed strain (0.1%) and 
at a fixed frequency (10 Hz). All the %IBU-AffinisolTMHPMC 100cP films were 
carried out at the temperature at which these blends were extruded and two 
temperatures below. 
 3.2.1.6.2 Capillary rheometer 
A constant shear rate test using twin-bore capillary rheometer was employed. 
Pellets of the extrudates were dried in an oven at 30°C for 24 hours prior to 
testing. Rosand RH10 capillary rheometer, Malvern Instruments Ltd, was used 
for the capillary rheometer studies. It was mounted with 30,000 psi (Long die) 
and 10,000 psi (short die) pressure transducers and were calibrated and 
allowed to stabilize before every run. Temperatures were controlled within ± 
0.5 °C of the set values and monitored by platinum resistance thermometers 
fitted in the three (top, middle, and bottom) zones of the barrel. The pellets 
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were fed into both barrels and manually compressed before the test was 
started. They were subjected to two-stage of the pre-compression pressure of 
0.6 & 0.3 MPa, for a total pre-heating time of 540 seconds. The experiment 
was run in an 8-stage discrete speed program (Table 3.1) and the material 
was passed through 2 dies having dimensions of 2.0 mm diameter with 20.0 
mm (long die) and 0.25mm (zero length die, short die) of length. The shear 
rate values mentioned were calculated by software upon fixing the 8-stage 
discrete speed program. 
Stage number Piston speed (mm/min) Wall shear rate (/s) 
1 5.31 19.90 
2 8.39 31.47 
3 13.37 50.13 
4 21.19 79.47 
5 33.54 125.78 
6 53.15 199.30 
7 84.17 315.65 
8 133.35 500.05 
Table 3.1 Steady shear rate test stages 
3.2.2 Processing studies 
3.2.2.1 Ibuprofen-AffinisolTMHPMC HME studies 
For extrusion experiments, Pharma Lab 16mm of Thermo Scientific UK with 
screw length to diameter ratio of 40:1 was used (Figure 3.7). Gravimetric twin-
screw feeder (Brabender, Germany) was used for the auto-feeding of the 
blends. Feeder calibration for all the IBU-AffinisolTMHPMC blends was carried 
out. A feed rate of 0.4Kg/hr was kept constant for all the studies except for the 
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DOE study. Residence time was recorded using an in-line UV-vis 
spectrophotometer probe and data was recorded using LabVIEW program. 
Extrudates from the extruder were air-cooled and were either pelletised or 
were kept as such for storage.  
 
Figure 3.7 Pharmalab 16 HME 
3.2.2.1.1 Screw configuration and screw speeds 
One of the critical process factors in formulation development using HME is 
the residence time. Residence time depends mainly on the feed rate, screw 
configuration, and speed. All the IBU-AffinisolTMHPMC trials except for the 
DOE study were carried out at one single type of screw configuration having 
an increased mixing zone which imparts high mixing and kneading (Figure 3.8 
and table 3.2). Screw speed for all the trials apart from the DOE study was 
kept constant at 100rpm. 
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Table 3.2  Type 4 Screw configuration used for extrusion 
 
Figure 3.8 Screw configuration used for extrusion   
3.2.2.1.2 Temperature profile and zones 
IBU-AffinisolTMHPMC 100cP blends with varying drug loadings were 
processed at different temperatures profiles. The Pharmalab 16mm extruder 
has 10 different zones starting from zone 1 till zone 10. The mixing section is 
located from zone 7 till 9 and was followed by discharge elements in zone 10 
and die. Typical temperature profile zones for all the trials are shown in table 
3.3:  
Length (D)* Element type 
28 Forwarding 
2.25 30° 
1.25 60° 
1 90° 
6 Forwarding 
1.5 Discharge 
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Temperature 
profile 
Zones 
2 3 4 5 6 7 8 9 Die 
AffinisolTMHPMC 
100cP 
40 60 90 110 180 180 180 180 180 
10% IBU load 40 60 90 110 170 170 170 170 170 
15% IBU load 40 60 90 110 170 170 170 170 170 
20% IBU load 40 60 90 110 160 160 160 160 160 
30% IBU load 40 60 90 110 150 150 150 150 150 
40% IBU load 40 60 90 110 130 130 130 130 130 
Table 3.3 Temperature profile used for extrusion 
3.2.2.2 Ibuprofen-AffinisolTMHPMC partial factorial DOE 
As stated above, residence time is one of the critical process attributes in 
formulation development using HME. Factors affecting the residence time 
include feed rate, screw speed, and screw configurations. The direct response 
effect of residence time was calculated by incorporation of a marker pellet 
made by 30%w/w load of fluorescent optical brightener called UVITEX with 
AffinisolTMHPMC 100cP using HME. 20mg of tracer pellet was put at regular 
intervals during the HME process and was tracked using an in-line high-
temperature UV-vis probe. The tracer pellet excites at 500nm wavelength and 
the amplitude was recorded as a function of time. A partial factorial DOE 
consisting of 3 levels of feed rate, screw speed and configuration was 
randomised using Minitab software keeping temperature profile constant. 40% 
IBU drug load with AffinisolTMHPMC 100cP blend was used for all the studies. 
Along with residence time, in line monitoring of %torque and pressure was 
used as a response. Off-line monitoring was done using DSC and dissolution 
which was also used as a response.  
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Figure 3.9 In-line UV measurement during extrusion 
 
No 
Processing Parameters 
Screw 
configuration 
Screw speed (rpm) Feed rate (Kg/hr) 
1 -1 100 0.4 
2 -1 300 0.5 
3 -1 500 0.6 
4 0 100 0.5 
5 0 300 0.6 
6 0 500 0.4 
7 1 100 0.6 
8 1 300 0.4 
9 1 500 0.5 
Table 3.4 Design of experiment for process parameter study 
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Figure 3.10 Screw configuration for process parameter study 
Three types of screw configuration used were:  
1. With only conveying elements (-1) 
2. With one mixing zone (0) 
3. With two mixing zones (1) 
3.2.2.3 Ibuprofen-AffinisolTMHPMC compression moulding  
For rheological studies, one of the key requirements is to have minimal sample 
variation. A significant variation of thickness uniformity was observed within 
the pelletised HME pellets. AffinisolTMHPMC is an amorphous polymer which 
only softens at elevated temperatures. Hence, it is difficult to form uniform 
extrudates/film without incorporating shear into the process. To overcome this, 
compression moulding (CM) was done to obtain flat square sheets which were 
further cut into circular discs. Compression moulding experiments were carried 
out using equipment provided by MOORE UK. Top and bottom plate were kept 
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at a constant temperature just below or above the temperature at which the 
blends were subjected during extrusion (Figure 3.11). Square sheets of 
thickness 0.3 and 0.9mm were used alternatively for the constant thickness of 
the film. The samples were placed on two larger metal plates with the center 
of the square bar for proper and uniform distribution. The hot plate was subject 
to variable pressure and cooling was carried out using water circulation 
through the outer parts of the plates.  
 
Figure 3.11 Compression Moulding equipment by MOORE UK 
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Properties Affinisol 
100cP 
10%IBU 20%IBU 30%IBU 40%IBU 
Process temp 
(°C) 
200°C 180°C 160°C 150°C 130°C 
Film 
Thickness 
(mm) 
0.6mm 0.6mm 0.6mm 0.6mm 0.6mm 
Weight of 
extrudates 
per batch (g) 
10g 10g 10g 10g 10g 
Table 3.5 Compression moulding trials 
3.2.2.4 Posaconazole-Dicarboxylic acids solid-state screening trials  
Solid state screening trials were carried out using a solvent assisted ball mill 
MM 200 from Retsch (Figure 3.12). Two stainless steel jars of 10ml volume 
were used. Two stainless steel balls of 7mm in diameter were used for milling. 
All the experiments were carried at vibrating frequency of 25Hz for 30mins. 
Molar ratios of 1:1 and 2:1 of Posaconazole and Dicarboxylic acids with 5ml 
of Acetonitrile solvent were used. Trials for binary phase diagram were plotted 
for Posaconazole-Succinic Acid and L-Malic Acid trials respectively. All 
samples were air dried and were analysed using DSC, XRD, Raman, and 
ATR-FTIR for solid-state stability.    
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Figure 3.12 Ball mill  
3.2.2.5 Posaconazole-AffinisolTMHPMC HME studies  
Extrusion trails were carried out using a Pharma Lab 16mm of Thermo 
Scientific UK with screw length to diameter ratio of 40:1. A gravimetric twin-
screw feeder (Brabender, Germany) was used for the auto-feeding of the 
blends. Posa-AffinisolTMHPMC 4M blends with varying drug percent w/w were 
processed at different temperatures profiles. Pharmalab 16mm extruder has 
10 different zones starting from zone 1 till zone 10 with zone one being the 
auto-feeder zone. The mixing section comprised from zone 7 till 9 and was 
followed by discharge elements in zone 10 and die. Typical temperature 
profiles for all trials are shown in the table 3.6:  
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Temperature profile 
Zones 
2 3 4 5 6 7 8 9 Die 
AffinisolTMHPMC 4M 40 60 100 120 180 180 180 180 180 
10% Posa load 40 60 100 120 180 180 180 180 180 
20% Posa load 40 60 100 120 180 180 180 180 180 
30% Posa load 40 60 100 120 180 180 180 180 180 
40% Posa load 40 60 100 120 180 180 180 180 180 
50% Posa load 40 60 100 120 180 180 180 180 180 
60% Posa load 40 60 100 120 180 180 180 180 180 
70% Posa load 40 60 100 120 180 180 180 180 180 
40%Posa+Maleic 
Acid+Aff 4M (1-1) 
40 60 100 120 170 170 170 170 170 
40%Posa+Succinic 
Acid+Aff 4M (2-1) 
40 60 100 120 180 180 180 180 180 
40%Posa+Malic 
Acid+Aff 4M (2-1) 
40 60 100 120 160 160 160 160 160 
40%Posa+Succinic 
Acid+Aff 4M (1-1) 
40 60 100 120 150 150 150 150 150 
40%Posa+Malic 
Acid+Aff 4M (1-1) 
40 60 100 120 160 160 160 160 160 
30%Posa+Succinic 
Acid+Aff 4M (1-1) 
40 60 100 120 150 150 150 150 150 
30%Posa+Succinic 
Acid+Aff 4M (1-1) 
40 60 100 120 160 160 160 160 160 
3.37%Succinic Acid+Aff 
4M  
40 60 100 120 180 180 180 180 180 
3.83%Malic Acid+Aff 
4M 
40 60 100 120 180 180 180 180 180 
Table 3.6 HME trials with posaconazole, Affinisol 4M and dicarboxylic acids 
The screw configuration described in Ibuprofen-AffinisolTMHPMC 100cP 
studies was used in the Posaconazole-AffinisolTMHPMC 4M studies. The 
screw speed for all the experiments was kept constant at 100rpm.  
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3.2.3 Characterisation of extrudates  
3.2.3.1 Accelerated stability conditions  
To check the long-term solid-state stability, the ASDs were stationed at three 
stability conditions 40°C/75% RH, 25°C/60% RH and room temperature. 
Samples were removed at regular intervals and analysed using ATR-FTIR, 
Raman microscopy, XRD, and DSC. 
3.2.3.2 Solid state characterisation of extrudates 
All extrudates were analysed using DSC, XRD, ATR-FTIR, and Raman to 
check for solid state stability. The protocol used was same as described in the 
earlier section of 3.2.1. 
3.2.3.3 Dynamic Mechanical Analyser (DMA) 
DMA analysis was carried out using TA Q 800 DMA. Extrudates and films were 
characterised using dual cantilever sample holder. The frequency was set at 
1Hz at a  temperature ramp was applied out from 20°C to just before the 
extrudates degrade at a rate of 1°C/min. Experiments were carried out using 
controlled strain thermal scan. A constant % stain of 0.1% was applied for all 
the experiments. Analysis of data was performed using TA Universal Analysis 
Software. Experiments were carried out with and without relative humidity 
chamber head. Outline of the DMA studies is summarised in Figure 3.13.  
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Figure 3.13 Outline of DMA Studies 
3.2.3.4 Dissolution  
Drug release studies were carried out using DS 8000 with auto-sampler from 
Lab India (Figure 3.14). USP apparatus II paddle type was used. Pellets or 
milled samples were placed directly within the dissolution vessels containing 
phosphate buffer pH 7.2 of 900ml.Paddle speed was set at 50-100 rpm and 
the dissolution test was carried out at 37.5°C. 5ml of sample volume was 
removed at various fixed time points and the samples removed were analysed 
using UV-Vis spectrometer at a fixed wavelength of 221 and 263nm by 
dilutions. The dissolution test was carried out under sink conditions. A 
calibration curve for Ibuprofen and Posaconazole was plotted by preparing 
serial dilutions of concentrations ranging from 1-10 µg/ml and taking UV 
readings at a fixed wavelength of 221 and 263nm using UV-vis spectrometer. 
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Figure 3.14 DS 8000 Dissolution apparatus with autosampler (paddle type) 
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Chapter 4: Material characterisation and feasibility studies 
The aim of this chapter is to provide an in-depth understanding of the material 
attributes affecting the formulation development of the ASDs. It will provide a 
detailed investigation of the physicochemical properties of IBU, Posa, and 
AffinisolTMHPMC. Further, it will detail the theoretical parameters like solubility 
parameter, fragility and binary phase diagram by Flory-Huggins theory using 
the depression of melting point approach. The rationale for selection of 
analytical instruments for detection of solid state stability of ASDs will also be 
discussed.  
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4.1 Thermal properties of the materials 
Thermal history of API and polymer of choice is an important attribute in 
formulation development of ASDs using HME. Thermal history of the material 
will supplement physicochemical properties like glass transition temperature, 
melting temperature, degradation and water/solvent loss events. 
Understanding of thermal history will help foresee gaps during process 
development.   
Degradation temperature of the IBU, Posa, and AffinisolTMHPMC was 
measured using TGA. Affinisol 100cP and 4M showed three events of weight 
loss at 150°C, 210°C, and 380°C respectively. The first weight loss could be 
due to water/solvent loss as the weight loss was gradual and over a 
temperature range. The second and third weight losses could be due to two-
step thermal degradation. DSC thermogram showed a change in baseline 
which could be due to glass transition temperature at 104.65°C and 106.64°C 
respectively (Figure 4.1). Thus, it was noted that Affinisol 100cP and 4M had 
a tendency to pick up surface moisture although reversible in nature can have 
an effect during HME. Either a vent needs to be provided during extrusion for 
the release of surface moisture or Affinisol should be dried in a preheated oven 
to remove surface moisture. Affinisol 100cP & 4M were dried in pre-heated 
vacuum oven at 50°C for 2hrs prior to use. Additionally, from TGA it was noted 
that all extrusion experiments involving Affinisol 100cP & 4M need to be 
carried out below 210°C to avoid solid state thermal degradation.  
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Figure 4.1 TGA (left) and DSC (right) thermograms of Affinisol 100cP and 4M 
Thermal degradation temperature of ibuprofen was found to be around 100°C. 
DSC thermogram of a heat-cool-heat method for ibuprofen showed a sharp 
endothermic event corresponding to melting of ibuprofen at a peak of 75.53°C 
(Lerdkanchanaporn and Dollimore 1997). In the second heat cycle, a change 
in baseline corresponding to glass transition temperature at -44.34°C was 
observed (Figure 4.2). It was observed that ibuprofen can be made amorphous 
using quench cooling method within DSC (Heat-Cool-Heat) and it stays 
amorphous as no recrystallisation or second melting event was observed. 
Despite this, Tg of the IBU is low and hence incorporating it within a high Tg 
polymer to form ASD proves to be a correct rationale.   
 
Figure 4.2 Thermal analysis of ibuprofen 
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DSC thermogram of posaconazole showed one broad endothermic event with 
a peak temperature at 135.44°C which is due to solid-solid impurity and sharp 
endothermic event with a peak temperature at 168.85°C which is due to the 
melting of posaconazole form I (Andrews et al. 2004; Andrews et al. 2005) 
(Figure 4.3).  
 
Figure 4.3 Thermal analysis of posaconazole 
DSC thermogram of heat-cool-heat cycle showed the presence of a change in 
baseline which could be due to a glass transition at 60.85°C followed by an 
exothermic event which could be due to recrystallisation with a peak at 
137.37°C and lastly two sharp endothermic events with peak temperatures at 
168.27°C and 172.50°C which could be due to melting of form I and IV 
respectively (Andrews et al. 2004; Andrews et al. 2005; Wieser et al. 2008). 
Thermal degradation of posaconazole was found to be around 300°C.  
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4.2 Theoretical considerations 
4.2.1 Solubility parameters  
The solubility parameter is a quick first step in predicting the miscibility 
between materials based on their chemical structure. The theoretical 
calculation can help in the selection of materials to form ASDs. Of the various 
methods available to calculate solubility parameter to predict miscibility, Van 
Krevelen and Hoftyzer’s group contribution method was used. A detailed 
calculation of group contribution for ibuprofen, posaconazole, and 
AffinisolTMHPMC is provided in Table 4.1. According to the van Krevelen 
method, the values of δ for ibuprofen, posaconazole, and AffinisolTMHPMC 
were found to be 19.66, 20.02 and 23.9 MPaP1/2Prespectively. Moreover, the δ 
difference between ibuprofen and AffinisolTMHPMC was noted to be 4.24 
MPaP1/2P (Table 4.2) 
Group FRdi 
F 
Rpi 
ERhi 
Repeat
ing 
units 
∑FRdi FP2PRpi ∑ERhi 
-CH3- 420 0 0 3 1260 0 0 
-CH2- 270 0 0 1 270 0 0 
-CH- 80 0 0 2 160 0 0 
Benzene 
ring 
143
0 
110 0 1 1430 12100 0 
-COOH 530 420 
1000
0 
1 530 176400 10000 
Total ∑    - 3650 188500 10000 
     
δRdR = 
18.22 
δRpiR 
=2.17 
δRhR 
=7.06 
Ibuprofen δ = 19.66 MPaP1/2P 
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Group FRdi 
F 
Rpi 
ERhi 
Repeat
ing 
units 
∑FRdi FP2PRpi ∑ERhi 
-CH3- 420 0 0 2 840 0 0 
-CH2- 270 0 0 3 810 0 0 
-CH- 80 0 0 2 160 0 0 
C 
(TETRAVAL
ENT) 
 
-70 0 0 1 -70 0 0 
 
1430 110 0 2 2860 48400 0 
-F 220 0 0 1 220 0 0 
-OH 210 500 
2000
0 
1 210 250000 20000 
-O- 100 400 3000 2 200 640000 6000 
-CO- 290 770 2000 1 290 592900 2000 
NH 160 210 3100 2 320 176400 6200 
N trivalent 20 800 5000 6 120 23040000 30000 
Ring 190 0 0 3 570 0 0 
Total ∑    - 3650 188500 10000 
     
δRdR = 
13.12 
δRpiR 
=9.99 
δRhR 
=11.35 
Posaconazole δ = 20.02 MPaP1/2P 
 
Group FRdi 
F 
Rpi 
ERhi 
Repeat
ing 
units 
∑FRdi FP2PRpi ∑ERhi 
-CH3- 420 0 0 2 840 0 0 
-CH2- 270 0 0 4 1080 0 0 
-CH- 80 0 0 5 400 0 0 
-0- 100 400 3000 3 300 1440000 9000 
COH 470 800 4500 2 940 2560000 9000 
R
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Total ∑    - 3560 4000000 18000 
     
δRdR = 
19.01 
δRpiR 
=10.68 
δRhR 
=9.80 
AffinisolTMHPMC δ = 23.90 MPaP1/2P 
Table 4.1 Calculation of group contribution for ibuprofen, posaconazole, and 
AffinisolTMHPMC 
No Materials δ of materials 
(MPa1/2) 
Δδ (MPa1/2) 
1 Ibuprofen 19.66 - 
2 Posaconazole 20.02 - 
3 AffinisolTMHPMC * 23.9 4.24 for IBU 
and 3.88 for 
Posa 
*Affinisol monomer Structure has not been released hence HPMC 
monomer structure was considered. 
Table 4.2 The solubility parameter (δ) of Ibuprofen and polymers 
The difference between the total solubility of drug and polymer i.e. Δδ is less 
than 7 MPa1/2 and hence are considered to be miscible (Greenhalgh et al. 
1999; Forster et al. 2001); (Garekani et al. 2001). 
4.2.2 Fragility parameter 
The fragility parameters for IBU and Posa were quantified using DSC at 
cooling rates of 1, 2, 5, 10, 12 16, 18 and 20 °C/min (Figure 4.4). A plot of ln 
(Q) against 1/Tg was produced – the slope of the line being utilised to calculate 
ΔH/ R for the crystalline components (Figure 4.4). ΔH/ R value obtained was 
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utilised to calculate the fragility parameter (m). If the fragility parameter values 
of m are < 70 and m are> 100 indicates the formation of strong and fragile 
glass respectively (Borde et al.). Fragility index for IBU was found to be 60.47 
hence it forms a strong glass. This can be supported by the DSC thermogram 
by using the heat-cool-heat method where ibuprofen exhibited no 
recrystallisation or second melting event. Fragility index for posaconazole was 
found to be 76.98 and hence forms a weak glass. However, fragility index only 
provides an indication about the type of glass and its ability to form glass but 
fails to provide direct relevance to the stability and its role in the stability of the 
solid dispersion is still unclear.  
 
Figure 4.4 Fragility parameter for IBU and POSA 
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4.2.3 Binary Phase Diagram 
Thermodynamics state that every solid solute will possess some solubility in 
the polymer. Before, going ahead to explain binary phase diagram, it is 
important to define the terms solid state solubility and miscibility. Solid state 
solubility is generally considered when a solid solute dissolves in the 
liquid/melt state of the polymer. This leads to a single phase consisting of 
solute and polymer to be molecularly mixed (also known as a solid solution). 
Solid state miscibility, on the other hand, is considered when a solid solute and 
polymer blend form a single phase system. This single phase system does not 
necessarily mean the molecular mixing between the solid solute and polymer. 
A single phase in this context will be the API-polymer blend with a single glass 
transition temperature (Olabisi et al. 1979).  
Construction of binary phase diagram and its limitations:  
Phase separation in ASD could be either due to the liquid-solid boundary or 
liquid-liquid boundary. Phase separation in the liquid-solid boundary occurs 
either by vitrification or crystallisation of the API. The mechanism for 
crystallisation is well defined and occurs in two stages of nucleation and 
growth. Liquid-liquid boundary separates due to the combined effects of 
thermodynamics or melt flow properties (Olabisi et al. 1979). Mostly, during 
extrusion, API-polymer immiscibility will be due to its liquid-liquid boundary as 
melt API solubilises in the softened polymer. However, over stability, the phase 
separation occurs due to the liquid-solid boundary. Hence for this main reason, 
the focus in the solid-state miscibility will be on the spinodal curve of 
decomposition. Solubility curve will not be studied for both ibuprofen-Affinisol 
100cP and posaconazole-Affinisol 4M blends.  
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Spinodal decomposition curve is a phase formed due to a kinetic process 
governed by crystal nucleation and growth. Amorphous phase separation also 
has a metastable separation line called the binodal curve (Chen et al. 2016). 
Kinetics of spinodal decomposition governs the miscibility between API-
polymer solution bends (Lin and Huang 2010). Thus, thermodynamic stability 
of the API-polymer solution blends is provided by the binodal and spinodal 
curve.  
A glass transition temperature curve is not a phase separation curve. It in 
principle provides information about the ability of a API-polymer blend to form 
a glass according to its molecular mobility. This, in turn, can be useful in 
predicting the phase separation kinetics and structure information (Lin and 
Huang 2010).  
A typical binary phase diagram based on the polymer solution theory is shown 
in figure 4.5. Solubility curve or liquid-solid transition boundary denotes the 
solubility of API within polymer matrix at different temperatures. The spinodal 
curve represents the metastable miscibility phase between API-polymer 
solution blend. The glass transition temperature line provides an overview of 
phase separation kinetics and molecular mobility within the glassy matrix (Qian 
et al. 2010).  
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 Figure 4.5 Typical binary phase diagram (Karandikar 2015) 
The single value solubility parameter approach was not successful in 
prediction of solid-state miscibility and new methods with more promise gained 
importance. The application of the Flory-Huggins solid-state solution theory 
assumes the drug solubilises within the polymer with a similar principle as for 
a solid solute dissolving in a solvent to form a solution (Tian et al. 2013). Two 
approaches of lattice theory and non-athermal mixing (interaction parameter 
approach) are used to confirm Flory-Huggins theory (Lin and Huang 2010). 
The current study will be utilising the non-athermal approach to predict the 
same. Flory-Huggins theory works on the principle of free energy of mixing. 
Free energy of mixing can be explained by understanding the Gibbs free 
energy. Gibbs free energy for mixing consists of entropy which energy of the 
system required for mixing and enthalpy which energy needed to break down 
the stable system. A negative value of Gibbs free energy promotes stability of 
the phase and vice-versa. According to the theory, the binary phase diagram 
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can be predicted by studying the drug-polymer interaction parameter 𝜒 as a 
function of temperature range (Lin and Huang 2010; Qian et al. 2010; Knopp 
et al. 2015). The mathematical equations are well defined in the chapter 3. 
Measurement methods used for Flory-Huggins polymer solution theory are 
well documented (Knopp et al. 2015; Rask et al. 2018). For the current study, 
melting point depression was chosen as the method of choice. The amorphous 
polymer in question is not easy to soften and for the formation of single-phase 
system with APIs, high shear is required which is generally generated in HME. 
From the feasibility point of view, melting point depression works best with 
minimal method error. Physical mixtures were pre-mixed for 30mins and were 
analysed in DSC for melting point depression of the APIs. For calculation of 
glass transition curve, direct measurement of glass transition temperature is 
the best method. However, it’s not feasible to produce single phase API-
polymer blends using heat-cool-heat cycle. Hence, theoretical methods like 
Gordon-Taylor equation, Fox equation, Couchman-Karaszor, and Kwei are 
used in prediction of glass transition temperature of API-polymer solution 
blend (Prudic et al. 2015; Song et al. 2015; Tian et al. 2015; Van Duong et al. 
2018). In the current study, the Fox equation was utilised for the prediction of 
glass transition temperature of API-polymer blends.  
Table 4.3 provides the parameters used to calculate the interaction parameter 
and free energy of mixing. 
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Parameter Ibuprofen Posaconazole Affinisol 
100cP 
Affinisol 
4M 
Mw (g/mole) 206.29 686.75 231708 552800 
Density (g/cm3) 1.03  1.38 1.326 1.326 
Glass transition 
temperature 
(°C) 
-44°C 60.85°C 128°C 128°C 
Table 4.3 Calculated parameters for ibuprofen, posaconazole, and Affinisol 
The parameters for ibuprofen and posaconazole were obtained by ChemDraw 
software while experimental values obtained were used for affinisol 100cP and 
4M. Glass transition temperature values for ibuprofen and posaconazole were 
obtained using DSC while, DMA was used for affinisol 100cP and 4M. The 
values generated using DSC were found to be lower than the DMA values for 
affinisol 100cP and 4M. The values also matched with values provided by the 
vendor. The degree of polymerization 𝑚 was calculated to be 872.48 & 837.73 
for ibuprofen and posaconazole. The interaction parameter 𝜒 at the melting 
point was calculated by a melting point depression method using DSC and 
was found out to be -0.6353 and -0.6337 for ibuprofen and posaconazole 
(Figure 4.6).(Lin and Huang 2010; Tian et al. 2013; Tian et al. 2014; Huang et 
al. 2016)  
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Figure 4.6 Calculation of interaction parameter 𝜒 at melting point by Flory-
Huggins equation 
For the spinodal curve, the interaction parameter was plotted as a function of 
inverse temperature to get components A and B (Figure 4.6).  
According to theory, at the melting temperature, the interaction parameter 
tends to infinity hence subtle changes in temperatures near the melting point 
will have a significant impact on the interaction parameter. Using values A and 
B obtained by plotting figure 4.6, the free energy of mixing 𝛥𝐺𝑚𝑖𝑥 at different 
temperature was theoretically calculated (Figure 4.7).  
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Figure 4.7 The plot of free energy of mixing (top) and phase diagram (bottom) 
of IBU (left) and Posa (right) 
𝛥𝐺𝑚𝑖𝑥 values were found to be positive for temperatures below 74°C and 
162°C for ibuprofen and posaconazole respectively which indicates de-mixing. 
The spinodal curve was obtained by calculating the second derivate of 𝛥𝐺𝑚𝑖𝑥 
at various temperatures close to the melting temperature. The theoretical glass 
transition temperature profile for ibuprofen-Affinisol 100cP and posaconazole-
Affinisol 4M was calculated using the Fox equation (Figure 4.7). Table 4.4 
summarises the calculated parameters for both the API-polymer blends.  
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Parameter Ibuprofen-Affinisol 
100cP 
Posaconazole-
Affinisol 4M 
The degree of 
polymerisation (𝑚) 
872.48 837.73 
Interaction parameter 
at melting point (𝜒) 
-0.6353 -0.6337 
Entropic contribution 
(A) 
-1090.6 378807 
Enthalpy contribution 
(B) 
-1071.4 472220 
Table 4.4 Calculated parameters for ibuprofen and posaconazole trials 
Affinisol 100cP molecular weight is more than 1000 times of that of ibuprofen. 
Due to which spinodal curve predicts complete solid-state miscibility between 
all the drug-polymer compositions and thus the binary phase diagram fails to 
predict solid-state miscibility between ibuprofen and Affinisol 100cP (Huang et 
al. 2016). A similar result was observed for the posaconazole-Affinisol 4M 
binary phase diagram. Hence, it can be inferred that theoretical binary phase 
diagram by Flory-Huggins theory fails to predict the stability of the ASD formed 
using ibuprofen and Affinisol 100cP. 
4.3 Water uptake capability 
The presence of water can pose an issue during hot melt extrusion and can 
cause extrudates to swell. Thus studying water uptake capability of the 
materials can help in identifying the precautions needed during extrusion. 
Dynamic Vapour Sorption (DVS) provides a complete overview of water 
uptake capability of API and polymers. Furthermore, it also highlights the 
ability of materials to hold onto surface water. DVS isotherm plots can also 
help in distinguishing whether water uptake is reversible (surface moisture) or 
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irreversible (hydrate) in nature (Aubuchon 2011). The absorption plots of 
ibuprofen, posaconazole, Affinisol 100cP and 4M are shown in figure 4.8. It 
was observed that ibuprofen and posaconazole are not at all hygroscopic in 
nature and exhibited saturated mass gain of 0.1% wt gain at 90%RH. Mass 
weight gain is also reversible in nature. Hence, both APIs showed no tendency 
to form irreversible hydrates.  
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Figure 4.8 DVS isotherms of ibuprofen (top) and posaconazole (bottom)  
In the case of AffinisolTMHPMC grades, no significant difference in their water 
uptake ability was observed, however, a saturated mass gain of 18% and 16% 
at 90%RH was observed for affinisol 100cP and affinisol 4M respectively 
(Table 4.5). One important thing to note was that the water uptake capability 
of AffinisolTMHPMC grades was found to be less than the commercially 
available grades of HPMC as shown in figure 4.9 (Gupta et al. 2016). This 
clearly affirms the advantage it offers over traditional HPMC available in terms 
of its water uptake capability. For extrudates, DVS study was not carried out 
as they need to be milled in order to check for its hygroscopicity. The tensile 
strength of the extrudates varies with the increasing amount of drug load and 
thus extrudates need to be cryo-milled for further studies.  
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Figure 4.9 DVS data for AffinisolTMHPMC 100cP, AffinisolTMHPMC 4M and 
Methocel K15M 
 
Table 4.5 Summary of dm/dt at a particular humidity 
4.4 Spectroscopic evaluation 
As explained in chapter 3, spectroscopic methods can be used in the 
identification of the solid state of the API and can be utilised to study the solid 
state stability of the ASD. Spectroscopic methods provide a quick, easy and 
non-invasive way of identification of the solid state of the material. Since the 
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stability of the ASD solely depends on the solid state of the drug within it, the 
current section will provide a detailed investigation of the spectral evaluations 
of the various states of ibuprofen and posaconazole. Crystalline, amorphous 
and melt form of ibuprofen and posaconazole were studied and qualitative 
methods were developed for detection of the solid state of ibuprofen and 
posaconazole.  
 4.4.1 FTIR spectroscopy  
Ibuprofen exists as a dimer in its crystalline and melts state 
(Lerdkanchanaporn and Dollimore 1997; Ryabenkova et al. 2017). However, 
ibuprofen was made amorphous within DSC by heat-cool-heat cycles but, 
quench cooling experiments failed to produce pure amorphous ibuprofen. This 
could be due to its low Tg and tendency to exist as a crystalline dimer. ATR-
FTIR spectra of melt ibuprofen, crystalline ibuprofen, and Affinisol 100cP are 
shown in figure 4.10. It is evident from ATR-FTIR spectra, that active bands 
between 1800-1700 cm-1 can be considered as a non-interfering region for the 
detection of IBU within ASD. Use of ATR-FTIR method will be detailed more 
in chapter 5.3.  
141 
 
 
 
Figure 4.10 ATR-FTIR spectra of ibuprofen (above) and posaconazole (below)  
ATR-FTIR spectra of Affinisol 4M, crystalline and melt posaconazole are seen 
in figure 4.10. All peaks observed are similar to the peaks observed in the 
posaconazole form I (Andrews et al. 2004). The spectral region of 1650-1710 
cm-1 was found to be non-interfering between posaconazole and affinisol 4M. 
A distinct peak at 1685 cm-1 in crystalline Posa which is due to the carbonyl 
group was found to shift to 1698cm-1 in the melt form of posaconazole.  
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4.4.2 Raman spectroscopy 
Several studies have reported the Raman spectra for crystalline ibuprofen and 
posaconazole (Breitenbach J 1999; Hedoux et al. 2011) (Andrews et al. 2004; 
Andrews et al. 2005). As reported in the FTIR section, quench cooling 
experiments had failed and hence an in-line technique was needed to confirm 
the Raman spectral fingerprint of amorphous ibuprofen and posaconazole. 
DSC coupled with a Raman probe was used to confirm the same. It is 
important to separate the exact temperature range within DSC to track the 
Raman spectra (Figure 4.2). Raman spectra for ibuprofen were collected at 
20°C & 80°C in the first heating cycle and -70°C and 80°C in the second 
heating cycle. Raman spectra of ibuprofen melt and amorphous ibuprofen 
were found to be similar. Amorphous and crystalline ibuprofen Raman spectra 
were found to be different at 1600-1650 and 750-850 cm-1 regions (Figure 
4.11). Overlay of Raman spectra of crystalline and amorphous ibuprofen with 
Affinisol 100cP confirmed the region of 1600-1650 cm-1 as a non-interfering 
region. Raman spectra exhibited a peak shift from 1607cm-1 to 1612-1617cm-
1, attributed to aryl chain deformation and C-H stretching and bending which 
occurs due to disorder within the structure and is characteristic of the 
amorphous state of ibuprofen (Liu and Gao 2012).  
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Figure 4.11 DSC-Raman of IBU and Affinisol 100cP 
 
Figure 4.12 DSC-Raman of posaconazole 
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Raman spectra for posaconazole were collected at 25°, 110°C, 170°C, and 
175°C. Raman spectra of the form I melt and amorphous posa were found to 
be similar. Subtle changes in the spectra were observed in the regions of 700-
900 cm-1 between crystalline and amorphous posa. These changes are due to 
the relaxation of the aryl chains of posaconazole. However, the distinct peak 
of carbonyl group at 1600 cm-1 remained unchanged for all the solid forms 
(Figure 4.12).  
4.4.3 Diffraction studies 
X-ray diffraction is a simple, non-destructive tool for identification of crystalline 
materials. Amorphous materials are characterised by the absence of diffracted 
peaks due to lack of unit cell. Hence, any peaks observed upon stability can 
be easily picked up by X-ray and can be a useful tool in detection of solid state 
solubility of the ASDs. Figure 4.13 show overlay of ibuprofen and Affinisol 
100cP. Characteristic peaks for ibuprofen confirmed its crystalline nature while 
Affinisol 100cP showed a halo region predominant for amorphous materials.  
 
Figure 4.13 XRD diffractogram of ibuprofen (red) and Affinisol 100cP (black) 
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Posaconazole characteristic peaks match with the peaks observed for the form 
I (Andrews et al. 2004; Andrews et al. 2005). Affinisol 4M showed a halo region 
due to its amorphous nature. Dicarboxylic acids used as additives and for co-
crystal/eutectic screening showed characteristic peaks which confirmed their 
crystalline nature (Shevchenko et al. 2012; Shevchenko et al. 2013) (Figure 
4.14).  
 
Figure 4.14 XRD diffractogram of posaconazole, Affinisol 4M and dicarboxylic 
acids 
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4.5 Conclusion 
Thermal history of IBU, Posa and AffinisolTMHPMC provided information like 
the glass transition temperature, bound and unbound water/solvent ability, 
decomposition and melting temperatures. Glass transition and 
decomposition temperatures gave an insight in the likely processing 
temperature window during HME. Irreversible water/solvent event within 
AffinisolTMHPMC confirmed the tendency to pick up surface moisture. 
Surface moisture uptake capability was further confirmed by hygroscopic 
studies by DVS. Either a vent needs to be provided during extrusion or 
Affinisol should be dried in a preheated oven to remove surface moisture.  
Rationale for selection of APIs and polymer was supported by solubility 
parameters approach which showed miscibility between APIs and polymer. 
Fragility index for IBU and Posa confirmed formation of strong and weak 
glasses respectively. This observation was supported by DSC thermograms 
where no recrystallisation event was observed for IBU and was observed for 
Posa. Additionally in open pan DSC experiments it took time for IBU to 
recrystallise.  
Region of non-interference between APIs and polymer were established 
using ATR-FTIR and Raman spectroscopy. Carbonyl bond was found to shift 
for both amorphous and crystalline domains of ibuprofen in ATR-FTIR and 
Raman while for Posa the shift was observed only in ATR-FTIR.  
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Chapter 5: Ibuprofen-Affinisol   
The aim of the current chapter is to focus on the critical attributes affecting the 
formulation development of the ASDs. These critical attributes were studied 
using IBU and Affinisol 100cP as API and polymer of choice to form ASD. The 
chapter is further subdivided into three studies. The objective of section 5.1 is 
to study the effect of drug concentration on the mechanical properties of the 
IBU-Affinisol 100cP ASD. Section 5.2 investigates the effect of critical process 
parameters on the product performance of IBU-Affinisol 100cP ASD using in-
line and off-line analytical tools. Lastly, Ibuprofen dimer in the solid dispersion 
as an early indicator of solid-state stability will be discussed in section 5.3. A 
schematic representation of the chapter is provided in figure 5.1.  
 
 
Figure 5.1 Schematic representation of ibuprofen-Affinisol 100cP studies 
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5.1 Effect of concentration of Ibuprofen on the mechanical properties of 
Ibuprofen-AffinisolTMHPMC extrudates 
Hot melt extrusion (HME) provides an attractive continuous green technology 
for formulation development of amorphous solid dispersions (ASD). Polymeric 
excipients comprise an integral part of the development of ASD using HME. 
Melt based processability of the API-polymer mixtures is highly dependent on 
the rheological properties of the system. Hence, understanding the melt 
rheology becomes a critical parameter in the formulation development of the 
ASD. Additionally, the polymeric excipients used are visco-elastic in nature 
and thus studying their mechanical properties will provide an insight into HME 
process development and stability. Effects of ibuprofen concentration on the 
rheological and mechanical properties of the extrudates with Affinisol 100cP 
were studied. A thorough investigation of melt rheology and mechanical 
properties of the extrudates is provided with the aim of examining links 
between the same. An attempt is also made to correlate the tan delta values 
obtained by mechanical studies and theoretical glass transition values 
obtained for the ibuprofen-Affinisol 100cP blends using the Fox equation. Off-
line tracking of the crystallisation kinetics of 40% drug load of ibuprofen was 
studied using Raman microscopy. Dissolution studies of all the ibuprofen-
Affinisol 100cP pellets were conducted. Model fitting for dissolution kinetics of 
all extrudates was carried out (Figure 5.2).  
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Figure 5.2 Schematic representation of ibuprofen-Affinisol 100cP mechanical 
study 
5.1.1 Introduction 
Melt rheology is one of the critical material attributes in the processing of ASDs 
using HME. It is important to understand the melt rheology of the API-polymer 
blends to gauge the challenges that may arise during HME. Furthermore, 
mechanical properties of the extrudates might provide an insight into 
downstream processing and stability challenges. Linking melt rheology and 
mechanical properties of extrudates will thus provide a detailed understanding 
of the shortcomings during formulation development of ASD using HME.  
Various processing stages like, solid state conveying, melting, mixing, melt 
conveying and shaping occur during HME. To aid this, suitable temperature 
profiles and pressure is required. Thus, investigating melt flow rheology 
becomes critical in minimising HME trails and optimisation.  
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Rheology is the study of flow and deformation and is generally studied by 
measuring effects generated by an applied force. Applied force per unit area 
is stress while deformation is a strain. The most important parameter 
describing melt rheology is viscosity. Viscosity is resistance to flow and is due 
to the relationship between applied stress and deformed strain (Aho et al. 
2015). Materials are broadly classified as Newtonian or non-Newtonian fluids. 
Melt flow behaviour to an applied stress can be categorised as viscous flow, 
elastic deformation or viscoelasticity. Elastic deformation means the material 
continues to deform as a function of stress but retards to its original form upon 
removal. Viscous flow works the exact opposite and does not retard upon 
removal of stress. Viscoelastic materials exhibit a mixture of both elastic and 
viscous flow. Most polymers are viscoelastic in nature and behave as non-
Newtonian fluids. The viscosity of non-Newtonian materials is not constant and 
the relationship between stress and strain can be non-linear (Mezger 2011). 
Polymer melts also show shear thinning behaviour as the melt viscosity 
decreases with increase in shear. This behaviour is of critical importance in 
terms of HME processing.  
During HME, processing parameters like torque, pressure and die swell will be 
impacted if appropriate temperature profiles are not used and a direct 
implication on the melt flow of the API-polymer blend will be observed. Further, 
surface roughness or shark skin effect can be observed due to less shear 
thinning (Mezger 2011). Hence, studying of melt rheology is important in HME 
process development. Similarly, understanding the effect of shear and strain 
on the extrudates will provide an insight into the selection of downstream 
processes and stability.  
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Another aspect impacting HME is the plasticisation effect imparted due to 
solubilisation of the API within the polymer. Solid state miscibility and solubility 
between API-polymer blends will impact the individual glass transition 
temperature to give mostly a single glass transition temperature to the system. 
This will have a huge impact on the processability of the materials as HME is 
carried out above the Tg or Tm of the blends and hence the impact of drug 
concentration on melt rheology in respect to plasticisation needs to be 
investigated in detail. Plasticisation will also have an impact on the mechanical 
properties of the extrudates which will have a direct effect on the choice of 
downstream processes (Van Renterghem et al. 2017b). The current work will 
focus on three aspects, material characterisation, melt processability and 
impact of plasticisation.  
Rheology of the materials can be characterised by the viscosity and modulus 
of the material. The slope of stress and strain depicts a measure of material 
stiffness which is the modulus of the materials. Storage modulus (elastic 
modulus) represents the amount of energy stored per cycle whereas loss 
modulus (viscous modulus) represents the portion of strain which is 90° out of 
phase (Jones et al. 2012). The storage modulus and loss modulus are 
symbolised as G', G'' and E', E'' for melt and solid phase. The ratio of loss 
modulus to storage modulus is the tangent of the phase angle between the 
stress and strain is called Tan delta (δ) (Cogswell 1981; Menard 2008; Mezger 
2011).  
Rheological measurements can be carried out using a time-temperature 
superimposition principle also called the Boltzmann superposition principle. 
The effect of modulus as a function of time or temperature at the constant time, 
152 
 
temperature, strain, stress, and amplitude is studied (Menard 2008; Jones et 
al. 2015). Rotational rheometer and DMA experiments are conducted in the 
linear viscoelastic region where applied stress is proportional to deformed 
strain. Measurement of melt rheology is done using rotational rheometry (low 
shear rates) and capillary rheometry (high shear rates).  
 
Figure 5.3 Schematic representation of rotational (left) and capillary (right) 
rheometer (Kelly 1997) 
Capillary rheometry mimics the melt flow through an extruder die by subjecting 
the samples in a pre-heated barrel through various shear rates (Figure 5.3). 
Capillary rheometers are used to determine shear and extensional properties 
of the fluid under a range of shear strain rates and temperatures. Capillary 
rheometers can measure shear rates from 10 to 106s-1. Melt viscosity is 
significantly affected by temperature, pressure and flow rate. In capillary 
rheometry, a sample is melted before being extruded by a piston through a 
capillary die. Pressure drop through the die is measured at a known flow rate, 
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defined by piston velocity. Shear stress across the wall is measured by the 
drop in pressure through the capillary die. Capillary rheometer typically 
generates shear rates similar to HME and thus mimics the process except 
mixing element. The values of wall shear stress (Ʈw) and the apparent shear 
strain rate (γ ° app) for Newtonian fluids is obtained using the following 
equation (Paradkar et al. 2009):   
Ʈw =
𝐷∆𝑃
4L
                              γ ° app =
4Q
πR3
                                      Equation 5.1 
Where,  
ΔP Pressure drop (Pa) 
L  Length of the die (m) 
D  Diameter of the die (m) 
Q  Volumetric flow rate (m3/s) 
R  Radius (m) 
As stated before, most of the polymers used in pharma are non-Newtonian 
fluids hence a correction is needed. Slip at the die wall and end pressure drop 
was corrected by using a zero die (orifice die) and Bagley correction. The 
revised equation for shear stress is:  
Ʈw =
(∆𝑃𝐿−∆𝑃𝑜)×𝑅
2𝐿
                                                                            Equation 5.2 
 
The complex viscosity is calculated by:  
ɳ =
Ʈw
γ app
                                                                                         Equation 5.3 
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Rotational rheometry is used to study the shear dependent behaviour of the 
materials. The effect of temperature and viscous and elastic behaviour can be 
studied using this rheometer. Rotational rheometry is useful in studying melt 
rheology between shear rates of 0.001 to 100s-1. A parallel plate rotational 
rheometer was used to decrease the equilibrium time between internal and 
external stress which is useful for viscoelastic polymers. This type of geometry 
is recommended for viscous polymers. Gap size between the plates is typically 
1mm. Stress was applied in an oscillatory mode which was generated with one 
bottom stationary plate and an upper moving plate (Figure 5.3). To understand 
at what strain the material can undergo without damage, amplitude sweeps 
were carried out where the samples was oscillated at a low frequency at 
increasing strains to find out the linear viscoelastic region (LVE) and yield point 
which point after which stress and strain are not directly proportional to each 
other. The samples were then held at constant strain with varying shear rates 
to calculate modulus and viscosity. The complex viscosity is calculated by:  
ɳ =
2𝑀𝐻
𝜋𝑅4𝜔
                                                                                         Equation 5.4 
Where, ɳ is the viscosity, M is the torque, ω is the angular frequency, R is the 
radius, H is the gap size (Mezger 2011).  
DMA is used to study the mechanical properties of the extrudates. Modulus is 
generated by applying an oscillating force to materials and analysing its 
response. DMA can be used to understand the following (Jones et al. 2012): 
1. The tendency to flow i.e. Dynamic viscosity in its solid state 
2. Stiffness within the material i.e. Storage and Loss modulus 
3. Ability to lose energy as a function of temperature i.e. damping 
155 
 
4. Ability to recover after release of energy i.e. Elasticity. 
The storage (elastic) modulus E' and loss (viscous) modulus E'' is defined as 
follows (Jones et al. 2012): 
E′ = (
𝜎0
γ0
) cos 𝛿         E′′ = (
𝜎0
γ0
) sin 𝛿                                                Equation 5.5 
Understanding rheology as stated not only will help in process development 
but also provide an insight into challenges during downstream processing and 
stability. Depending on the viscosity, tensile strength, and modulus of the 
extrudates, downstream process can be selected. Stability plays an important 
in formulation development of the ASD. Tracing of crystallisation of API is one 
of the key parameters during product development of ASD. The objective of 
the present study is to understand the effect of ibuprofen concentration on the 
mechanical and rheological properties of IBU-AffTMHPMC extrudates by HME. 
The extrudates were pelletised and compressed into films for rheological 
studies. Detailed investigation of extrudates include (1) effect of % IBU load 
on the extrusion temperature and torque along with tracking of of-line 
crystallisation kinetics for 40% drug load extrudates, (2) complex viscosity 
variation using capillary and rotational rheometers (3) effect of the G',G'', E' 
and E'' with increase in % ibuprofen concentration within the extrudates. 
Additionally, correlation of tan delta values with theoretical glass transition 
values obtained using Fox equation. Dissolution of all the pellets was 
compared. Type of release mechanisms were studied by model fitting to 
calculate the rate of release constant using different models.  
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5.1.2 Results and Discussion 
Preparation of the extrudates and films with HME and CM (Figure 5.4) was 
briefly described in chapter 3. Confirmation of solid state stability of the 
extrudates is explained in chapter 5.3.  
 
Figure 5.4 Ibuprofen-Affinisol 100cP extrudates and films  
5.1.2.1 Effect of drug concentration on the extrusion temperature and 
torque 
Set temperature profile for HME is an important parameter for consideration. 
The temperature profile will have a direct impact on the torque and pressure 
generated during HME. Torque is generated by the resistance provided by the 
twin screws on the molten material blends at the processing parameter. 
Maximum torque generated by the Pharmalab 16mm extruder is 32Nm i.e. 
16Nm by each screw. For data equality, the higher range of extrusion 
temperature window for each ibuprofen-Affinisol 100cP blend was selected. 
To ensure similar conditions for each blend, screw configuration, screw speed 
and feed rate were kept constant. A linear decrease in torque was observed 
with an increase in the concentration of IBU in the extrudates (Figure 5.5). This 
affirms the plasticisation effect of ibuprofen on the ibuprofen-Affinisol 100cP 
blends which decreased the Tg of the ASDs.  
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Figure 5.5 Torque analysis for ibuprofen-Affinisol 100cP blends 
5.1.2.2 Melt Rheology  
5.1.2.2.1 Effect of IBU concentration on complex viscosity at different 
temperatures 
Shear rates affect the melt viscosity of the material and hence their effect 
should be studied in detail. Figure 5.6 shows an overlay of shear viscosity vs 
shear rate for Affinisol 100cP and ibuprofen-Affinisol 100cP extrudates. The 
correlation was established for at least one common temperature between 
each % IBU load except for 40% IBU load. An increase in shear viscosity was 
observed for each blend with a decrease in temperature. Additionally, shear 
viscosity at the extrusion temperature for each blend was observed to 
decrease with increase in % IBU load. This affirms the decrease in torque 
observed during extrusion of all the blends. 
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Figure 5.6 Overlay of capillary data for ibuprofen and Affinisol 100cP blends 
The data obtained from capillary rheometry was using the Power law equation 
(Paradkar et al. 2009):  
ɳ = K ∗ (σ)𝑛−1                                                                 Equation 5.5 
Whereby, σ is shear rate, 𝑛 is the power law index and K is consistency index. 
They both are obtained by plotting log shear stress vs log shear rate. The slope 
of the line provides the power law index where the consistency index is the 
intercept.  
Power law index indicates whether the blends depict shear thinning or 
thickening capability, n < 1 indicates shear thinning. Table 5.1 provides the 
power law index and consistency index for the ibuprofen-Affinisol 100cP 
blends.  
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% IBU-Affinisol 
100cP 
extrudates  
Shear Thinning 
index (n) 
Consistenc
y index (k) 
Temperatur
e (°C) 
R2 
Affinisol 100cP  
0.2026 134.66 180 0.94 
0.3202 151.03 170 0.96 
0.2525 208.58 160 0.54 
10%IBU  
0.115 128.59 170 0.93 
0.1631 143.66 160 0.96 
0.2441 162.55 150 0.96 
20%IBU  
0.0683 117.42 160 0.92 
0.0841 118.32 150 0.91 
0.0965 136.02 140 0.93 
30%IBU 
0.0481 102.56 150 0.90 
0.0564 98.202 140 0.93 
0.0719 99.685 130 0.90 
40%IBU 
0.0416 85.778 130 0.91 
0.05 85.121 120 0.91 
0.0541 89.66 110 0.84 
Table 5.1 Power law and consistency index of ibuprofen and Affinisol 100cP 
blends 
All the blends showed shear thinning and an increase in the shear thinning 
index was observed with decrease in temperature with an exception of Affinisol 
100cP at 160°C which also showed lower regression value. However, the 
shear thinning ability of extrudates increased with an increase in % IBU load 
within the extrudates.  
5.1.2.2.2 Effect of Angular Frequency/Time sweep on Complex Viscosity 
of different % drug load extrudates  
Shear thinning was observed in all ibuprofen-Affinisol 100cP blends. Hence a 
detailed investigation of the effect shear rate on viscosity is important. 
Rotational rheometry was used to study the viscosity with respect to angular 
frequency. Additionally, shear rheology provides storage modulus (G') and 
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loss modulus (G'') which provide information on the elastic and viscous 
behaviour of the polymer respectively. As stated previously, polymers used for 
Pharma are viscoelastic in nature hence, G' and complex viscosity will be used 
for correlation with other rheometry. All experiments on the rotational 
rheometer were carried out at 0.1% strain. Figure 5.8 shows an overlay of G' 
vs angular frequency for Affinisol 100cP and ibuprofen-Affinisol 100cP blends. 
For similar comparison purposes correlation was established for at least one 
common temperature between each % IBU load except for 40% IBU load. A 
decrease in storage modulus was noted with a decrease in temperature within 
the particular blend. However, storage modulus decreased with increase in 
ibuprofen concentration of the films. Time sweep experiments for all the blends 
showed no variation in G' and G'' which indicated that the extrudates showed 
no thermal degradation for 30 mins thus confirming no solid state degradation 
(Figure 5.7).   
 
Figure 5.7 Time sweep experiments of ibuprofen and Affinisol 100cP blends 
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Figure 5.8 Frequency sweep experiments of ibuprofen and Affinisol 100cP 
blends 
Complex viscosity at given measuring point can be calculated by using values 
of shear stress, strain, time and temperature. For comparison and to provide 
a better understanding of the rotational rheometer data, various mathematical 
models functions are available for curve fitting (Aho et al. 2016). These can be 
utilised to calculate complex viscosity which can further determine important 
parameters like yield point and zero shear viscosities. For the following study, 
a Carreau-Yasuda model was used to calculate complex viscosities and 
correlate the same with experimental values. The model predicts the complex 
viscosity by using material time constant ʎ, power law index ɳ which denotes 
shear thinning capability and Yasuda constant p which provides a transition 
region between zero shear-rate and power law.   
Experimental results and model fitting results were found to be in accordance 
with all the blends. Figure 5.9 shows the overlay of complex viscosity obtained 
from Carreau-Yasuda model vs angular frequency.  
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Figure 5.9 Complex viscosity obtained using Carreau-Yasuda model fit for 
Affinisol 100cP  
  
Figure 5.10 Complex viscosity obtained using Carreau-Yasuda model fit for 
ibuprofen and Affinisol 100cP blends 
A similar trend was observed for complex viscosity. Complex viscosity 
increased with a decrease in temperature within the same blend whereas it 
increased with decrease in %IBU (Figure 5.10).  
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The focus of the study was to understand the melt behaviour of the API-
polymer blends over a range of temperature and shear rates. Linking rotational 
rheometer data over a range of angular frequencies with capillary rheometer 
data over a range of shear rates can help map and track complex melt viscosity 
behaviour over a range of shear rates. These effects can be studied by using 
Cox-Mertz rule. 
Cox and Merz (Cox and Merz, 1958) derived an equation which links complex 
viscosity obtained from rotational to steady shear rate-viscosity obtained from 
capillary rheometers: 
|
𝝎→𝟎
(ɳ∗ 𝝎) = |
𝜸→𝟎
ɳ (𝜸.)                                                                 Equation 5.6 
Data obtained from capillary and rotational rheometer were fitted together 
using Cox-Mertz equation. Figure 5.11 shows an overlay of Cox-Mertz rule for 
all ibuprofen-Affinisol 100cP blends.  
  
 
Figure 5.11 Cox-Mertz rule for ibuprofen and Affinisol 100cP blends 
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All blends did not follow the Cox-Mertz rule as rotational data and capillary 
data were found not to overlap. Generally, Cox-Mertz holds true for polymeric 
blends which melt and dilute and is generally seen in polymers with linear 
branching. Also, G' data was higher than G'' data for all the blends which 
indicated the visco-elastic nature and thus does not follow the rule. However, 
the difference was found to be less for Affinisol 100cP and 10% IBU-Affinisol 
100cP blends compared to other blends. This can attributed to the sudden 
decrease in the viscosity of the extrudates with increase in ibuprofen content. 
Generally, the Cox-Mertz rule is not followed when the polymer has more than 
one phase or have additives added.  
5.1.2.2.3 Effect of mechanical force and modulus generated by DMA on 
different % drug load extrudates 
Understanding melt rheology has gained importance and detailed studies 
have been increasingly carried out. However, less attention has been given to 
understanding the rheology of the extrudates in its solid state. This is of 
importance as different drug loads have an effect on the tensile strength of the 
extrudates and can provide an insight into understanding the crystallisation of 
the extrudates. Additionally, storage and loss modulus can highlight the 
challenges arising during downstream process like milling.  
The current focus is on mechanical studies carried out using a Dynamic 
Mechanical Analyser (DMA). Modulus is generated within DMA by applying an 
oscillating force to a sample and analysing its response (Jones et al. 2012). It 
is predominantly done to study the viscoelastic properties of the extrudates 
which are primarily contributed to by the polymer used in the physical mixture. 
% strain for the current studies was found to be 0.1% which was calculated by 
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performing strain sweep experiments at an isothermal temperature of 25°C 
and at a constant frequency of 1Hz. Storage modulus or elastic modulus E' 
represents the amount of energy stored per cycle. Loss modulus (viscous 
modulus) E'' represents the portion of strain that is 90° out of phase. The ratio 
of loss modulus to storage modulus is the tangent of the phase angle between 
the stress and strain is called Tan delta (δ). Effect of temperature ramp on both 
moduli was studied using DMA. 
  
Figure 5.12 DMA thermograms for ibuprofen and Affinisol 100cP blends 
Figure 5.12 shows an overlay of Temperature ramp DMA runs at a controlled 
strain of 0.1% for all the ibuprofen-Affinisol 100cP blends. Interestingly, the 
viscous modulus (E'') drastically decreased with an increase in % IBU load. A 
similar decrease in Storage modulus (E') and Tan delta (Δ) values was 
observed with increase in % IBU load. This could be due to plasticity imparted 
by increased ibuprofen content. Thus, high ibuprofen content increases the 
elasticity of the extrudates which could be detrimental to a downstream 
process like milling. Extrudates above 20% ibuprofen load are prone to provide 
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a challenge during milling and therefore cryo-milling of those extrudates 
should be considered. Hence viscosity of the extrudates decreased with 
increase in ibuprofen content which showed a similar trend to melt rheology 
values.   
%IBU 
load 
Storage 
Modulus 
°C (mid-
point) 
Storage 
Modulus 
Mpa 
Loss 
Modulus 
°C 
(peak) 
Loss 
Modulus 
Mpa 
Max Tan 
delta (°C) 
(peak) 
Fox Eqt 
predicted 
values (°C) 
0 113.19 1372 112.03 145.20 128.67 120 
10 73.58 1377 74.06 151.23 93.77 93 
20 41.77 703.33 53.99 131.83 73.60 71 
30 36.02 455.6 40.22 189.67 59.32 53 
40 34.73 191.57 34.39 99.46 45.03 34.91 
Table 5.2 DMA data of ibuprofen and Affinisol 100cP blends 
Glass transition temperature for API-polymer blends represents the kinetic 
boundary of molecular mobility (Qian et al. 2010). Below glass transition 
temperature molecules have less molecular mobility and thus decrease 
chances of recrystallisation and thus are more stable. Of various techniques 
available DSC and DMA are commonly used for detection of glass transition 
temperature (Lin and Huang 2010). For the current ibuprofen-Affinisol 100cP 
blends, no glass transition event was observed in DSC. This could be due to 
the viscous nature of the Affinisol 100cP. DMA was also used to detect Tg. The 
peak observed in Tan delta is considered as the glass transition temperature 
of the blend due to the crossing over of E' and E''. This point signifies relaxation 
within the extrudates.  
Predictive equation models for determination of glass transition temperature 
of solid dispersion blends are available (Jayachandra Babu et al. 2009). Of 
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these, the Fox equation is the simplest and assumes random mixing between 
two components and equal heat capacity value contribution (Kalogeras and 
Brostow 2009). It is the only equation which calculates the glass transition from 
pure components only and does not involve any fitting parameters 
(Jayachandra Babu et al. 2009; Kalogeras and Brostow 2009). Thus, it can be 
inferred that ASDs formed purely due to solid-state miscibility should follow 
values generated using the Fox equation.   
 
Figure 5.13 Experimental and theoretical glass transition temperature values 
of ibuprofen and Affinisol 100cP blends 
The Tan delta values obtained were found to correlate with the theoretical 
values obtained by the Fox equation (Table 5.2 and Figure 5.13). Also, co-
relation was seen more for 10 and 20%w/w drug loading. Fox equation as 
stated, assumes random kinetic mixing between API and polymer and hence 
slight deviation will be due to insolubility. Thus, the deviation suggests the 
supersaturation of IBU within Affinisol 100cP above 20%w/w. 
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Formation of amorphous solid dispersions between ibuprofen and Affinisol 
100cP thus could be purely due to solid-state miscibility of the two. Correlation 
between values obtained by the Fox equation and DMA confirm the absence 
of inter-component interaction in the melt and glassy state of the ibuprofen-
Affinisol 100cP mixture. Along with an overview of the visco-elastic nature of 
extrudates, the DMA was also helpful to identify the absence of inter-
component interaction between ibuprofen-Affinisol 100cP blends.    
The main aim of the study was to understand and track the rheology of the 
API-polymer blends from the melt phase to an amorphous solid dispersion 
phase. Rotational and capillary rheometers were able to provide an overview 
of the complex viscosity over a range of shear rates. Time sweep data from 
rotational rheometry confirmed the absence of solid state degradation with the 
ibuprofen-Affinisol 100cP blends for 30mins. Confidence in data was 
confirmed by applying a model fit using the power law model (capillary 
rheometer) and Carreau-Yasuda model (rotational rheometer). Model fit data 
were found to correlate with experimental values.  
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Figure 5.14 Rotational and DMA data for ibuprofen and Affinisol 100cP blends  
Visco-elastic properties of extrudates were confirmed using DMA. A similar 
trend of decrease in viscosity was observed with increase in ibuprofen content. 
It also provided an insight ibuprofen drug loads which can provide a challenge 
during milling. Tan delta values from DMA overlapped with theoretical values 
obtained from Fox equation and thus confirmed the absence of inter-
component interaction between ibuprofen and Affinisol 100cP in ASD. An 
attempt to map the storage modulus E' & G' obtained from DMA and rotational 
rheometry over a range of temperature can be seen in figure 5.14. A large 
difference was observed between the moduli of melt and a solid phase for all 
the ibuprofen-Affinisol 100cP blends. Thus, understanding shear thinning 
behaviour and visco-elastic nature of extrudates provide a platform for 
optimisation of process for amorphous solid dispersion using HME. 
5.1.2.2.4 Crystallisation kinetics using an ortho-analytical approach 
Solid state stability of amorphous solid dispersions is one of the limiting steps 
in its development. A detailed investigation of the rheology of ibuprofen and 
Affinisol 100cP from its melt phase to the solid phase was conducted. In-line 
tracking of crystallisation of extrudates of 40% ibuprofen load was carried out. 
Off-line tracking of extrudates were carried out at three different stability 
conditions and recrystallisation analysed with an ortho-analytical approach 
using XRD, DSC and Raman spectroscopy. These studies are discussed in 
detail in chapter 5.3.  
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Figure 5.15 In-line Raman studies of 40% ibuprofen and Affinisol 100cP blend 
40%ibuprofen-Affinisol 100cP extrudates took 15 days for recrystallisation on 
open exposure (Figure 5.15). A decrease in a shift of the Raman band of 
1615cm-1 to 1607cm-1 was observed. This shift is attributed to aryl chain 
deformation and C-H stretching and bending which occurs due to disorder 
within the structure and is characteristic of the amorphous state of ibuprofen 
(Liu and Gao 2012). The recrystallisation of the extrudates was quicker due to 
its low glass transition temperature of 45°C which was calculated using DMA. 
Raman spectroscopy was able to track the recrystallisation of the 40% 
ibuprofen loaded extrudates.  
5.1.2.2.4 Drug release  
Drug release mechanisms of solid dispersions were described in chapter 2. In 
ASDs, the release of the drug primarily depends on the drug entrapment within 
the polymer matrix. However, physicochemical properties of the product and 
thermal processing history can also have an effect on dissolution (Yang et al. 
2016; Chen et al. 2017a; Chen et al. 2017b). Dissolution of the product follows 
the Noyes-Whitney equation where the rate of dissolution (dc/dt) is directly 
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proportional to surface area and inversely proportional to the drug-polymer 
layer thickness (Siepmann and Siepmann 2013).  
𝒅𝒄
𝒅𝒕
=
𝐃 𝐀
𝐝
  (𝐂𝐬 − 𝐂)                                                                           Equation 5.7 
Where 
𝒅𝒄
𝒅𝒕
 is the  rate of dissolution, 𝐃 is the diffusion co-efficient, 𝐝 is boundary 
layer thickness, 𝐂𝐬 is the saturation solubility, 𝐂 amount of drug dissolved at 
time T. 
Visual observations of the pellets at the start and end of dissolution time can 
be seen in Figure 5.16. Visual observations show that the release of ibuprofen 
through the matrix is dual in nature. The polymer boundary swells but drug 
releases through erosion. More studies need to be performed to confirm these 
mechanisms.   
 
Figure 5.16 Dissolution of ibuprofen and Affinisol 100cP pellets 
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Figure 5.17 Drug release of ibuprofen and Affinisol 100cP pellets  
All the ibuprofen-Affinisol 100cP pellets showed sustained release. Drug 
release reduced with increased ibuprofen concentration in the extrudates. This 
could be due to recrystallisation of ibuprofen within the matrix which will act as 
a barrier to the boundary layer and thus decrease drug release (Costa et al. 
2003). Also, ibuprofen dose was not kept constant across all the %drug load 
extrudates.  
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Figure 5.18 Dissolution kinetic model fitting for ibuprofen and Affinisol 100cP 
pellets 
Drug-polymer 
system 
Model fitting Release 
mechan
ism 
Zero-
order 
1st 
Order 
Higuc
hi 
Hix. 
Crow 
Peppas 
10%Ibuprofen- 
Affinisol 100cP 
pellets 
R2 = 
0.8665 
𝑘 = 
0.1740 
* 
R2 = 
0.9982 
𝑘 = 
3.8343 
 
R2 = 
0.9938 
𝑘 = -
0.0015 
 
R2 = 
0.9938 
n = 
0.4943 
k = 
3.9002 
Peppas  
20%Ibuprofen- 
Affinisol 100cP 
pellets 
R2 = 
0.9408 
𝑘 = 
0.1211 
R2 = 
0.9916 
𝑘 = -
0.002 
R2 = 
0.9875 
𝑘 = 
2.6049 
R2 = 
0.9861 
𝑘 = -
0.0006 
R2 = 
0.9970 
n = 
0.580 
k = 
1.5896 
Peppas  
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30%Ibuprofen- 
Affinisol 100cP 
pellets 
R2 = 
0.7975 
𝑘 = 
0.0854 
R2 = 
0.9082 
𝑘 = -
0.0011 
R2 = 
0.9963 
𝑘 = 
1.9076 
R2 = 
0.8780 
𝑘 = -
0.0003 
R2 = 
0.9963 
n = 
0.4586 
K = 
2.4154 
Peppas  
40%Ibuprofen- 
Affinisol 100cP 
pellets 
R2 = 
0.7739 
𝑘 = 
0.0772 
R2 = 
0.8873 
𝑘 = -
0.001 
R2 = 
0.9934 
𝑘 = 
1.7285 
R2 = 
0.8559 
𝑘 = -
0.0003 
R2 = 
0.9888 
n = 
0.4128 
k = 
2.8131 
Peppas  
Table 5.3 Model fit parameters for ibuprofen and Affinisol 100cP pellets 
*Insignificant  
To obtain a detailed understanding of the drug release of all blends, release 
kinetics with different model fitting was carried out. Mathematical models are 
well established and extensively used for release kinetic prediction (Costa et 
al. 2003; Baishya et al. 2017; Hirai et al. 2017). The current study involves the 
use of Zero order, 1st order, Higuchi, Hixson-Crowell and Korsmeyer-Peppas 
model to study release kinetics. These models were specifically developed for 
drug-polymer diffusion systems.  
Zero-order release kinetics is one of the simplest where constant drug release 
is achieved at all given time points. If the drug dissolution follows zero order 
kinetics then the release is found to be controlled release.  
First order kinetics depends on the concentration of the drug within the 
polymer matrix.  
The Higuchi or Matrix model was the first model developed for drug-polymeric 
diffusion systems. Drug diffusion through a polymer matrix can either be 
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Fickian or non-Fickian. Fickian diffusion is when the rate of drug release is 
independent of the drug concentration. The Higuchi model assumes the drug 
diffusion to be Fickian in nature and assumes both dissolution and diffusion 
happening at same time.  
The Korsmeyer-Peppas model builds upon Higuchi model. Once, drug 
diffusion is established by the Higuchi model, the Korsmeyer-Peppas model 
focuses on the mechanisms of dissolution from the matrix. It also considers 
swelling of polymer which is not considered in Higuchi model. Along with 
kinetic constant 𝑘 ,it also calculates the release component n. Depending on 
the value of n, one can predict the type of diffusion (Costa et al. 2003).  
The Hixson-Croswell model takes into consideration the surface area and 
diameter of the particles. Thus, it is a strong model for the understanding of 
drug-diffusion within polymer matrix by an erosion mechanism. However, this 
model is used for powders and thus is not applicable for pellets. An overview 
of the models used is provided in table 5.4. 
Release models Type of release mechanism  
Zero-order Constant release rate 
First order Dependent on the concentration of the drug 
Higuchi Fickian diffusion mechanism 
Krosmeyer-Peppas 
model 
Diffusion based mechanism  
n<0.45 = Fickian Diffusion, 0.45<n<0.89 = Non 
Fickian Diffusion, n>0.89 = Zero order release 
Hixson-Croswell Erosion based mechanism 
Table 5.4 Overview of dissolution kinetic model fitting (Costa et al. 2003; 
Baishya et al. 2017) 
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The entire model fit graph and calculated release constant with a regression 
coefficient for all the extrudates can be seen in Figures 5.17 and 5.18 and 
Table 5.3 and 5.4.  
All the ibuprofen-Affinisol 100cP pellets showed best fit for Korsmeyer-Peppas 
models. The release rate constant was also highest for the Korsmeyer-Peppas 
model. The release component n was higher than 0.45 for all the pellets hence, 
drug diffusion follows a non-Fickian mechanism. This could be due to a solid 
barrier formed due to crystallisation of extrudates for higher drug loading of 30 
and 40%w/w. Thus, dissolution kinetics is dependent on ibuprofen 
concentration for all pellets. 
To summarise, model fitting of dissolution data for the extrudates confirmed 
that the drug release for all pellets was sustained release. Drug diffusion 
through the polymer matrix was due to a dual mechanism of swelling and 
erosion. The decrease in dissolution rate with increase in ibuprofen 
concentration was due to recrystallisation of ibuprofen within the polymer 
matrix.  
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5.2 Effect of process parameters on the product performance if IBU-
Affinisol 100cP solid dispersion 
The current study focusses on the effect of process parameters on the product 
performance using hot melt extrusion. Taguchi method was used to analyse 
the effect of process variables, feed rate, screw speed and configuration. 
Mean residence time, torque and pressure were used as in-line responses 
while DSC and dissolution were used as responses for the extrudates 
generated. A detailed description about process parameters and responses 
used was provided in chapter 3.  
5.2.1 Introduction 
To understand the effect of critical process parameters on the critical quality 
attributes, a design of experiments or multivariate analysis can be carried out. 
Depending on the criticality, level of the factorial design is fixed (Montgomery 
2000). A full factorial design provides insight on effect of a single parameter 
as well as interactions between parameters.  
As discussed in chapter 5.1, the HME process window was set for all drug 
loadings of ibuprofen and Affinisol 100cP blends. The aim was to focus on 
process parameters apart from temperature profiles, hence independent 
parameters like feed rate, screw speed and screw design were selected. In-
line response data was collected using residence time, torque and pressure 
while offline response data was collected using DSC and dissolution. The 
entire design was carried out using a Taguchi method as the focus was on 
finding the robustness of the ibuprofen-Affinisol 100cP blends. Hence, 
interactions between the parameters was not investigated.  
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A typical stage of conducting design of experiments involves a clearly defined 
design space and selection of critical process parameters. After design of the 
experimental space, processing runs are carried out and data is generated 
using in-line and off-line responses. Data generated may be refined or data 
treatment carried out to compensate for any personal or analytical errors. 
Multiple regression analysis is carried out using different responses and a 
model developed to establish the relationship between the dependent and 
independent variables. Lastly, to confirm the predictive model, Annova is 
applied.  
The current study investigates process parameters in terms of process 
robustness but a full factorial design should be carried out to study the deep 
impact of interaction of process parameters. Responses were analysed using 
Taguchi method. Furthermore, multiple regression analysis using analysis of 
variance (ANOVA) was carried out to statistically find critical impacts by the 
single parameters using P-value. Non-significant variables were eliminated 
using backward elimination method. For the current study, 40% drug load of 
ibuprofen was selected. The process temperature window was wide for this 
drug load and viscosity of the extrudates is low due to plasticity imparted by 
the ibuprofen. Additionally, for offline studies the extrudates crystallise out 
within 3 day and a good correlation of the crystallisation kinetics can be 
observed at 15 days on 40°C/75%RH conditions.  
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5.2.2 Residence time measurement 
HME consists of feeding, degassing and extruding in a continuous phase 
(Wesholowski et al. 2018). This process can be further broken down into solid 
state conveying, melting, mixing, melt conveying and shaping which are 
heavily impacted by different critical process parameters like feed, 
temperature, screw speed and configuration. A common parameter linking 
them all is residence time distribution.  
Residence time during HME is important to determine the extent of solid state 
miscibility and solubility between the API and polymer to produce single phase 
solid dispersion. Higher residence times have a direct impact on the thermal 
degradation of the material. This may result in decreasing the purity of the API 
and increase of impurities with the extrudates (Karandikar et al. 2015). Lower 
residence time will impact the mixing and kneading of the blend and may in 
turn not produce a single phase extrudate (Ziegler and Aguilar 2003). Hence 
optimising residence time plays a crucial role in process optimisation using 
HME.  
Very few studies have been reported in literature about residence time 
distribution. Residence time distribution (RTD) can be calculated either by a 
formulation/step change (Ziegler and Aguilar 2003) or by placing a tracer 
within the process (Reitz et al. 2013; Engisch and Muzzio 2016; Wesholowski 
et al. 2018). Wahl et al. calculated residence time distribution using in-line 
video analysis, however, analysis was performed off-line (Wahl et al. 2018). 
Although, residence time distribution is important factor, very few studies have 
been reported highlighting its importance.  
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A typical residence time distribution plot looks similar to a normal distribution 
plot (Figure 5.19). Tonset represents the minimum time required for molten mass 
to reach the die and extrude out. This parameter denotes duration time 
required for the process and is critical if solid state impurity is one of the critical 
product performances.  T50% represents time required for the 50%w/w of 
marker to extrude out from the process. This parameter is more robust and 
provides an average transit and mean processing time (Wesholowski et al. 
2018).  
 
Figure 5. 19 Typical residence time distribution curve 
For determination of RTD of HME, various PAT tools are available. Off-line 
techniques like intensity of colour (Mu and Thompson 2012), UV absorption 
(Reitz et al. 2013) or radioactive radiation (Janssen et al. 1979) are reported 
for determination of RTD. However, these techniques do not provide a true 
representation of the process and loss of material will be significant as 
compared to in-line measurements. In-line tools using magnetic susceptibility 
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(Puaux 2000), light scattering (Wahl et al. 2018) and UV-fluorescence 
spectroscopy (Wesholowski et al. 2018) are reported in calculating RTD in 
HME.  
This study utilises an in-line high temperature UV-vis probe in continuous 
mode and uses a UV tracer to calculate the RTD. The method for residence 
time measurement was explained in chapter 3. For the DOE study, only 40% 
drug load was selected. However, a mono variate experiment to calculate the 
mean residence time was conducted for all the drug loads of ibuprofen and 
Affinisol 100cP blends (Figure 5.20). Screw configuration for the blends had 
one mixing and kneading zone and feed rate was kept constant at 0.4 kg/hr 
(Figure 5.21) 
 
Figure 5.20 In-line UV measurement during extrusion 
 
182 
 
 
Figure 5.21 Screw configuration used for extrusion   
For all drug loads the total batch size was 0.8kg. Duplicate runs were obtained 
for average and standard deviation. Data obtained is variation with respect to 
time (Figure 5.22). Good correlation was observed within the duplicate runs.  
 
Figure 5.22 Residence time data for all ibuprofen and Affinisol 100cP blends 
The data was further normalised to calculate mean residence time (MRT) 
(Figure 5.23).  
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Figure 5.23 Normalised cumulative residence time data for all ibuprofen and 
Affinisol 100cP blends 
Table 5.5 provides MRT for all the ibuprofen and Affinisol 100cP blends.  
 
%Drug load 
Mean Residence Time (secs) 
Run 1 Run 2 Avg SD 
Affinisol 100cP 380.22 362.00 371.11 12.89 
10% IBU 576.91 586.61 581.76 6.86 
20% IBU 615.58 617.57 616.58 1.41 
30% IBU 627.46 611.51 619.49 11.28 
40% IBU 694.11 672.00 683.06 15.63 
Table 5.5 Mean residence time for ibuprofen and Affinisol 100cP blends 
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MRT for Affinisol 100cP was found to be the lowest. This could be due to its 
decreased particle size and good flow properties. As ibuprofen concentration 
increased, an increase in mean residence time was observed at same feed 
rate. This confirms that the viscosity of the blend decrease with increase in 
ibuprofen concentration.  
5.2.3 Results and Discussion 
Preparation of extrudates using HME was detailed in chapter 3. Pressure and 
Torque was recorded in-line by the instrument, while residence time 
measurements were carried out using a tracer and in-line UV probe. 
Extrudates were further pelletised and used for dissolution studies. Duplicate 
runs were carried out for dissolution. Additionally, extrudates were stationed 
at 40°C/75%RH and analysed for recrystallisation on 15th day using DSC in 
duplicates.  
 
Run 
order 
Processing Parameters Response 
Screw 
configuration 
Screw 
speed 
(rpm) 
Feed 
rate 
(kg/hr) 
Residence 
time (secs) 
% 
Torque 
Pressure 
(bar) 
DSC 
(J/g) 
%Drug 
release at 
720 mins 
1 -1 100 0.4 533.42 13 12 20.64 34.92 
2 -1 300 0.5 411.06 14 9 10.89 31.33 
3 -1 500 0.6 297.24 10 6 11.03 39.32 
4 0 100 0.5 705.41 20 12 13.67 30.34 
5 0 300 0.6 345.62 15 8 16.55 29.19 
6 0 500 0.4 603.84 13 4 11.29 27.40 
7 1 100 0.6 318.43 24 15 11.23 45.26 
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8 1 300 0.4 554.22 18 9 11.14 45.47 
9 1 500 0.5 597.60 17 4 10.86 39.31 
Table 5.6 Taguchi method with response for 40%IBU-Affinisol 100cP blend 
Table 5.6 provides taguchi design with responses observed during and after 
extrusion.  
5.2.3.1 Residence time measurement 
The main effects and residual plots for means of the response generated were 
calculated using Minitab software. Larger the better option was selected for 
signal to noise ratio. Since it is a Taguchi design, interaction parameters were 
not selected. Figure 5.24 shows the main effects and residual plot for 
residence time response. 
 
Figure 5.24 Main effects and residual plot for residence time measurement 
response 
For the main effects plot it can be noted that feed rate is the only parameter 
which had effect on the residence compared to screw configuration and speed. 
To confirm the same, a regression analysis was carried out by applying 
ANOVA to find out P-values of the process parameters (Table 5.8).  
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Analysis of Variance for residence time 
Source DF Seq SS Adjusted 
MS 
F-Value p-Value 
Regression 
 
117993 29498.3 2.25 0.226 
Screw speed 2 572 572 0.04 0.845 
Feed rate 2 88864 88864.1 6.78 0.06 
Screw 
Configuration 
2 28557 14278.5 1.09 0.419 
Error 2 52421 13105.3 
  
Total 8 170414 
   
Model Summary 
S R-sq R-sq (adj) 
   
114.478 69.24% 38.48% 
   
Regression Equation 
Screw 
configuration 
-1             Residence time = 1037 - 0.049 Screw speed - 1217 Feed rate 
 
0              Residence time = 1175 - 0.049 Screw speed - 1217 Feed rate 
 
1              Residence time = 1113 - 0.049 Screw speed - 1217 Feed rate 
 Table 5.7 Analysis of variance for residence time response.  
Thus, only feed rate was found to be a critical factor affecting residence time 
measurement. This confirms the observations of the model fitted for main 
effects plot using the Taguchi method. It can be inferred that residence time 
measurement for 40%IBU-Affinisol 100cP blend is only affected by feed rate 
for the current DOE. Higher feed rate will significantly lower the residence time 
of the 40%IBU-Affinisol 100cP blend. 
5.2.3.2 Torque 
Torque as explained before, is one of the critical parameters in process 
optimisation. An increase in torque can have a significant impact on the 
stability of the end product. Detailed investigation of the melt rheology of the 
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API-Polymer blends will provides an insight to challenges to expect during 
HME process. This was explained in chapter 5.1 for all drug loads. Current 
focus was only on the 40% drug load of ibuprofen-Affinisol 100cP blend.  
Main effects and residual plot for % torque as response was analysed using 
Minitab software (Figure 5.25). It was observed that screw configuration and 
screw speed had a significant impact on the torque compared to feed rate.  
 
 
Figure 5.25 Main effects and residual plot for % torque response 
Torque was highest for the screw configuration with two mixing elements and 
low screw speed. To confirm the model fit a multiple regression analysis using 
ANOVA was carried out. P-values for screw configuration and screw speeds 
were found to be significant (5.9).  
Analysis of Variance for Torque 
Source  DF Seq SS 
Adjusted 
MS F-Value 
p-
Value 
Regression 4 133 33.25 12.09 0.017 
Screw speed 1 48.167 48.167 17.52 0.014 
Feed rate 1 4.167 4.167 1.52 0.286 
Screw 
configuration 2 80.667 40.333 14.67 0.014 
Error 4 11 2.75     
Total  8 144       
Model Summary 
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S R-sq 
R-sq 
(adj) 
R-
sq(pred)     
1.65831 92.36% 84.72% 63.18%     
Regression Equation 
Screw 
configuration 
-1             Torque = 12.42 - 0.01417 Screw speed + 8.33 Feed rate 
 
0              Torque = 16.08 - 0.01417 Screw speed + 8.33 Feed rate 
 
1              Torque = 19.75 - 0.01417 Screw speed + 8.33 Feed rate 
Table 5.8 Analysis of variance for % torque response 
By using a back elimination method a response surface plot was plot using 
screw configuration and screw speed as variables (Figure 5.26).   
 
Figure 5.26 Response surface plot for %torque as response 
Higher screw speed and no mixing elements resulted in the lowest % torque. 
This will hold true if solid state solubility and miscibility remains the same 
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irrespective mixing element contribution. This needs to be cross-checked with 
off-line responses of DSC and Dissolution.  
5.2.3.3 Pressure 
Pressure generation during HME occurs due to resistance in melt flow of API-
polymer blend. From a safety perspective, this can have a significant impact 
and is a critical parameter for consideration during FMEA analysis.  
Main effects and residual plots for pressure as a response are shown in figure 
5.27. It was observed that screw speed was the only parameter which had a 
huge impact on the pressure generated. However, it is worth noting that the 
highest pressure generated was below the limit of 80bar which is a safety cut 
off for the extruder.  
 
Figure 5.27 Main effects and residual plot for pressure response  
Anova for confirming the model fit showed only screw speed as parameter 
affecting pressure (Table 5.10). An assumption was that the screw 
configuration will also have an impact on the pressure but was found to be 
insignificant for the 40%IBU-Affinisol 100cP blend. 
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Analysis of Variance for Pressure 
Source  DF Seq SS 
Adjusted 
MS F-Value 
p-
Value 
Regression  4 109.722 27.431 28.62 0.003 
Screw speed 1 104.167 104.167 108.7 0 
Feed rate 1 2.667 2.667 2.78 0.171 
Screw 
configuration 2 2.889 1.444 1.51 0.325 
Error 4 3.833 0.958     
Total  8 113.556       
Model Summary 
S R-sq 
R-sq 
(adj) 
R-
sq(pred)     
0.978945 96.62% 93.25% 78.8     
Regression Equation 
Screw 
configuration 
-1             Pressure = 11.92 - 0.02083 Screw speed + 6.67 Feed rate 
 
0              Pressure = 10.92 - 0.02083 Screw speed + 6.67 Feed rate 
 
1              Pressure = 12.25 - 0.02083 Screw speed + 6.67 Feed rate 
Table 5.9 Analysis of variance for pressure response 
A higher screw speed resulted in lower pressure generation. Thus for process 
optimisation, highest screw speed of 500rpm was found to optimum for 
minimisation of %torque, residence time and pressure.  
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5.2.3.4 DSC 
DSC was used as response to determine the effect of process parameters on 
the crystallisation kinetics of the blend. Tracking of stability of the extrudates 
over stability conditions was explained in chapter 5.3. It was understood that 
40%IBU-Affinisol 100cP extrudates recrystallised within 15 days on 
40°C/75%RH and hence DSC analysis were carried out on all runs to find out 
the melting enthalpy of the recrystallised ibuprofen. This was then used as a 
comparative response of percent crystallinity. However, for data integrity only 
enthalpy values were used as a response.  
Main effects and residual plot using DSC as a response is depicted in figure 
5.28. Screw configuration and screw speed were found to have a slight effect 
on the enthalpy values of ibuprofen. Screw configuration with two mixing zones 
and screw speed of 500rpm were found to result in lowest enthalpy of 
ibuprofen. However, enthalpy values were found to be close to each other and 
p-values generated by the model fit showed screw configuration and screw 
speed to be insignificant.  
 
Figure 5.28 Main effect and residual plot for DSC response  
Anova applied using screw configuration and screw speed proved the same 
and can be seen in table 5.11.  
192 
 
Analysis of Variance for DSC 
Source  DF Seq SS 
Adjusted 
MS F-Value 
p-
Value 
Regression  4 45.948 11.487 0.96 0.516 
Screw speed 1 25.508 25.508 2.13 0.218 
Feed rate 1 3.03 3.03 0.25 0.641 
Screw 
configuration 2 17.411 8.705 0.73 0.538 
Error 4 47.902 11.976     
Total  8 93.85       
Model Summary 
S R-sq 
R-sq 
(adj) 
R-
sq(pred)     
3.46057 48.96% 0.00% 0%     
Regression Equation 
Screw 
configuration 
-1             DSC = 20.83 - 0.01031 Screw speed - 7.1 Feed rate 
 
0              DSC = 20.48 - 0.01031 Screw speed - 7.1 Feed rate 
 
1              DSC = 17.72 - 0.01031 Screw speed - 7.1 Feed rate 
Table 5.10 Analysis of variance for DSC response  
Thus, screw configuration and screw speed were found to have minimal 
impact on the crystallisation process of the 40%IBU-Affinisol 100cP 
extrudates. However, an increase in mixing zones and screw speed will slightly 
lower the crystallisation of the ibuprofen.  
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5.2.3.4 Dissolution 
Drug release of ibuprofen-Affinisol 100cP blends across all drug loads was 
detailed in chapter 5.1. Drug release plays the most important role in 
formulation development using any process. It has direct impact on the critical 
target profile for and is part of release specifications for any formulated 
product. In this study, only the drug release at 720mins was used as response.  
Main effects and residual plots for dissolution as a response was analysed 
using Minitab software. Screw configuration was seen to have significant 
impact on the drug release compared to screw speed and feed rate (Figure 
5.29).  
 
Figure 5.29 Main effect and residual plot for dissolution response  
Anova was used to confirm the model fit. Screw configuration had a p-value 
less than 0.05 while other two parameters were found to have higher p-values 
(Table 5.12).  
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Analysis of Variance for Disso 
Source  DF Seq SS 
Adjusted 
MS 
F-
Value 
p-
Value 
Regression  4 320.825 80.206 6.23 0.052 
Screw speed 1 3.351 3.351 0.26 0.637 
Feed rate 1 5.959 5.959 0.46 0.534 
Screw configuration 2 311.516 155.758 12.11 0.02 
Error 4 51.462 12.865     
Total  8 372.287       
Model Summary 
S R-sq 
R-sq 
(adj) 
R-
sq(pred)     
3.68683 86.18% 72.35% 31.43%     
Regression Equation 
Screw 
configuration 
-1             Disso = 31.33 - 0.00374 Screw speed + 10.0 Feed rate 
 
0              Disso = 25.11 - 0.00374 Screw speed + 10.0 Feed rate 
 
1              Disso = 39.48 - 0.00374 Screw speed + 10.0 Feed rate 
Table 5.11 Analysis of variance for dissolution response 
Increase in the number of mixing elements had a significant impact on the drug 
release. Higher drug release was achieved in screw configurations with two 
mixing zones. A stark decrease was observed in the screw configuration with 
one mixing zone and it was lower compared to screw configuration with no 
mixing elements. Hence, elongation of mixing zone will increase the solid state 
solubility and miscibility of the ibuprofen-Affinisol 100cP blends and will in turn 
have a significant increase in drug release of the product. This result overlaps 
with the observations of DSC although these were insignificant.  
195 
 
5.2.4 Summary 
A Taguchi method was used to optimise the HME process of 40%IBU-Affinisol 
100cP blend. Feed rate, screw configuration and screw speed were chosen 
as process parameters of interest. Temperature profiles across all HME zones 
and batch size were kept constant for all the runs. Impact of the process 
parameters was studied using in process responses like mean residence time, 
%torque and pressure. Off-line responses of DSC and dissolution were 
studied to link the effect of process parameters to stability and product 
performance of the extrudates. All data collected were run in duplicate and a 
Taguchi method was analysed using Minitab software. To cross check the 
model fit generated, multiple regression analysis using ANOVA was calculated 
and a response surface plot was generated where needed.  
Mean residence time was calculated using a UV tracer which was tracked 
using an in-line UV probe placed at the die. %torque and pressure was 
detected by extruder software. The pressure probe was calibrated before 
every run at extruder temperature. Extrudates generated were air cooled and 
pelletised for dissolution. Additionally, extrudates were stationed at 40°C/75% 
RH for stability and samples were taken out on the 15th Day and analysed 
using DSC.  
Feed rate was found to be the only significant parameter to affect residence 
time measurement. Higher feed rate reduced residence time measurement by 
half. Torque was found to be affected by screw configuration and screw speed 
while pressure was affected only by screw speed. Higher screw speed of 
500rpm was found to be ideal for generating lower torque and pressure. 
Increase in mixing intensity increased the torque while pressure remained 
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unaffected. Thus from a processing perspective a screw configuration with no 
mixing element, screw speed of 500rpm and feed rate of 0.6Kg/hr were found 
to be ideal for generation of low torque, pressure and residence time.  
Off-line measurement of DSC showed that the set extrusion variables had little 
impact on the crystallisation kinetics. Ibuprofen crystallised out of all samples. 
Thus, the process parameters selected had negligible impact on the stability 
of the extrudates. Although insignificant, screw configuration with two mixing 
zones at a screw speed of 500rpm was found ideal to decrease in ibuprofen 
crystallisation. For dissolution, screw configuration with two mixing zones had 
a positive effect on the drug release and was the only significant factor. DSC 
and dissolution response confirm the assumption of higher mixing zone 
favouring the increase in solid state solubility and miscibility between 40%IBU-
Affinisol 100cP extrudates. Thus, from stability and product performance 
perspective screw configuration with two mixing elements and higher screw 
speed of 500rpm is preferred with no significant impact due to feed rate.  
To summarise, for process optimisation of 40%IBU-Affinisol 100cP blends, 
feed rate should be kept the highest at 0.6kg/hr. Screw speed for the blend 
should be 500rpm. Screw configuration with no mixing elements produced less 
torque, but still below the process capability and hence screw configuration 
with two mixing zones should be preferred. The latter, had a significant positive 
effect on the drug release and a slightly significant effect on the stability. Hence 
screw configuration with two mixing zones, screw speed of 500rpm and feed 
rate of 0.6kg/hr were found to be ideal parameters for optimisation of 40%IBU-
Affinisol 100cP blends.  
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5.3 Ibuprofen dimer in the solid dispersion as an early indicator of solid-
state stability  
Achieving high drug load while maintaining stability of amorphous solid 
dispersions (ASD) is one of the critical formulation challenge during the 
developmental phase. Here the early detection of ibuprofen dimer in the ASD 
was investigated as an indicator of potential physical destabilisation of the 
ASD. Conventional approaches to determine this parameter involve exposure 
of prepared ASDs to different stress conditions in order to observe drug 
recrystallisation. The approaches are time-consuming and often considered 
as a limiting factor in the use of ASD. Attenuated total reflection fourier 
transform infrared spectroscopy (ATR-FTIR) has been used as a tool to detect 
ibuprofen dimer in the ibuprofen and hydroxypropyl methylcellulose (HPMC) 
ASD prepared using hot melt extrusion (HME). X-ray diffractometry (XRD), 
differential scanning calorimetry (DSC) and Raman spectrometry were used 
to support the investigation. Ibuprofen dimerisation in the ASD was found to 
correlate well with the solid-state stability of ASDs. Results confirmed that 
15%w/w drug loading of ibuprofen within HPMC ASD was the maximum drug 
concentration to produce a stable ASD. 
5.3.1 Introduction 
Poor water solubility of Active Pharmaceutical Ingredients (APIs) is a major 
challenge for the pharmaceutical industry (Serajuddin 1999). One approach to 
address low solubility is to produce an amorphous solid dispersion (ASD), 
which is formed when the drug is molecularly dispersed and stabilised in a 
polymer matrix. The polymer matrix retards the molecular mobility of the API 
and stabilises the API in an amorphous state (Craig 2002). Solid dispersions 
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are obtained either by solvent evaporation or melt fusion methods (Limbachiya 
2012). Melt based processing involves melting a physical mixture of API and 
polymer to obtain a homogeneous molten phase, for example by application 
of shear and heat in a twin screw extruder (Michael A. Repka 2007; Michael 
M. Crowley 2007). This is followed by cooling to ambient temperature to lock 
the API in its amorphous form. The concentration of the API in the solid 
dispersion is a critical factor affecting stability which depends on the miscibility 
of the API in the polymer.(Yang et al. 2013) The glass transition temperature 
(Tg) of the solid dispersion related to temperature and humidity during storage 
will affect the stability of the solid dispersion. It is generally desirable to 
incorporate the highest possible concentration of the API in ASD to control 
size and weight and to minimise the cost of the final dosage form. High drug 
loading is the preferred choice but has the drawback of solid-state stability 
(Yang et al. 2013). Drug entrapped within the polymer, if not molecularly 
mixed, may recrystallise thus affecting the stability of the drug.  
The objective of this work was to study the relationship between molecular 
association of the drug within an ASD and its long-term stability. Molecular 
associations like dimerisation can provide an insight into drug aggregation 
within ASDs which can be further used as an indirect measure to study solid 
state stability. Current understanding of the stability of ASDs is predominantly 
based on theoretical predictions of drug-polymer miscibility (Lin and Huang 
2010; Thakral and Thakral 2013; Tian et al. 2015; Wang et al. 2017), analytical 
measurements of molecular mobility and dynamics (Mistry and 
Suryanarayanan 2016; Sibik and Zeitler 2016; Kissi et al. 2018), onset of 
crystallisation, crystal growth kinetics (Weuts et al. 2011; Nurzynska et al. 
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2015; Schram et al. 2016) and intermolecular interactions between the drug 
and polymer (Kothari et al. 2015; Maniruzzaman et al. 2015; Nie et al. 2016).    
One common approach for the prediction of the solid-state stability is to use 
the Flory-Huggins polymer solution theory as a function of temperature (Zhao 
et al. 2011; Tian et al. 2013; Tian et al. 2014; Tian et al. 2015; Rask et al. 
2018). However, the method fails to provide a link between molecular 
distributions of the drug within the polymer matrix and stability of the ASD. 
Hence, a basic practical screening tool is needed for early detection of the 
solid state stability of amorphous solid dispersions. 
Currently, the stability of an ASD is determined empirically then estimated by 
exposing it to different temperature and humidity conditions while monitoring 
it for the appearance of crystalline API using suitable analytical tools such as 
powder XRD and DSC (Baird and Taylor 2012; Thakral et al. 2015). Various 
studies using in-line and off-line spectroscopic techniques have reported the 
monitoring of the crystalline phase (Breitenbach J 1999; Wu et al. 2012; 
Rehder et al. 2013; Korang-Yeboah et al. 2016). Suryanarayanan et al. used 
dielectric spectroscopy (DES) to predict stability based on molecular mobility 
and studied the effect of hygroscopicity (Bhardwaj et al. 2014; O'Donnell and 
Woodward 2015; Mehta and Suryanarayanan 2016). Findings from these 
works are selective and moreover, the approaches involved studying either 
the glass forming ability or crystal growth mechanism and not the molecular 
association of drug within the polymer matrix. Additionally, analytical 
techniques available for solid state detection are limited and require that 
samples be exposed to different time-consuming stability conditions. The 
difficulties in proving long term stability during storage can restrict use of 
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amorphous solid dispersions for solubility enhancement of poorly soluble 
drugs (Serajuddin 1999; Sarode et al. 2013).  
Several studies have also reported the use of a solid dispersion of IBU with 
polymers to increase its oral bioavailability (Ryabenkova et al. 2017; Varghese 
and Ghoroi 2017). The main focus of those studies was to enhance the product 
performance and investigate the relationship between ibuprofen and 
polymers. However, none have studied systematically the identification of the 
molecular association of ibuprofen within the polymer matrix and attempted its 
correlation with the solid state stability of the ASD.  
In the current study, solid dispersions of ibuprofen and AffinisolTMHPMC 100cP 
(Affinisol 100cP) of varying drug concentrations (10, 15, 20, 30 and 40%w/w) 
were prepared using HME. The extrudates were characterised using 
attenuated total reflection fourier transform infrared spectroscopy (ATR-FTIR) 
to identify the IBU aggregation and Raman spectroscopy, X-ray diffraction 
(XRD) and differential scanning calorimetry (DSC) to provide an ortho-
analytical approach to monitor recrystallisation of the extrudates. Prepared 
extrudates were subjected to conditions of 40°C/75% RH, 25°C/60% RH and 
room temperature (RT) to investigate stability. Attempts were also made to 
understand the solid state solubility and miscibility using the Flory-Huggins 
polymer solution theory. 
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5.3.2 Results and Discussion  
Construction of binary phase diagram and its limitations:  
The binary phase diagram was explained in detail in chapter 4. 
The molecular weight of Affinisol 100cP is more than 1000 times of that of 
ibuprofen. Due to which spinodal curve predicts complete solid-state miscibility 
between all the drug-polymer compositions and thus binary phase diagram 
fails to predict solid-state miscibility between ibuprofen and affinisol 100cP 
(Huang et al. 2016). Hence, it can be inferred that the theoretical binary phase 
diagram by Flory-Huggins theory fails to predict the stability of the ASD formed 
using ibuprofen and Affinisol 100cP.  
Confirmation of Solid dispersion prepared by Hot Melt Extrusion:  
The formation of an ASD was confirmed through analysis by DSC, XRD, and 
Raman spectroscopy. The absence of any crystalline IBU melting endothermic 
peak in DSC confirmed the amorphous solid state of solid dispersions 
(Lerdkanchanaporn and Dollimore 1997). No distinct crystalline ibuprofen 
peaks were observed in XRD diffractograms and a halo region confirmed the 
amorphous nature of the extrudates at all concentrations of ibuprofen (Figure 
5.31) (Xu et al. 2009; Thakral et al. 2015; Ryabenkova et al. 2017). Raman 
spectra exhibited a peak shift from 1607cm-1 to 1612-1617cm-1, attributed to 
aryl chain deformation and C-H stretching and bending which occurs due to 
disorder within the structure and is characteristic of the amorphous state of 
ibuprofen (Liu and Gao 2012). Thus, the peak shift affirmed the amorphous 
nature of the solid dispersions for all ibuprofen-Affinisol 100cP extrudates at 
varying drug concentrations (Figure 5.30).  
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Figure 5.30 XRD spectra (top) and Raman spectra (zoomed view) of ibuprofen 
powder (blue), affinisol 100cP (purple), 10 (purple), 15 (red), 20 (pink), 30 
(dark blue) and 40%w/w (green) ibuprofen-affinisol 100cP extrudates 
Ibuprofen Dimer as an early indicator of solid-state stability by ATR-FTIR:  
Ibuprofen exists as a dimer in both its crystalline and melt states (Ryabenkova 
et al. 2017). However, when IBU solubilises within Affinisol 100cP, the dimer 
of IBU is broken down into its monomeric form either due to shear-induced or 
by the effect of temperature during the process and is entrapped within the 
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polymer resulting in an amorphous solid dispersion. A single phase ASD 
affirmed uniform mixing between IBU and Affinisol 100cP. No chemical 
interaction was observed between the spectral bands of the drug and polymer 
which confirms the formation of a solid dispersion due to its solid state 
solubility and miscibility. 
 
Figure 5.31 ATR-FTIR of IBU powder (blue), 10% IBU-Affinisol 100cP 
extrudate (red) and Affinisol 100cP powder (green)  
It is evident from ATR-FTIR spectra, that active bands between 1800-1700 cm-
1 can be considered as a non-interfering region for the detection of IBU within 
ASD (circled in figure 5.31). A distinct shift in the 1707 cm-1 band of IBU 
powder which is attributed to the carbonyl bond to 1732 cm-1 in the solid 
dispersion was observed. Several studies have reported similar shifts which 
have been attributed to the breaking of hydrogen bonding of the IBU with other 
polymers within ASD (Lerdkanchanaporn and Dollimore 1997; Ryabenkova et 
al. 2017). Thus, the shift in the carbonyl bond of the ibuprofen to 1732 cm-1 
was due to the formation of monomeric form within the ASD.  
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Using this as a reference indirect measurement to understand the IBU solid 
state within the ASD, ASDs with different percent drug loading of IBU were 
prepared. It was observed that all ASDs above 15% drug loading showed the 
presence of the dimer along with some monomeric form (Figure 5.32). This 
suggests that presence of ibuprofen dimer can be used as a measure in 
predicting the solid state stability of the ASDs.   
 
Figure 5.32 ATR-FTIR spectra (zoomed view) of 10 (blue), 15 (pink), 20 (dark 
blue), 30 (red) and 40%w/w (purple) ibuprofen-Affinisol 100cP extrudates 
Although all the extrudates above 15% IBU load showed some presence of 
the dimer form of IBU, the traditional analytical techniques like XRD, DSC, and 
Raman which are predominantly used in the detection of the crystalline phase 
of API within ASD showed the absence of crystalline domains (figures 5.30).  
To confirm the approach of ibuprofen dimer detection by ATR-FTIR studies, 
ASDs of different IBU concentration were stationed for accelerated stability 
studies. All the samples were stationed at three different stability conditions of 
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40°C/75% RH, 25°C/60% RH and room temperature. Extrudates were 
analysed off-line using ATR-FTIR, Raman, XRD, and DSC to check for 
recrystallisation of ibuprofen. Table 5.12 provides a summary of these stability 
studies. It was observed that 40% IBU loaded extrudates recrystallised within 
a week at 40°C/75% RH whereas 30% IBU loaded extrudates took 30 days to 
recrystallise (Figure 5.33). Lower IBU concentration extrudates at 20, 15 and 
10% loadings were stable at all three stability conditions measured up to 8 
months. The 20% IBU concentration extrudates were predicted to recrystallise 
due to the presence of ibuprofen dimer domains but this was not observed 
with 8 months of the study.  
IBU-Affinisol 
100cP extrudates 
Day 
15 
Day 
30 
Day 
120 
Day 
180 
Day 
240 
Ibuprofen 
dimer at 
Day 0 
40% IBU + + + + + 
 
Yes 
30% IBU - + + + + 
 
Yes 
20%IBU - - - - - 
 
Yes 
15%IBU - - - - - 
 
No 
10%IBU - - - - - 
 
No 
Table 5.12 Summary of stability studies. (-) & (+) denotes amorphous and 
crystalline extrudates respectively. 
206 
 
 
Figure 5.33 XRD diffractogram of ibuprofen powder (red), 30% T=0 day (blue), 
30% R.T T=30 days (maroon), 40% T=0 day (green), and 40% 40°C/74% RH 
T=15 days (purple) of Ibuprofen-Affinisol 100cP extrudates 
ATR-FTIR was able to provide an early indication of the presence of the dimer 
form of ibuprofen within the ibuprofen—Affinisol 100cP ASDs. Detection of this 
dimer form within ASDs represents free IBU domains either in crystalline or 
melt form within the extrudates which appeared to correlate with IBU 
recrystallisation. Thus, ATR-FTIR provided a quick and simple pre-formulation 
tool for detection of drug-drug interaction within the extrudates which could be 
used to predict solid state stability of the ASDs.  
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5.3.3 Summary 
The above results suggest that ATR-FTIR can be used as a predictive tool to 
indicate long-term stability of ASDs by providing a mechanistic understanding 
of the drug-drug molecular association within the polymer matrix. This 
approach has significant advantages over conventional methods such as 
theoretical binary phase diagrams by Flory-Huggins polymer solution theory, 
or by subjecting samples to accelerated stability tests. The use of advanced 
analytical tools can help identify molecular level interaction within ASDs at the 
initial stage and provide a simple, rapid and robust prediction technique to 
identify solid-state stability of the ASDs. Identification of molecular level 
interaction led to significant reduction of time required to confirm solid state 
solubility of the ASDs using conventional approaches of monitoring 
crystallisation by charging to accelerated stability conditions. 
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Chapter 6: Novel dosage form of Posaconazole 
This chapter will detail investigation of process and product attributes affecting 
the formulated ASD products. For this, posaconazole (POSA) and Affinisol 4M 
were selected as API and polymer of choice. The objective of section 6.1 will 
be a complete investigation of preparation of ASD using HME with aim to 
determine the maximum drug concentration that can be incorporated within 
the polymer. section 6.2 will discuss the use of dicarboxylic acids as a strategy 
to overcome food effects on oral bioavailability of POSA (Figure 6.1).  
 
Figure 6.1 Schematic representation of Posaconazole study  
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6.1 Posaconazole-Affinisol  
As discussed in the chapter 5.3, from a formulation perspective it is desirable 
to incorporate the maximum possible concentration of drug within polymer for 
a stable ASD. This will control size and weight and also minimise the cost and 
dose frequency of the final dosage form. Hence, determining the API 
maximum concentration is one of the key critical attributes during product 
development.  
6.1.1 HME trials and solid state stability  
Parameters for HME have been detailed in chapter 3. Systematic HME trials 
with increasing posaconazole content were carried out to check the maximum 
concentration for drug loading within polymer to form stable amorphous solid 
dispersions. Table 6.1 summarises the HME trials taken.  
Properties Affinisol 
4M 
10%w/
w Posa 
20%w/w 
Posa 
30%w/
w 
Posa 
40%w
/w 
Posa 
50%w
/w 
Posa 
60%w/
w 
Posa 
70%w/
w 
Posa 
Tg at day 
0 
110°C 80.364°
C 
70.17°C 64.68°
C 
60.16
°C 
57.1°
C 
54.07°
C 
Melt 
observ
ed 
Solvent 
loss in 
DSC 
Yes Yes Yes Yes Yes Yes Yes Yes 
Feed rate  0.65 
Kg/hr 
0.71 
Kg/hr 
0.54 
Kg/hr 
0.34 
Kg/hr 
0.28 
Kg/hr 
0.27 
Kg/hr 
0.24 
Kg/hr 
0.23 
Kg/hr 
Pressure 
(bar) 
 NA 41-42 37-38 23-24 16-17 15-16 10-12 7-8 
% Torque  NA 41-46 36-39 34-36 22-23 22-23 13-15 5-6 
Table 6.1 Posaconazole and Affinisol 4M HME trials at screw speed of 100 
rpm and extrusion temperature of 180°C 
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A decrease in glass transition temperature of the ASDs was observed with an 
increase in Posa content. However, the observed glass transition temperature 
was lower than the theoretically calculated glass transition temperatures using 
the Fox equation. A key observation noted was the decrease in pressure and 
% torque with increase Posa content even though, the temperature profiles 
were same for all drug loadings. Thus, Posa had plasticisation effect which is 
typical of low Tg APIs on the ASDs.    
Temperature profiles were kept constant for all the drug loadings due to the 
high melting point of posaconazole. Additionally, the temperature window for 
processing is small as Affinisol 4M degradation temperature is around 210°C 
respectively. Hence, all the drug loadings were extruded at a temperature of 
180°C.  
 
 
 
  
211 
 
 
 
Figure 6.2 DSC thermogram (above) and XRD diffractogram (below) for Posa-
Affinisol 4M trials 
Confirmation of the solid state of the ASDs was carried out using DSC and 
XRD. All the extrudates were pelletised and milled to form a fine powder which 
was then used for DSC and XRD. DSC of the extrudates and milled samples 
showed similar results confirming the amorphous state of ASDs in its milled 
state (Figure 6.2). XRD complimented the DSC results with showing a halo 
212 
 
region with absence of any distinct diffractive peaks in the powder XRD 
pattern.  
Posa-Affinisol 4M 
extrudates 
Day 60 Day 90 Day 120 Day 180 
Day 
240 
10% Posa - - - - - 
20% Posa - - - - - 
30% Posa - - - - - 
40% Posa - - - - - 
50% Posa - + + + + 
60% Posa + + + + + 
Table 6.2 Summary of stability studies. (-) & (+) denotes amorphous and 
crystalline extrudates respectively 
40%w/w drug loading of Posa with Affinisol 4M was found to be the maximum 
stable concentration for ASD (Table 6.2). Higher drug loadings of 60% and 
50%w/w were found to be stable for 2 and 3 months respectively on 
40°C/75%RH conditions (Figure 6.3). 70%w/w extrudates are possible but 
recrystallise within 24hrs. Hence, 40%w/w drug loading was used for further 
analysis in chapter 6.2.  
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Figure 6.3 DSC thermogram of 50%Posa+ Affinisol 4M on day 0 and day 90 
6.1.2 Drug release 
Drug release mechanism and dissolution model fitting was described in 
chapter 2 and 5 respectively. Dissolution was carried out on the milled samples 
using 0.1N HCL (Figure 6.4).  
 
Figure 6.4 Dissolution studies of Posa and Affinisol 4M extrudates 
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Maximum release for all the batches was observed within 120 mins followed 
by plateau region. A slight increase in dissolution release profile was observed 
with increase in posaconazole content.  
Dissolution strategy used for POSA-Affinisol 4M extrudates will be explained 
in detail in chapter 6.2.  
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6.2 Dicarboxylic acid study 
The current study will provide an overview of the evolution of marketed 
products containing posaconazole and their shortcomings. Furthermore, it will 
highlight the importance to study effect of food on the oral bioavailability of the 
formulated products. A detailed investigation on use of dicarboxylic acids as a 
formulation strategy to enhance bioavailability to avoid effect of food will be 
discussed.  
6.2.1 Introduction 
To understand the shortcomings of in-vitro dissolution of Posa-Affinisol 4M 
extrudates, it is important to study the formulation strategies used for marketed 
products containing posaconazole.  
Noxafil is the trade name for the marketed products containing posaconazole 
and is developed by MSD US. Initially, it was developed as a suspension with 
dose of 40mg/ml. Also, a concentrate for solution for IV infusion was 
developed for critical patients. According to the EMEA application by the 
company, the oral suspension is administered 3-4 times daily and was to be 
taken with food (high fat meal) to ensure adequate systemic exposure (MSD 
2014).  
To overcome the food effect and to maximise systemic absorption, a gastro 
resistant tablet was developed. The product was developed using the pH 
sensitive polymer (HPMCAS) by HME and coated to limit its dissolution in the 
stomach whilst maximising dissolution and absorption in the small intestine 
(Fang et al. 2011).   
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Thus, studying the bioavailability problems of drug formulation becomes one 
of the critical quality attribute in product development. Based on in-vitro 
dissolution results, several models are available to predict in-vivo performance 
of the drug formulations. 
6.2.2 Effect of food and the role of biorelevant media   
Failure to identify bioavailability issues is one important shortcoming during 
formulation development. This may arise if proper attention is not given to the 
robust method development of the dissolution study (Klein 2010). Drug 
dissolution is achieved through its solubility and dissolution rate. Kinetics of 
dissolution were explained by use of the Nernst-Brumer and Levich model 
equations which build upon the Noyes-Whitney equation (Kostewicz 2002). A 
brief explanation about dissolution and its kinetic models is detailed in chapter 
5.1.  
A drug’s ability to diffuse and dissolve is governed by its physicochemical 
properties like pKa, solubility, lattice energy, particle size and shape and, 
partition coefficient and surface area (Kostewicz 2002; Klein 2010; Kostewicz 
et al. 2014). Physiological parameters might also hinder the drugs ability to 
dissolve within the GI tract (Kostewicz et al. 2014). Choice of excipients also 
plays an important role in affecting a drug’s dissolution (Chen et al. 2015; 
Elkhabaz et al. 2018). Thus, the scope of in-vitro dissolution testing has 
expanded to prediction of in-vivo performance of the drug formulations. This 
is of prime importance if the choice of drug is poorly soluble in nature.  
Most of the poorly soluble drugs are weakly acidic or basic in nature. The 
presence or absence of food can have a huge impact on the bioavailability of 
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the drug in the formulation. Presence of food can affect bioavailability of the 
drug and give rise to pharmacokinetic variability (Mathias et al. 2015). This is 
affirmed by FDA guidance on bioavailability/bioequivalence studies to be 
conducted in both fast and fed state. Presence of food in the stomach can 
delay gastric emptying, change pH, affect solubilisation of bile salts present 
and food components can interact with the drug and affect its physicochemical 
properties which in turn affect dissolution and diffusion. Due to this, it becomes 
imperative to study the effect of food on a drug’s bioavailability.  
A key drawback of fed state studies is its cost and selection of the type of food 
chosen during clinical trials. Type of dosing, thus has a huge impact on 
studying food effects. To prepare better, it is vital to develop in-vitro models 
which can closely resemble in vivo performance. This has led to an increase 
in the use of biorelevant media for dissolution testing. The choice of 
biorelevant media however, is critical for predicting effect of food on the 
formulations. Figure 6.5 gives an overview of the types of media available.  
 
Figure 6.5 Biorelevant media available for in-vitro dissolution studies 
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USP describes traditional medium to simulate gastric and intestinal fluids. 
Simulated gastric fluid (SGF) contains hydrochloric acid, sodium chloride, 
pepsin and water. The pH is around 1-1.3. Simulated intestinal fluid (SIF) 
consists of potassium phosphate and sodium hydroxide with pH around 6.5-
6.8. Certain key parameters like presence of bile salts, pepsin concentration 
and surface tension are not taken into consideration in the traditional simulated 
fluid (Klein 2010). Several studies have reported the role of bile salts and their 
shortcomings in affecting bioavailability of poorly soluble drugs (Chen et al. 
2015; Li et al. 2016b; Lu et al. 2017a; Lu et al. 2017b; Lu et al. 2017c). Also, 
there are no recommendations and guidance over preparation of media to 
simulated fed states. Studies using milk and other fatty and lipophilic foods to 
simulate the fed states have been reported (Vertzoni et al. 2005; Klein 2010; 
Kostewicz et al. 2014; Dey et al. 2015; Baxevanis et al. 2016; Zaheer and 
Langguth 2018).  
Thus to summarise, use of biorelevant medias is necessary to highlight food 
effect on oral bioavailability. Traditional simulated medium does not 
necessarily provide an exact representation of GI and intestinal physiology 
and should be altered according to the drug formulation in contention. Use of 
in-vitro dissolution with biorelevant medias can be helpful in predicting its in-
vivo performance and to reduce the cost of clinical trials.  
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6.2.3 Formulation strategies to overcome food effects 
It is well established that food can cause pharmacokinetic variability of drug 
dissolution by affecting stomach pH, delaying gastric emptying time and 
interacting with drug. Hence, identification of food effect in the early 
development phase plays a key role in developing formulation products. A 
change in pH can have a huge impact on the dissolution of poorly soluble 
drugs which are weak acids and bases in nature. Additionally, it may impair 
dissolution of drugs which have a high partition coefficient due to presence of 
lipophilic meal.  
Poorly soluble drugs which are weak acids generally will dissolve in the small 
intestine where pH is about 6.8-7. Weak bases are likely to dissolve more in 
the acidic pH of the stomach whereas neutral molecules are shown to open in 
gastric as well as small intestine (Dressman et al. 2007). Fig 6.6 provides 
examples of poorly soluble drugs which show food effect on the oral 
bioavailability. A positive food effect was seen in neutral compound-Danazol 
and weak acid-Phenytoin. For weak bases, itraconzole and ketoconazole 
higher release was observed in acidic pH of gastric fluid compared to fast and 
fed state of simulated intestinal fluid. Thus identification of food effect and type 
of dosing is important during pre-clinical stages to develop the formulation 
accordingly.  
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Figure 6.6 Food effect on oral bioavailability (Klein 2010) 
Identification of food effect using adequate in-vitro dissolution trials with 
biorelevant media and formulation development should seamlessly overlap 
with each other. Figure 6.7 shows the type of formulation strategies employed 
by researchers with the aim of overcoming oral bioavailability issues. Apart 
from physicochemical properties of drug, type of drug release, gastric 
emptying rate, circadian difference, interaction with food, individual variation 
of GI tract and disease state are major factors contributing to oral 
bioavailability variation. Poor bioavailability could be due to solubility, partition 
coefficient, first pass metabolism, degradation in the GI tract and drug-food 
interaction (Thakkar 2010).  
Formulation strategies should be developed according to the factors 
responsible for affecting oral bioavailability. Formulation strategies are broken 
down into three strategies (Figure 6.7).  
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Figure 6.7 Formulation strategies to overcome food effects (Thakkar 2010) 
Crystal habit modifications are utilised in cases where oral bioavailability is 
affected due to the drug’s poor solubility (Ghule 2018). A detailed discussion 
on the crystal habit modification is discussed in chapter 2.  
Lipid based formulations are utilised by incorporating drug in the lipid based 
carrier system. This will increase the drug’s diffusion within the body which in 
turn increases dissolution (Gupta et al. 2013).  
Alternative strategies involve modification within the formulation. To protect 
the drug from stomach variation, encapsulation or enteric coating strategies 
can be utilised to bypass first pass metabolism. Enzyme inhibitors can be 
incorporated within the formulation to neutralise the drug’s interaction with 
enzymes (Thakkar 2010; Borbas et al. 2018).  
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6.2.4 Novel formulation strategy for oral bioavailability of Posaconazole 
Dissolution of drugs depends on its solubility and diffusion rate. For a weak 
base like Posaconazole, the solubility should be higher in stomach but 
maximum systemic absorption was observed in the small intestine. Due to 
which, the market suspension was suggested to be taken on a fatty meal which 
will increase the pH of stomach to 6-7 {Fang, 2011 #653}. Orally administered 
tablet was enteric coated to limit its release in stomach and a pH sensitive 
polymer HPMCAS was used which released the drug in small intestine where 
pH is 6.8. Posaconazole thus behaves differently from similar analogues like 
itraconzole which has a maximum systemic release in acidic pH.  
Although maximum systemic release for posaconazole was observed in the 
small intestine, there are several studies which concluded that this was not 
solely due to the change in  pH (Hens et al. 2016; Kourentas et al. 2016; Hens 
et al. 2017). Hence, a formulation strategy to enhance dissolution in acidic pH 
can be investigated. Use of di-carboxylic acids as additives to posaconazole-
affinisol extrudates can be employed as a strategy to enhance dissolution of 
posaconazole in acidic pH to avoid food effects.  
6.2.4.1 Selection and characterisation of additives and posaconazole 
Addition of dicarboxylic acids as additives will impart a slight acidity to the solid 
dispersion of posaconazole and Affinisol 4M and thus enhance dissolution in 
acidic media.  
A literature search revealed the ability of posaconazole and itraconazole to 
form co-crystals and eutectics with aliphatic dicarboxylic acids. Several studies 
reported detailed investigation of co-crystal formation of itraconazole with 
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aliphatic dicarboxylic acids (Nonappa et al. 2012; Shevchenko et al. 2012; 
Shevchenko et al. 2013). Itraconazole-amino acid co-crystals have also been 
well investigated (Shete et al. 2015). It was found that itraconazole forms co-
crystals with succinic acid and L-malic acid in a 2:1 ratio. Different methods to 
generate the itraconazole co-crystals are also reported (Ober and Gupta 2012; 
Ober et al. 2013). It would be vital to screen posaconazole which is structurally 
similar to itraconazole to check its affinity with aliphatic dicarboxylic acids.  
With posaconazole being a poorly water soluble compound, the co-crystal 
strategy may not be attractive to achieve the desired dissolution. On the other 
hand, a eutectic which is multicomponent solid mixed in stoichiometry to form 
a solid solution can be a more viable option to resolve dissolution issues 
(Cherukuvada and Nangia 2014). Eutectics have recently gained importance 
as an alternative formulation strategy (Cherukuvada and Nangia 2012; 
Cherukuvada and Guru Row 2014; Cherukuvada and Nangia 2014). Positive 
dissolution enhancement was investigated in the case of eutectic formed by 
posaconazole and benznidazole (Figueiredo et al. 2017).  
It becomes important to check the interaction of posaconazole with aliphatic 
dicarboxylic acids used as additives in the solid dispersion. Screening of 
posaconazole with aliphatic dicarboxylic acid was done using solvent 
mediated ball milling using acetonitrile. Details of the method and 
characterisation techniques were provided in chapter 3. Figure 6.8 shows an 
overview of the trials of posaconazole with selected aliphatic dicarboxylic 
acids.  
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Figure 6.8 Posaconazole and dicarboxylic acid primary screening plan 
To overcome the solvent effect of acetonitrile, trials were taken using the same 
method parameters on the posaconazole and co-formers (succinic acid and L-
malic acid). No change in solid form was observed for all the trials and these 
were thus used as reference for comparison with trials with posaconazole and 
co-formers. 
No interaction was observed in trials with oxalic acid, ascorbic acid and maleic 
acid. Trials with succinic acid and L-malic acid showed different DSC and ATR-
FTIR patterns (Figure 6.9). DSC thermograms of Posa-Succinic acid trials 
showed a broad endothermic event which could be due to solvent loss at 
108°C and an endothermic event at 150°C. Melting endothermic events of 
Posa and succinic acid were not observed. In ATR-FTIR spectra, an additional 
new peak shoulder was observed at 1710 cm-1 which could be due to an 
interaction between posaconazole and succinic acid. Initial conclusion for 
Posa-succinic acid trial suggested formation of eutectic as XRD patterns were 
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crystalline with no shift and Raman pattern showed no change. Also, melting 
endotherm of Posa-Succinic acid was found to be lower than its starting 
materials.  
 
 
Figure 6.9 DSC thermogram (above) and ATR-FTIR (below) of Posa and 
succinic acid trials  
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DSC thermogram of Posa-Malic acid showed a sharp melting endothermic 
peak at 149°C and absence of a melting endothermic event of starting 
materials. ATR-FTIR spectra showed a broad shoulder 1732 cm-1 which could 
be due to interaction between Posa and L-malic acid. XRD and Raman 
showed no distinct change. Results suggested it be a co-crystal and was only 
based of DSC result as the melting was observed within melting range of the 
starting materials (Figure 6.10).  
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Figure 6.10 DSC thermogram (above) and ATR-FTIR (below) of Posa and L-
malic acid trials  
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Primary screening trials were carried out in the ratio of 2:1 of the molecular 
weight of posaconazole and co-formers. To confirm the stoichiometry between 
posaconazole and co-formers (succinic acid and L-Malic acid), binary phase 
diagrams were constructed for the systems.  
DSC thermogram of all the Posa-Succinic acid mixtures showed the presence 
of an endothermic event at 150°C which could be due to eutectic from 50:50 
to 90:10 ratios of Posa and succinic acid. For mixture between 60:40 and 
70:30, no other endothermic events of the starting materials was observed 
(Figure 6.11). Similar shift in spectra were observed for ATR-FTIR (Figure 
6.14). A slight shift was observed in XRD patterns for 60:40 and 70:30 mixtures 
(Figure 6.13). Thus, Posa and succinic acid form eutectic in 2:1 ratio (Figure 
6.12).  
   
Figure 6.11 DSC thermogram of Posa and Succinic acid binary mixtures 
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Figure 6.12 Binary phase diagram of Posa and succinic acid 
 
 
Figure 6.13 XRD diffractogram of Posa and Succinic acid binary mixtures 
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Figure 6.14 ATR-FTIR spectra of Posa and Succinic acid binary mixtures 
Similar results were observed in Posa-Malic acid trials. The absence of melting 
endotherms of starting material was observed in 60:40 mixtures. Thus, Posa 
and malic acid form co-crystal in 2:1 ratio (Figures 6.15, 6.16, 6.17 and 6.18).  
 
Figure 6.15 DSC thermogram of Posa and L-malic acid binary mixtures 
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Figure 6.16 Binary phase diagram of Posa and L-malic acid 
 
Figure 6.17 XRD diffractogram of Posa and L-malic acid binary mixtures 
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Figure 6.18 ATR-FTIR spectra of Posa and L-malic acid binary mixtures 
Posaconazole thus forms a eutectic with succinic acid and a co-crystal with L-
malic acid in 2:1 molecular ratio. This interaction however needs to be further 
proven by either single crystal XRD or solid state NMR studies.  
Incorporation of dicarboxylic acid within posaconazole will have an impact on 
its solubility and dissolution. To investigate dissolution performance, intrinsic 
dissolution studies were carried out. In intrinsic dissolution rate the diffusion 
and dissolution is carried out with controlled specific surface area. Dissolution 
parameters were kept constant as used for Posa-Affinisol 4M extrudates. 
Physical mixtures of 2:1 Posa-succinic acid and 2:1 Posa-malic acid were 
found to show similar drug release as that of posaconazole alone.  
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Figure 6.19 Intrinsic dissolution studies of Posa and dicarboxylic trials  
2:1 Posa-succinic acid and 2:1 Posa-malic acid showed higher drug release 
compared to posaconazole alone. 2:1 Posa-succinic acid showed the highest 
drug release compared to all the other trials (Figure 6.19). Posa: SA 2:1 > 
Posa: MA 2:1 > Posa. Eutectics generally show higher and faster dissolution 
compared to co-crystal since its high energy state compared to co-crystals. A 
t-Test paired two samples for means was applied to the % drug released at 
360 mins. P-value for all the means was found to be significant and thus the 
difference in % drug release is significant (Table 6.3). Linear regression was 
applied to the first initial solubilisation phase in the dissolution to check for 
significance in the rate of reaction. Data till 120 mins was selected for 
correlation. A clear difference in slope was observed which agreed with the 
trend and Posa: SA 2:1 > Posa: MA 2:1 > Posa (Figure 6.20).  
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Figure 6.20 Intrinsic dissolution studies of Posa and dicarboxylic trials for 
120mins 
 
Table 6. 3 t-Test paired to sample for means of Posa and dicarboxylic trials 
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Thus, posaconazole was screened with five dicarboxylic acids as co-formers. 
Of which posaconazole interacted with succinic acid and malic acid to form 
eutectic and co-crystal in 2:1 ratio respectively. Posa: SA 2:1 was proven to 
have higher drug release compared to Posa: MA 2:1 and posaconazole. 
Hence, these dicarboxylic acids when used as additives could interact with 
posaconazole in Posa-Affinisol 4M mixtures to prepare ASD using HME.  
6.2.4.2 Formulation strategy to enhance posaconazole dissolution 
Aim of the study was to enhance dissolution of posaconazole in acidic pH by 
the addition of di-carboxylic acids. This strategy is designed for higher 
dissolution of posaconazole in an empty stomach. Primary screening of 
posaconazole and dicarboxylic acids, showed interaction only with succinic 
acid and L-malic acid and in 2:1 stoichiometry. Posaconazole formed eutectic 
with succinic acid and a co-crystal with L-malic acid.  
Since here dicarboxylic acids are evaluated as additives for posaconazole and 
Affinisol 4M binary blends, initial trials were taken with all dicarboxylic acids 
with 40% posaconazole load in Affinisol 4M (Figure 6.21). Dicarboxylic acids 
were added in the stoichiometry of 1:1 ratio of molecular weight equivalent to 
posaconazole load. Oxalic acid and ascorbic acid trials as additives did not 
form single phase extrudates with 40% posaconazole and Affinisol 4M and 
hence were discarded for further trials. Maleic acid, succinic acid and L-malic 
acid trials gave single phase extrudates with 40% posaconazole and Affinisol 
4M (Figure 6.22).  
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Figure 6.21 Primary screening for additive study for Posa and Affinisol 4M 
blends 
 
Figure 6.22 HME trials of dicarboxylic acids with Posa and Affinisol 4M blends 
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40%Posa+Maleic Acid+ Affinisol 4M (1-1) extrudates were dark brown in 
colour and were extruded at 170°C (Figure 6.22). However, dissolution studies 
showed an insignificant increase in drug release compared to 40%Posa+Aff 
4M extrudates (Figure 6.23). Hence, maleic acid was not used for further trials.  
 
Figure 6.23 Dissolution study of Posa and Affinisol 4M milled samples with 
maleic acid as an additive 
Thus, only succinic acid and L-malic acid were used for further trials. Trials of 
succinic acid and L-malic acid with 30%Posa and Affinisol 4M were also 
conducted in the stoichiometry of 1:1 molecular ratio. It was observed that 
posaconazole forms eutectic and co-crystal with succinic acid and L-malic acid 
in 2:1 ratio, hence for comparative purpose 40% posaconazole load was 
selected and equivalent 2:1 trials with Affinisol 4M were carried out (Figure 
6.24). Increase in extrusion temperature was required for 40%Posa+Succinic 
acid+ Affinisol 4M (2-1) compared to 1-1 trials while the extrusion temperature 
remained constant for the L-malic acid trials. The extrudates were pelletised 
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and milled for further analysis. Additionally, the extrudates were stationed at 
three different stability conditions of 40°C/75%RH, 25°C/60%RH and room 
temperature for tracking of solid state stability.  
 
Figure 6.24 TGA thermograms of physical mix Posa and Affinisol with 
dicarboxylic acid  
P-XRD results showed absence of crystalline domains and presence of halo 
region which confirmed amorphous nature of the extrudates on day 0 (Figure 
6.25).  
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Figure 6.25 XRD diffractogram of milled extrudates of 40%Posa and Affinisol 
4M with succinic and L-malic acid 
DSC showed an absence of melting points of posaconazole and dicarboxylic 
acids respectively (not shown). ATR-FTIR showed presence of additional 
hump in the 1730-1740cm-1 region which could be due to interaction between 
posaconazole and dicarboxylic acid within Affinisol 4M. To confirm this, trials 
were taken with only dicarboxylic acid and Affinisol 4M. The additional hump 
was due to a shift observed in the dicarboxylic acid within Affinisol 4M and 
hence it can be inferred that no interaction was observed between 
posaconazole and dicarboxylic acids within Affinisol 4M and single phase 
extrudates were observed due to solid state miscibility and solubility (Figure 
6.26).  
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Figure 6.26 ATR-FTIR spectra of milled extrudates of 40%Posa and Affinisol 
4M with succinic (top) and L-malic acid (bottom) 
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Day 0 dissolution studies of milled samples showed a slight increase drug 
release in 40%Posa+Malic acid+ Affinisol 4M (2-1) compared to 
40%Posa+Affinisol 4M batch (Figure 6.27). However, highest release was 
observed in 40%Posa+Succinic acid+ Affinisol 4M batch.  
 
Figure 6.27 Dissolution studies of milled extrudates of 40%Posa and Affinisol 
4M with succinic and L-malic acid at day 0 
The current comparison is only based on the dose of 100mg of posaconazole; 
hence the release could increase with increase in drug content. Dissolution of 
pellets was also carried out but very low release was observed due to 
crystallisation of surface of the posaconazole pellets which formed a barrier 
for buffer (Figure 6.28).  
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Figure 6.28 Pellets of 40%Posa and Affinisol 4M with succinic and L-malic acid 
at day 0 post dissolution 
Hence, dissolution studies for all Posa+ Affinisol 4M extrudates were carried 
out only on the milled samples.  
Upon stability, it was observed that 40%Posa+Malic acid+ Affinisol 4M (2-1) 
batch recrystallised at 40°C/75%RH condition on the 30th day while 
40%Posa+Succininc acid+ Affinisol 4M (2-1) batch recrystallised at same 
condition on the 60th day. 40%Posa+ Affinisol 4M batch was still stable at all 
conditions after 360 days.  
However, when the extrudates were analysed for solid state stability, 
posaconazole was not found to be completely crystalline. ATR-FTIR spectra 
showed the shift of amorphous posaconazole band to crystalline 
posaconazole band for both succinic and L-malic acid (Figure 6.29).  
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Figure 6.29 ATR-FTIR spectra of 40%Posa and Affinisol 4M with succinic and 
L-malic acid 
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Figure 6.30 DSC thermogram of 40%Posa and Affinisol 4M with succinic and 
L-malic acid 
DSC thermograms showed an absence of melting endothermic events for both 
the day 0 extrudates. Additionally, endothermic peak at the position of eutectic 
and co-crystal formed between Posa with succinic and L-malic acid was 
observed (Figure 6.30). Thus, it was interesting to note that crashing of the 
ternary system caused an interaction between crystalline posaconazole and 
succinic and L-malic acid to form eutectic and co-crystal within Affinisol 4M. 
Hence, posaconazole upon recrystallisation still was partly amorphous and 
partly eutectic/co-crystal with the additive dicarboxylic acids.  
It would be worth studying the impact of the eutectic and co-crystal formed 
within Affinisol 4M on the drug release of posaconazole. Dissolution studies 
were again carried out on the milled samples to check for drug release.  
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Figure 6.31 Dissolution studies of 40%Posa and Affinisol 4M with succinic and 
L-malic acid 
The general convention would dictate a decrease in drug release due to 
formation of crystalline posaconazole. However, an increase in drug release 
was observed in both the batches. The release was also higher compared to 
the observed release on day 0 (Figure 6.31). But both the batches showed 
similar release patterns even though being analysed on 30th and 60th day 
respectively. This proves that the formation of either eutectic or co-crystal of 
posaconazole with succinic and L-malic acid within Affinisol 4M had a positive 
impact on the drug release. Thus, addition of dicarboxylic acids had a positive 
impact on the drug release of posaconazole in acidic pH.  
T-Test paired two samples for means was applied to the % drug released at 
360 mins for all samples. P-value for all the means was found to be significant 
and thus the difference in % drug release is significant (Table 6.4).  
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Table 6. 4 t-Test paired to sample for means of milled Posa extrudates.  
6.3 Summary 
For determining the maximum concentration for a stable Posa-Affinisol 4M 
extrudates, HME trials with varying in Posa concentration were carried out. 
70%w/w of Posa concentration was found to be the maximum loading for HME 
processing. Due to the high melting point of posaconazole and degradation 
temperature of Affinisol 4M, the processing HME temperature window was 
narrow between 180°C-190°C. All the trials were carried out with same 
temperature profiles. All extrudates were stationed at different stability 
conditions to check for its solid state stability. 40%w/w Posa-Affinisol 4M 
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extrudates were found to stable for more than 8 months. Subsequently, 
concentrations below 40% were also found to be stable.  
Marketed posaconazole suspensions had the drawback of negative effect of 
oral bioavailability due to the presence of food. Hence to overcome this 
drawback an enteric coated tablet is marketed which limits drug release in the 
stomach. However, a formulation strategy to overcome the effect of food by 
enhancing the drug release in an empty stomach has not previously been 
studied. In this chapter, an alternative strategy of incorporating dicarboxylic 
acid as additives was studied. The rationale was to use dicarboxylic acids to 
impart acidity to the product to enhance the drug release in empty stomach.  
Posaconazole formed a eutectic and a co-crystal with succinic acid and L-
malic acid respectively in the 2:1 stoichiometry. To confirm this, a binary phase 
diagram was plotted and solid state was confirmed using thermal, 
spectroscopic and diffraction methods. An improved intrinsic dissolution rate 
was observed in the eutectic and co-crystal states compared to posaconazole 
alone.  
Of all the five selected additives, only maleic acid, succinic acid and L-malic 
acid trials gave single phase extrudates with 40% posaconazole and Affinisol 
4M. Trials with maleic acid showed no comparable increase in dissolution 
compared to 40%Posa+Aff 4M extrudates. Increase in drug release was 
observed for the other two acids. Following stability studies, the 
40%Posa+Malic acid+ Affinisol 4M (2-1) batch and 40%Posa+Succininc acid+ 
Affinisol 4M (2-1) batch recrystallised but showed increase in drug release as 
compared to 40%Posa+Aff4M batch. A positive effect in the drug release was 
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observed which could be due to formation of eutectic and co-crystal with the 
free succinic acid and L-malic acid.  
Single crystal XRD or solid state NMR studies are needed to affirm the 
formation of eutectic or co-crystal of Posa with succinic acid and L-Malic acid. 
The formulation strategy to incorporate dicarboxylic acids as additives had a 
positive effect on drug release but had a negative effect on the solid state 
stability of the extrudates. Also, complete drug release was not observed. 
Trials with low molecular weight AffinisolTMHPMC should be carried out to 
check its effect on dissolution.  
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 Chapter 7:  Global Conclusions and suggestions for future work 
This chapter will summarise the conclusion made from studies carried out and 
provide suggestions for future work.  
7.1 Global conclusions 
The work carried out provides a detailed study of formulation development of 
pharmaceutical dosage forms using hot melt extrusion process. Focus was on 
the challenges and the findings of the work were divided into three main critical 
attributes important for process feasibility and optimisation. Further relevant 
studies focussing on the same were carried out to address the relevant issues 
arising during formulation development using HME. Robust HME process was 
developed using IBU and POSA as API and AffinisolTMHPMC as amorphous 
polymer.  
Understanding the material attributes affecting formulation development is one 
of the critical attribute during process development using HME. A detailed 
investigation in the physicochemical properties of IBU, Posa and 
AffinisolTMHPMC was carried out. Theoretical methods like solubility 
parameters, fragility index and binary phase diagram were utilised to predict 
solid state solubility and miscibility between API-polymer combinations. 
Rationale, method development and validation of solid state characterisation 
methods like thermal, spectroscopic, diffraction, and water uptake were 
developed for both API-polymer combinations. All the above mentioned 
methods were used to identify the crystalline and amorphous domains of the 
APIs. HME trials for ibuprofen-Affinisol 100cP were carried out to form 
amorphous solid dispersion.  
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Material behaviour during melt processing is another critical quality attribute 
for process optimisation using HME. The behaviour is heavily dependent 
upon physicochemical properties. Effects of ibuprofen concentration on the 
rheological and mechanical properties of the extrudates with Affinisol 100cP 
were studied. A decrease in complex viscosity from rotational and capillary 
rheometer was observed with increase in ibuprofen concentration. The data 
generated was analysed using Carreau-Yasuda and Power law model. 
Shear thinning was observed for all the ibuprofen-Affinisol 100cP blends. 
Data obtained from rotational and capillary rheometer were fitted using Cox-
Mertz rule. All the ibuprofen-Affinisol 100cP blends failed to follow the Cox-
Mertz rule. Storage or elastic modulus (E') generated using DMA showed a 
decrease with increase in ibuprofen concentration. A similar trend was 
observed with tan delta (Δ) values. Thus, from melt rheology and visco-
elastic properties of extrudates it was observed that an increase in ibuprofen 
concentration imparts plasticisation by decreasing the glass transition 
temperature of the extrudates. Tan delta (Δ) values were found to be in good 
correlation with predicted values by the Fox equation. Correlation between 
values obtained from the Fox equation and DMA confirmed the absence of 
inter-component interaction in the melt and glassy state of the ibuprofen-
Affinisol 100cP mixture. An attempt was made to map the storage modulus 
E' & G' obtained from DMA and rotational rheometer over a range of 
temperature. A large difference was observed between the moduli of melt 
and a solid phase for all the ibuprofen-Affinisol 100cP blends. Thus, 
understanding shear thinning behaviour and visco-elastic nature of 
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extrudates provide a platform for optimisation of process for amorphous solid 
dispersion using HME.  
Drug release from ibuprofen-Affinisol 100cP extrudates showed a dual 
mechanism of swelling and erosion. 10% and 20% loadings followed Peppas 
and zero order showing controlled release while higher drug loads of 30% 
and 40% followed Peppas and first order models showing sustained release.  
Effect of process parameters on the product performance using HME was 
studied using the Taguchi method. Feed rate, screw speed and screw 
configuration were selected as process variables while mean residence time, 
torque, pressure, DSC and dissolution were used as response. Although the 
process study was carried out on 40% drug load only, but mean residence 
time was calculated for all drug loadings. Mean residence time increase with 
increase in ibuprofen concentration within extrudates.  
Feed rate was found to be the only significant parameter to affect residence 
time measurement. Higher feed rate reduced residence time measurement by 
half. Torque was found to be affected by screw configuration and screw speed 
while pressure was affected only by screw speed. For dissolution, a screw 
configuration with two mixing zones had a positive effect on the drug release 
and was found to be the only significant factor. DSC and dissolution response 
confirm the assumption that higher mixing favoured an increase in solid state 
solubility and miscibility between 40%IBU-Affinisol 100cP extrudates. 
For process optimisation of 40%IBU-Affinisol 100cP blends, feed rate should 
be kept the highest at 0.6kg/hr. Screw speed for the blend should be 500rpm. 
Screw configuration with no mixing element produces less torque, but it’s still 
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way below the process capability and hence screw configuration with two 
mixing zones should be preferred. 
One of the critical formulation factors in the development of amorphous solid 
dispersions (ASD) is prediction of the maximum drug concentration which a 
stable ASD can support. Ibuprofen dimer in the solid dispersion was found to 
be an early indicator of solid-state stability. ATR-FTIR was used as a predictive 
tool to indicate long-term stability of ASDs by providing a mechanistic 
understanding of the drug-drug molecular association within the polymer 
matrix. This approach has significant advantages over conventional methods 
such as theoretical binary phase diagrams by Flory-Huggins polymer solution 
theory, or by subjecting samples to accelerated stability tests. 15% ibuprofen 
loaded extrudates were found to show an absence of dimer and were stable 
for more than 8 months. Lower IBU concentration extrudates at 20, 15 and 
10% loadings were stable at all three stability conditions measured up to 8 
months. The 20% IBU concentration extrudates were predicted to recrystallise 
due to decrease presence of ibuprofen dimer domains but this was not 
observed with 8 months of the study. 
From formulation a perspective, it is desirable to incorporate maximum 
possible concentration of drug within polymer to for ASD. This will control size 
and weight and also minimise the cost and dose frequency of the final dosage 
form. Hence, finding out the API maximum concentration is one of the key 
critical attribute during product development. To overcome effect of food on 
the oral bioavailability of posaconazole, an alternative formulation strategy 
was studied. Rationale was to use additives containing dicarboxylic acid to 
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enhance dissolution of posaconazole in acidic pH. Since here dicarboxylic 
acids are evaluated as additives for posaconazole and affinisol 4M binary 
blends, initial trials were taken with all dicarboxylic acids with 40% 
posaconazole load in Affinisol 4M.HME trials and solid state stability of Posa 
and Affinisol 4M blends were carried out. 70% of Posa loading was found to 
be the maximum feasible concentration for HME. Due to high melting point of 
posaconazole, extrusion trials were extruded at same temperature. 
Processing temperature window was also found to be narrow, between 180°C 
and 190°C. All concentrations from 40%w/w and below of Posa loadings were 
found to be stable for more than 8 months. Of the five additives selected, 
posaconazole was found to form a eutectic and co-crystal with succinic acid 
and L-malic acid in the 2:1 stoichiometry. Stoichiometry was confirmed by 
plotting a binary phase diagram. Formation of eutectic and co-crystal were 
confirmed using thermal, spectroscopic and diffraction analytical methods. An 
improved intrinsic dissolution rate was observed in the eutectic and co-crystal 
compared to posaconazole alone. Only maleic acid, succinic acid and L-malic 
acid trials produced single phase extrudates with 40% posaconazole and 
Affinisol 4M. Trials with maleic acid showed no comparable increase in 
dissolution compared with 40%Posa+Aff 4M extrudates. Day 0 dissolution 
studies of milled samples showed a slight increase drug release in 
40%Posa+Malic acid+ Affinisol 4M (2-1) compared to 40%Posa+Affinisol 4M 
batch (Figure 6.26). However, highest release was observed in 
40%Posa+Succinic acid+ Affinisol 4M batch. Upon stability, it was observed 
that 40%Posa+Malic acid+ Affinisol 4M (2-1) batch recrystallised at 
40°C/75%RH condition on the 30th day while 40%Posa+Succininc acid+ 
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Affinisol 4M (2-1) batch recrystallised at same condition on the 60th day. 
40%Posa+ Affinisol 4M batch was still stable at all conditions for over 360 
days. 
The general convention would dictate a decrease in drug release due to the 
formation of crystalline posaconazole. However, an increase in drug release 
was observed in both the batches. The release was also higher compared to 
the observed release on day 0. The formation of either eutectic or co-crystal 
of posaconazole with succinic and L-malic acid within Affinisol 4M had a 
positive impact on the drug release. Thus, addition of dicarboxylic acids had a 
positive impact on the drug release of posaconazole in acidic pH. 
7.2 Suggestions for future studies 
The aim of the project was to develop controlled/sustained release products 
using HME. Due to which, higher molecular weight grades of AffinisolTMHPMC 
were used to achieve sustained release. However, feasibility studies need to 
be carried out to check the drug release using lower molecular weight grades 
of AffinisolTMHPMC. The aim would be to check whether incorporation in lower 
molecular weight grades of AffinisolTMHPMC show sustained release.  
The study did not focus on one critical quality attribute of product 
impurity/relative substance. Relative substances for both the API-polymer 
blends need to be studied. Solution state degradation need to be studied in 
detail. Also, Studies to confirm drug purity within extrudates and pellets needs 
to be carried out by HPLC.  
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Drug release mechanism was concluded by visual observations of the pellet 
during and after dissolution. More studies should be carried out to confirm the 
mechanism of drug release during in-vitro dissolution. Analytical tools like 
particle video microscopy (PVM) and focussed beam reflectance microscopy 
(FBRM) should be used to confirm drug release. Surface dissolution can also 
be studied using in-situ monitoring by UV imaging. Pion’s SDi2 is one such 
powerful analytical tool which can help in understanding the same.  
Solid state degradation were indirectly studied using TGA and rotational 
rheometer but thermal/forced degradation of IBU and POSA during HME 
process needs to be studied in detail. Effect of high temperature and shear on 
AffinisolTMHPMC degradation should be studied. This will help in building 
confidence on the process.   
Down-streaming process like milling and tabletting should be investigated and 
studied to develop robust formulated products. With increase in IBU load an 
increase in plasticity was observed. Also, deviation to Fox equation was 
observed which could be due to saturated solubility between IBU and polymer. 
Taking values of Tan ∆ as reference a study needs to be carried out to 
understand its implications on the milling process.   
To fully understand the effect of process variables, a full factorial design of 
experiments should be carried out. The study will highlight the effect of 
interaction of variables. A more robust process model can be developed.  
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To confirm the sensitivity and selectivity of ibuprofen dimer as early indicator 
of solid state stability, trials need to be carried out with different polymers apart 
from cellulose based derivatives.  
Single crystal XRD or solid state NMR studies are needed to affirm the 
formation of eutectic or co-crystal of Posa with succinic acid and L-Malic acid. 
The aim of this project was to achieve sustained release, however for Posa an 
immediate release profile is preferred due to its anti-fungal activity. Hence, 
trials with low molecular weight AffinisolTMHPMC and Posa should be carried 
out to check its effect on dissolution.    
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Abstract:   
Achieving high drug load while maintaining stability of amorphous solid 
dispersions (ASD) is one of the critical formulation challenge during 
developmental phase. We propose here that early detection of ibuprofen dimer 
in the ASD is an indicator of potential physical destabilization of the ASD. 
Conventional approaches to determine this parameter involve exposure of 
prepared ASDs to different stress conditions in order to observe drug 
recrystallization. The approaches are time-consuming and often considered 
as limiting factor for the use of ASD. Attenuated Total Reflection Fourier 
Transform Infrared spectroscopy (ATR-FTIR) has been used as a tool to 
detect ibuprofen dimer in the ibuprofen and hydroxypropyl methylcellulose 
(HPMC) ASD prepared using hot melt extrusion (HME). X-ray diffractometry 
(XRD), Differential Scanning Calorimetry (DSC) and Raman spectrometry 
were used to support our hypothesis. Ibuprofen dimerization in the ASD was 
found to correlate well with the solid-state stability of ASDs. Results confirmed 
that 15%w/w drug loading of ibuprofen within HPMC ASD was the maximum 
drug concentration to produce a stable ASD. 
Ibuprofen dimerization is used as an indirect approach to presage solid state 
stability of the amorphous solid dispersions (ASD). Prediction of the maximum 
drug concentration for stable ASD is one of the critical formulation factors 
during developmental phase. Conventional approaches to determine this 
parameter involve exposure of prepared ASDs to different stress conditions in 
order to observe drug recrystallization. The approaches are time-consuming 
and often considered as limiting factor for the use of ASD. Here Attenuated 
Total Reflection Fourier Transform Infrared spectroscopy (ATR-FTIR) has 
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been used as a tool to identify ibuprofen dimer formation as an early predictor 
of solid state stability of an ASD of ibuprofen and hydroxypropyl 
methylcellulose (HPMC). Predictive approach was further confirmed by 
exposing the extrudates of different ibuprofen concentration to various stress 
conditions. XRD, DSC and Raman spectrometry were used to confirm solid 
state stability of the ASD by providing an ortho-analytical approach. Drug 
aggregation approach observed after preparation of ASD was found to be in 
good correlation in forecasting the solid state stability of ASDs. Results 
confirmed that 15%w/w drug loading of ibuprofen within HPMC ASD was the 
maximum drug concentration to produce a stable ASD. 
Keywords: Affinisol™ HPMC HME; hot melt extrusion; hydroxypropyl 
methylcellulose; solid dispersion; thermal analysis; FTIR Spectroscopy; 
Ibuprofen; Raman spectroscopy; solid-state stability; binary phase diagram  
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Introduction: 
Poor water solubility of Active Pharmaceutical Ingredients (APIs) is a major 
challenge for the pharmaceutical industry.1One approach to address low 
solubility is to produce an amorphous solid dispersion (ASD), which is formed 
when the drug is molecularly dispersed and stabilized in a polymer matrix. The 
polymer matrix retards the molecular mobility of the API and stabilizes the API 
in an amorphous state.2 Solid dispersions are obtained either by solvent 
evaporation or melt fusion methods.3 Melt based processing involves melting 
a physical mixture of API and polymer to obtain a homogeneous molten phase, 
for example by application of shear and heat in a twin screw extruder.4, 5 This 
is followed by cooling to ambient temperature to lock the API in its amorphous 
form. The concentration of the API in the solid dispersion is a critical factor 
affecting stability which depends on the miscibility of the API in the polymer.6 
The glass transition temperature (Tg) of the solid dispersion related to 
temperature and humidity during storage will affect the stability of the solid 
dispersion. It is generally desirable to incorporate the highest possible 
concentration of the API in ASD to control size and weight and to minimize the 
cost of the final dosage form. High drug loading is the preferred choice but has 
the drawback of solid-state stability.6 Drug entrapped within the polymer, if not 
molecularly mixed, may recrystallize thus affecting the stability of the drug.  
The objective of this work was to study the relationship between molecular 
association of the drug within an ASD and its long-term stability. Molecular 
associations like dimerization can provide insight about drug aggregation 
within ASD which can be further used as an indirect measure to study solid 
state stability. Current understanding of the stability of ASDs is predominantly 
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based on the theoretical predictions of drug-polymer miscibility7-10, analytical 
measurements of molecular mobility and dynamics11-13, onset of 
crystallization, crystal growth kinetics14-16 and intermolecular interactions 
between the drug and polymer.17-19    
One common approach for the prediction of the solid-state stability is to use 
the Flory-Huggins polymer solution theory as a function of temperature.10, 20-23 
However, the method fails to provide a link between molecular distributions of 
the drug within the polymer matrix and stability of the ASD. Hence, a basic 
practical screening tool is needed for early detection of the solid state stability 
of amorphous solid dispersions. 
Currently, the stability of an ASD is determined empirically then estimated by 
exposing it to different temperature and humidity conditions while monitoring 
it for the appearance of crystalline API using suitable analytical tools such as 
powder XRD and DSC.24, 25 Various studies using in-line and off-line 
spectroscopic techniques reported the monitoring of the crystalline phase.26-29 
Suryanarayanan et al. used dielectric spectroscopy (DES) to predict stability 
based on molecular mobility and studied the effect of hygroscopicity.30-32 
Findings from these works are selective and moreover, the approaches 
involved studying either the glass forming ability or crystal growth mechanism 
and not the molecular association of drug within the polymer matrix. 
Additionally, analytical techniques available for solid state detection are limited 
and require that samples be exposed to different time-consuming stability 
conditions. The difficulties in proving long term stability during storage can 
restrict use of amorphous solid dispersions for solubility enhancement of 
poorly soluble drugs.1, 33 
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Ibuprofen (IBU) or 2-(4-isobutylphenyl) propionic acid is a nonsteroidal anti-
inflammatory drug (NSAID) used for reducing inflammation and pain in the 
body. It has a molecular weight of 206.29g/mol and melting point of 75-77°C.34 
It belongs to class II of Biopharmaceutical Classification System (BCS) due to 
its poor aqueous solubility. IBU exists as a cyclic bonded dimer in its crystalline 
state (Figure 1b).34 Previous studies have shown the existence of this dimer 
in the melt state.34, 35  
 
Figure 1. Structure of (a) ibuprofen monomer and (b) ibuprofen dimer with 
hydrogen bonding 
Several studies have also reported the use of a solid dispersion of IBU with 
polymers to increase its oral bioavailability (Figure 1a).35, 36 Main focus of those 
studies was on enhancing the product performance and investigation was 
about interfaces between ibuprofen and polymers. However, none have 
studied systematically the identification of the molecular association of 
ibuprofen within the polymer matrix and attempted its correlation with the solid 
state stability of the ASD.  
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The relatively recent emergence of melt-based techniques for preparation of 
ASD may be partially attributed to the lack of approved polymers for 
formulation. Conventionally used pharmaceutical polymers have major 
drawbacks of high Tg, and/or high melt viscosity, and thermal degradation.1 To 
overcome this, various new polymers were developed either by co-
polymerization or substitution and rearrangement within the monomers of the 
polymers.37 This lead to the introduction of new polymers like Soluplus® 
(copolymer of PVC-PVA-PEG), HPMCAS, HPMCP, and AffinisolTMHPMC. 
AffinisolTMHPMC marketed by DowDupont is specifically developed for HME. 
It is amorphous in nature, water soluble and has a wide temperature window 
for hot melt processing.37, 38 Three grades of AffinisolTMHPMC 15cP, 100cP 
and 4M are commercially available of which 100cP was used for the current 
research. 
In the current study, solid dispersions of ibuprofen and AffinisolTMHPMC 100cP 
(Affinisol 100cP) of varying drug concentrations (10, 15, 20, 30 and 40%w/w) 
were prepared using HME. The extrudates were characterized using 
attenuated total reflection fourier transform infrared spectroscopy (ATR-FTIR) 
to identify the IBU aggregation and Raman spectroscopy, X-ray diffraction 
(XRD) and differential scanning calorimetry (DSC) to provide an ortho-
analytical approach to monitor recrystallization of the extrudates. Prepared 
extrudates were subjected to conditions of 40°C/75% RH, 25°C/60% RH and 
room temperature (RT) to investigate stability. Attempts were also made to 
understand the solid state solubility and miscibility using the Flory-Huggins 
polymer solution theory.  
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Materials and Methods:  
Materials: 
Affinisol™ HPMC 100 cP (Affinisol 100cP) was provided as a gift sample by 
DowDupont., MI, USA. According to the manufacturer, the material was from 
batches prepared for distribution to researchers as experimental samples. 
Ibuprofen was procured from Medex UK.  
Methods: 
Theoretical considerations:  
Melting point depression approach  
The Flory-Huggins polymer solution theory proposes the drug-polymer 
temperature-composition phase diagram by understanding the interaction 
parameter 𝜒 between the drug-polymer and its change with temperature. This 
can be achieved by using melting point depression data to predict 𝜒 by using 
Equation 1:9, 38 
1
𝑇𝑚
−  
1
𝑇𝑚𝑜
= −
𝑅
𝛥𝐻
[𝑙𝑜𝑔 𝜙𝑑𝑟𝑢𝑔 + 𝜙𝑝𝑜𝑙𝑦 (1 −
1
𝑚
) +  𝜒ϕ 𝑝𝑜𝑙𝑦
2 ]                                     
Equation 1 
Where 𝑚 = [(Mol wt_poly/Density_poly )/(Mol wt_drug/Density_drug )] 
Tm and Tmo are the melting points of the drug-polymer blend and pure drug 
respectively, 𝜙 is the volume fraction of the components. ΔH and R denote 
enthalpy of fusion and the gas constant respectively.  
𝜒 is a function of temperature which can be empirically described by Equation 
2: 
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𝜒 = 𝐴 + 𝐵/𝑇                                                                                                              Equation 
2 
Where A is the entropic contribution and B is enthalpy contribution of the 
system.9, 38 
Prediction of spinodal curve 
According to the Flory–Huggins theory, the free energy of mixing for a drug-
polymer solid dispersion can be described by Equation 3: 
𝛥𝐺𝑚𝑖𝑥 = 𝑅𝑇[ϕdrug log 𝜙𝑑𝑟𝑢𝑔 +
ϕpoly
m
 log 𝜙𝑝𝑜𝑙𝑦 + 𝜒 ϕdrugϕpoly]              
 Equation 3 
The second derivative of 𝛥𝐺𝑚𝑖𝑥 at different temperatures will give the spinodal 
curve.  
Theoretical glass transition temperature calculation by Fox equation 
Researchers often co-relate the extent of plasticization based on 𝑇𝑔 values of 
polymeric blends. Generally, values of 𝑇𝑔 reduce with increase in plasticizer 
concentration and a plot of 𝑇𝑔 against the concentration of plasticizer yields a 
relationship which determines the plasticization efficiency. Such a relationship 
can also be obtained theoretically using the Fox equation.9  
1
𝑇𝑔𝑚𝑖𝑥𝑡𝑢𝑟𝑒⁄
= (
𝑤1
𝑇𝑔1 ⁄
) + (
𝑤2
𝑇𝑔2 ⁄
)                                                                 Equation 
4 where 𝑤1 & 𝑤2 are weight fractions while 𝑇𝑔1 & 𝑇𝑔2 are the glass transition 
temperatures of drug and polymer respectively.  
Preparation of ASDs using HME: 
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Pre-mixed dry blends of ibuprofen and Affinisol 100cP with varying drug 
concentration were prepared by HME using a 16mm twin screw Pharmalab 
extruder from ThermoScientific UK with screw length to diameter ratio of 40:1. 
A twin screw configuration consisting of one high mixing and kneading zone 
was used for all experiments; screw rotation speed of 100 rpm and feed rate 
of 0.4 kg/hr was kept constant for all experiments (Table S1). Temperature 
profiles were varied according to the blend concentrations used due to the 
plasticity induced by the ibuprofen and the associated decrease in Tg of the 
ibuprofen-Affinisol 100cP blends. Extrudates were air-cooled and pelletized 
for further analysis. 
Analytical evaluations of the ASDs:   
Raman spectroscopy  
Raman spectra for all prepared samples were taken using a Thermo Scientific 
DXR spectrometer with a 780nm laser at 50mW power. A slit aperture of 50µm 
was used to give an estimated area spot size of 3.1µm. Samples were either 
placed in glass vials (for powder samples) or were placed on the sample plate 
as is (for extrudates). 64 scans of 30 secs duration were collected within the 
spectral range 50-3360 cm-1. Total time of collection per sample was 33 mins. 
X-ray Scattering 
X-ray scattering of the samples was acquired using a SAXSspace from Anton 
Paar Austria. The samples were placed on the stainless steel sample holder 
and sealed with transparent film. The distance between sample and detector 
was 112mm and the intensity I (q) was monitored at a wavelength of 
0.15418nm. An XYZ stage was used for auto-recognition of the sample stages. 
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A fast read-out detector (Pilatus 100K-S) was used with the total acquisition of 
20 frames with an exposure time of 60 secs and data was analyzed using 
SAXSdrive™ software. The scattering vector q range was used to calculate 
2Ө values (q = 4π/λ sin θ, where λ = 0.15418nm).39-41   
ATR-FTIR spectroscopy 
Fourier transform infrared (FTIR) spectra were acquired from extrudates using 
a Thermo-Scientific Nicolet iS50 FTIR spectrophotometer equipped with a 
diamond attenuated total reflection (ATR) module. A thin section of extrudate 
was sliced and placed on the ATR and clamped to avoid spaces between 
holder and sample. Spectra were recorded in absorbance mode from 4000 
cm–1 to 400 cm–1 at 4 cm–1 resolution, and averaged over 64 scans. Total scan 
time was 1 min 35 secs.  
Differential Scanning Calorimetry (DSC) 
DSC runs were performed using TA Q2000 and TA Discovery calorimeters 
with standard aluminum pans. Samples of weight around 2mg were used and 
crimped with a pinhole in the aluminum lid. A heating rate of 10°C/min was 
applied up to the reported degradation temperature of the samples. 
Thermograms generated were analyzed using TA Universal Analysis and 
Trios software. 
For melting point depression experiments, physical mixtures of various 
concentrations of ibuprofen and Affinisol 100cP were accurately weighed in 
standard aluminum pans and crimped with pin holed aluminum lids. Samples 
were run in duplicate at a heating rate of 2°C/min up to 85°C. Thermograms 
generated were analyzed using TA Instruments Trios software.  
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Accelerated Stability Studies:  
To investigate solid-state stability, the ASDs were exposed to stability 
conditions at 40°C/75% RH, 25°C/60% RH, and room temperature. Samples 
were removed at regular intervals and analyzed using ATR-FTIR, Raman 
microscopy, XRD, and DSC. 
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Results and Discussion:  
Construction of binary phase diagram:  
The application of the Flory-Huggins solid-state solution theory assumes the 
drug solubilizes within the polymer with a similar principle as for a solid solute 
dissolving in a solvent to form a solution.21 Table 1 provides the parameters 
used to calculate the interaction parameter and free energy of mixing. 
Table 1. Calculated parameters for Ibuprofen and Affinisol 
Parameter Ibuprofen Affinisol 100cP 
Mw (g/mole) 206.29 231708 
Density (g/cm3) 1.03  1.326 
Glass transition temperature 
(°C) 
-44°C 128°C 
 
The parameters for ibuprofen were obtained by ChemDraw software while 
experimental values obtained were used for Affinisol 100cP. Glass transition 
temperature values for ibuprofen and Affinisol 100cP were obtained from DSC 
and DMA respectively. The interaction parameter 𝜒 at the melting point was 
calculated by a melting point depression method using DSC and was found to 
be -0.6353 (Figure 2.).9, 21, 22, 38  
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Figure 2. Calculation of interaction parameter 𝜒 at melting point (left) and over 
different temperatures (right) by Flory-Huggins equation 
For the spinodal curve, the interaction parameter was plotted as a function of 
inverse temperature to get components A and B (Figure 2).  
According to theory, at the melting temperature, the interaction parameter 
tends to infinity hence subtle changes in temperatures near the melting point 
will have a significant impact on the interaction parameter. Using values A and 
B obtained by plotting (figure 2), the free energy of mixing 𝛥𝐺𝑚𝑖𝑥 at different 
temperature was theoretically calculated (Figure 3).  
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Figure 3. The plot of free energy of mixing (top) and phase diagram (bottom) 
𝛥𝐺𝑚𝑖𝑥 values were found to be positive for temperatures below 74°C which 
indicates de-mixing. The spinodal curve was obtained by calculating the 
second derivate of 𝛥𝐺𝑚𝑖𝑥 at various temperatures close to the melting 
temperature. The theoretical glass transition temperature profile for ibuprofen-
affinisol 100cP was calculated using the Fox equation (Figure 3).  
The molecular weight of Affinisol 100cP is more than 1000 times of that of 
ibuprofen. Due to which spinodal curve predicts complete solid-state miscibility 
between all the drug-polymer compositions and thus binary phase diagram 
fails to predict solid-state miscibility between ibuprofen and affinisol 100cP.38 
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Hence, it can be inferred that theoretical binary phase diagram by Flory-
Huggins theory fails to predict the stability of the ASD formed using ibuprofen 
and Affinisol 100cP.  
Confirmation of amorphous solid dispersion prepared by hot melt extrusion:  
The formation of an ASD was confirmed through analysis by DSC, XRD, and 
Raman spectroscopy. The absence of any crystalline IBU melting endothermic 
peak in DSC confirmed the amorphous solid state of solid dispersions (figure 
S1).34 No distinct crystalline ibuprofen peaks were observed in XRD 
diffractograms and a halo region confirmed the amorphous nature of the 
extrudates at all concentrations of ibuprofen (figure 4).25, 35, 42 Raman spectra 
exhibited a peak shift from 1607cm-1 to 1612-1617cm-1, attributed to aryl chain 
deformation and C-H stretching and bending which occurs due to disorder 
within the structure and is characteristic of the amorphous state of ibuprofen.43 
Thus, the peak shift affirmed the amorphous solid dispersions for all the 
ibuprofen-Affinisol 100cP extrudates at varying drug concentrations (Figure 4).   
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Figure 4. XRD patterns (top) and Raman spectra (zoomed view) for ibuprofen 
powder (blue), affinisol 100cP (purple), 10 (purple), 15 (red), 20 (pink), 30 
(dark blue) and 40%w/w (green) ibuprofen-affinisol 100cP extrudates 
Ibuprofen dimer as an early indicator of solid-state stability by ATR-FTIR:  
Ibuprofen exists as a dimer in both its crystalline and melt states.35 However, 
when IBU solubilizes within Affinisol 100cP, the dimer of IBU is broken down 
into its monomeric form either due to shear or by the effect of temperature 
during the process and is entrapped within the polymer resulting in an 
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amorphous solid dispersion. A single phase ASD affirmed uniform mixing 
between IBU and Affinisol 100cP. No chemical interaction was observed 
between the spectral bands of the drug and polymer which confirms the 
formation of a solid dispersion due to its solid state solubility and miscibility. 
 
Figure 5. ATR-FTIR of IBU powder (blue), 10% IBU-affinisol 100cP extrudate 
(red) and affinisol 100cP powder (green)  
It is evident from ATR-FTIR spectra, that active bands between 1800-1700 cm-
1 can be considered as a non-interfering region for the detection of IBU within 
ASD (circled in figure 5). A distinct shift in the 1707 cm-1 band of IBU powder 
which is attributed to the carbonyl band to 1732 cm-1 in the solid dispersion 
was observed. Several studies have reported similar shifts which have been 
attributed to the breaking of hydrogen bonding of the IBU with other polymers 
within ASD.34, 35 Thus, the shift in the carbonyl bond of the ibuprofen to 1732 
cm-1 was due to the formation of monomeric form within the ASD.  
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Using this as a reference indirect measurement to understand the IBU solid 
state within the ASD, ASDs with different percent drug loading of IBU were 
prepared. It was observed that all ASDs above 15% drug loading showed the 
presence of the dimer along with some monomeric form (figure 6). This 
suggests that presence of ibuprofen dimer can be used as a measure in 
predicting the solid state stability of the ASDs.  
 
Figure 6. ATR-FTIR spectra (zoomed view) of 10 (blue), 15 (pink), 20 (dark 
blue), 30 (red) and 40%w/w (purple) ibuprofen-affinisol 100cP extrudates 
Although all the extrudates above 15% IBU load showed some presence of 
the dimer form of IBU, traditional analytical techniques such as XRD, DSC, 
and Raman which are predominantly used in the detection of the crystalline 
phase of API within ASD showed the absence of crystalline domains (figures 
4).  
The theoretical binary phase diagram provided an overview of solid solubility 
and miscibility between the drug and polymer as a function of temperature. 
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However this is not a fair reflection of the process as it considers only the effect 
of temperature on the solubility. Furthermore, it fails to link the solid state 
solubility and miscibility to the actual stability of the ASD. Thus, the need for a 
simple, pre-formulation tool for the early detection of solid state stability of ASD 
led to the investigation of monomer and dimer formation of ibuprofen within 
ASD using ATR-FTIR.  
To confirm the approach of ibuprofen dimer detection by ATR-FTIR studies, 
ASDs of different IBU concentration were stationed for accelerated stability 
studies. All the samples were stationed at three different stability conditions of 
40°C/75% RH, 25°C/60% RH and room temperature. Extrudates were 
analyzed off-line at regular intervals using ATR-FTIR, Raman, XRD, and DSC 
to check for recrystallization of ibuprofen. Table 2 provides a summary of these 
stability studies. It was observed that 40% IBU loaded extrudates recrystallized 
within a week at 40°C/75% RH whereas 30% IBU loaded extrudates took 30 
days to recrystallize (figure 7). Lower IBU concentration extrudates at 20, 15 
and 10% loadings were stable at all three stability conditions measured up to 
8 months (figure S2). The 20% IBU concentration extrudates were predicted 
to recrystallize due to presence of ibuprofen dimer domains but this was not 
observed with 8 months of the study.  
 
 
Table 2. Summary of stability studies. (-) & (+) denotes amorphous and 
crystalline extrudates respectively. 
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IBU-Affinisol 
100cP extrudates 
Day 
15 
Day 
30 
Day 
120 
Day 
180 
Day 
240 
Ibuprofen 
dimer at 
Day 0 
40% IBU + + + + + 
 
Yes 
30% IBU - + + + + 
 
Yes 
20%IBU - - - - - 
 
Yes 
15%IBU - - - - - 
 
No 
10%IBU - - - - - 
 
No 
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Figure 7: XRD diffractogram of ibuprofen powder (red), 30% T=0 day (blue), 
30% R.T T=30 days (maroon), 40% T=0 day (green), and 40% 40°C/74% RH 
T=15 days (purple) of ibuprofen-Affinisol 100cP extrudates 
ATR-FTIR was able to provide an early indication of the presence of the dimer 
form of ibuprofen within the ibuprofen—Affinisol 100cP ASDs. Detection of this 
dimer form within ASDs represents free IBU domains either in crystalline or 
melt form within the extrudates which appeared to correlate with IBU 
recrystallization. Thus, ATR-FTIR provided a quick and simple pre-formulation 
tool for detection of drug-drug interaction within the extrudates which could be 
used to predict the solid-state stability of the ASDs.  
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Conclusion: 
The above results suggest that ATR-FTIR can be used as a predictive tool to 
indicate long-term stability of ASDs by providing a mechanistic understanding 
of the drug-drug molecular association within the polymer matrix. This 
approach has significant advantages over conventional methods such as 
theoretical binary phase diagrams by Flory-Huggins polymer solution theory, 
or by subjecting samples to accelerated stability tests. The use of advanced 
analytical tools can help identify molecular level interaction within ASDs at the 
initial stage and provide a simple, rapid and robust prediction technique to 
identify solid-state stability of the ASDs. Identification of molecular level 
interaction led to significant reduction of time required to confirm solid state 
solubility of ASD using conventional approach of monitoring crystallization by 
charging to accelerated stability conditions.   
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Appendix 2 
PROFESSIONAL DEVELOPMENT: 
 Poster titled ‘Effect of concentration of Ibuprofen on the rheological & 
mechanical properties of Ibuprofen-AffinisolTMHPMC extrudates’ accepted 
for AAPS San Diego 2017.  
 Delivered a presentation titled ‘Stability prediction for solid dispersion of 
Ibuprofen- AffinisolTMHPMC extrudates using ATR-FTIR spectroscopy’ at 
PPE-AMRI Bradford UK 2017.  
 Presented Poster titled ‘Suitability of AffinisolTMHPMC HME polymers with 
Ibuprofen using thermal, spectroscopic and rheological properties’ at 
AAPS, Colorado 2016.  
 Presented poster titled ‘Role of DMA in understanding the in-line effect of 
humidity on the Ibuprofen- AffinisolTMHPMC extrudates’ at PharmSci 
2016.  
 Presented two posters titled ‘Mechanistic understanding of sphere 
formation during melt granulation of Lactose monohydrate and PEG-
6000’ and ‘Effect of plasticisers on the degradation kinetics of cellulose 
ester derivative polymers’ at APGI 2016  
 Presented poster titled 'Calculation of fragility index and prediction of 
binary phase diagram of Ibuprofen-HPMCP using DSC' at Thermal 
Activity Conference April 2015  
 Student Representative of PhD (full-time) students of Pharmacy degree 
at University of Bradford. 
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